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Abstract
The surface of P. falciparum-infected erythrocytes is modified by the insertion of 
immunogenic parasite-encoded proteins; the most extensively studied family is 
Plasmodium falciparum erythrocyte membrane protein 1, (P/EMP1). P/EMP1 
undergoes clonal antigenic variation and is responsible for mediating cytoadherence 
of infected erythrocytes within the microvasculature, characteristics underpinning 
the virulence associated with Plasmodium falciparum infection. Protection against 
disease following exposure to a parasite displaying a particular variant of PfEMPl is 
associated with agglutinating antibodies against that variant, antibodies associated 
with protection. However, the role of cross-reactive responses to heterologous 
isolates in protection from subsequent disease remains poorly understood. The target 
and epitope specificity of both the variant specific protective response and any cross­
reactive antibody response is unknown.
Individuals from two areas with differing transmission characteristics were screened 
at the end of a low transmission season for recognition of a panel of laboratory and 
clinical isolates. Using in particular an isolate selected to express one specific 
variant of PyEMPl, A4 P/EMP1, on the surface of the host erythrocyte, the 
relationship between the presence of asymptomatic parasite carriage and cross­
reactive antibody responses was established. Subsequently the domain and 
interdomain regions of A4 PJBMPl were cloned and expressed as recombinant 
proteins and used to screen the same individuals in an attempt to identify the targets 
for these measured responses. This study demonstrated differences in antibody 
acquisition between domains, individuals and areas. In a longitudinal study, the
3
interaction between having detectable parasites and the ability to recognise the 
surface of erythrocytes infected with four different parasite isolates led to the 
identification of a susceptible group of children responsible for the burden of clinical 
malaria in this area.
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Chapter 1
Introduction
Plasmodium falciparum malaria -  a perspective
In 2002, 2.2 billion individuals were at risk of Plasmodium falciparum malaria and 
there were approximately 515 million episodes of clinical malaria caused by this 
parasite worldwide (Snow, Guerra et al. 2005). 70% of all P. falciparum malaria 
cases occurred in sub-Saharan Africa with 25% occurring in South East Asia. It is 
estimated that 1 million people die in Africa alone as a direct result of P. falciparum 
malaria each year with the majority of these being less than 5 years of age (Snow, 
Craig et al. 1999). In areas of stable endemic transmission around 25% of all 
mortality in those aged less than 5 years has been attributed directly to malaria 
(Snow, Craig et al. 2003). Additionally, many randomised controlled intervention 
trials aimed at reducing the incidence of infection have resulted in reductions in 
mortality in excess of that attributed to malaria alone (Molineaux 1997; Snow, 
Korenromp et al. 2004). This has led to speculation that not only does P. 
falciparum infection directly cause death in some individuals but in many others it is 
a contributor. Despite a continued decline in all-cause mortality in children less than 
5 years in sub-Saharan Africa since the 1960s, a similar downward trend in malaria- 
specific mortality has reversed over the last 15 years (Snow, Trape et al. 2001). The 
reasons for this are undoubtedly complex but the most parsimonious explanation is 
unquestionably the rapid decline in efficacy of chloroquine, a cheap, effective and 
readily available anti-malarial which, until the mid 1990’s was in widespread use 
throughout sub-Saharan Africa.
Widespread implementation of successful and accessible case-management of 
disease using effective anti-malarial drugs, such as the artemisin-based combination 
treatments, and the use of preventative measures such as insecticide-treated bednets, 
capable of reducing all childhood deaths by around 20% (Lengeler 2004), may 
reverse the rising mortality due to malaria in Africa. However, this will require a 
far greater financial commitment from the Governments of wealthy countries than 
currently exists. While these strategies could be implemented to great effect today, it 
is the development of an efficacious malaria vaccine that remains the holy grail of 
basic malaria research. Intense research efforts towards this goal have been 
undertaken over the past 20 years, however the complex biology of the malaria 
parasite has resulted in an effective vaccine remaining elusive. More recently, a 
renewed global commitment to funding malaria vaccine research, (Malaria Vaccine 
Initiative MVI, Global alliance for Vaccines and Immunisations GAVI)(Boseley and 
Elliott 2005) and the rapid development of new technology allowing fuller access to 
the parasite genome have led to a new and determined effort to develop an effective 
and accessible malaria vaccine. The studies undertaken towards this thesis aim to 
improve our understanding of the naturally occurring acquired immune response to 
the asexual intra-erythrocytic stage of the P. falciparum life cycle and thus in turn 
aid progress towards the development o f a vaccine effective against P. falciparum 
malaria,.
Plasmodium life cycle (Figure 1.1)
The infected female anopholene mosquito injects between 1 and 100 infective 
sporozoites from her salivary glands into the host bloodstream at the time of blood
18
meal (Rosenberg, Wirtz et al. 1990; Ponnudurai, Lensen et al. 1991). These rapidly 
pass through the bloodstream to the liver where 5-10% successfully invade 
hepatocytes (Ferreira, Enea et al. 1986). Within the hepatocyte these sporozoites 
divide forming pre-erythrocytic schizonts in which around 30,000 daughter 
merozoites develop. After a minimum of 5 V2 days, the merozoites lyse the 
hepatocyte and enter the bloodstream within the hepatic sinusoids. The stage of 
development from sporozoite inoculation to hepatocyte rupture is the pre- 
erythrocytic stage of infection and, other than a local inflammatory reaction at the 
site of inoculation, is asymptomatic to the host.
The erythrocytic-stage of infection begins with the entry of merozoites into host 
erythrocytes. After invasion they divide to become schizonts containing around lb- 
32 merozoites. The erythrocyte eventually ruptures releasing these daughter 
merozoites into the bloodstream where they each invade a fresh erythrocyte and 
begin the cycle again. The entire erythrocyte stage of infection takes around 48 
hours from invasion to rupture of the erythrocyte and this leads to an exponential 
increase in parasites. It is thought that it is the intermittent release of merozoites 
which give rise to the symptoms of malaria in the host through stimulation of the 
release of endogenous pyrogens, which in turn are responsible for the classical 
cyclical fevers. A proportion of merozoites enter the sexual stage by differentiating 
into male and female gametocytes within erythrocytes. These sexual forms are 
responsible for transmission of P. falciparum through ingestion by feeding 
mosquitoes. Once ingested, they travel to the mosquito’s midgut, where they mature 
and fuse to form zygotes. Zygotes develop into ookinetes, which invade midgut
19
Sporozoites
Pre-erythrocytic
stage
Liver
Ookinete
Zygote
Merozoites
Gamete Erythrocytic
stage
RBC
Sexual stage
Gametocytes
Figure 1.1
The life cycle of Plasmodium falciparum, indicating the three stages occurring 
within the human host.
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epithelial cells and develop into thousands of sporozoites. These enter the mosquito 
salivary glands from whence they transmit a further P. falciparum infection when the 
mosquito feeds again on a human host. This thesis will only discuss humoral 
immune responses to antigens present during the intra-erythocytic stage of the life 
cycle.
The global distribution of malaria
The probability of malaria transmission occurring is dependent upon climatic and 
ecological factors. Conditions appropriate for the survival of the anopheline 
mosquito, the major vector transmitting P. falciparum, and for the development of 
sporozoites within the vector include at least 80mm of rainfall annually and average 
temperatures greater than 18°C for at least five contiguous months of the year (Craig, 
Snow et al. 1999). Even with these climatic necessities, transmission can be 
influenced by human activities such as agriculture, urbanisation, mass population 
movement and malaria control programmes.
Until recently, the only global map of malaria endemicity dated from 1968 (Lysenko 
and Semashko 1968). This map combined historical records and maps of different 
malariometric indices collected up until the late 1960’s. Efforts to update this, 
taking into account both population denominator changes and malaria control efforts 
over the last 30 years have demonstrated that despite the total land area supporting 
malaria being reduced by half, there has been a 2 billion increase in the total 
population exposed to malaria (figure 1.2) (Hay, Guerra et al. 2004; Snow, Guerra et 
al. 2005).
21
Measuring malaria transmission
Malaria is most commonly classified according to whether transmission is stable or 
unstable. Rather than two completely discrete situations, individuals reside in areas 
across a spectrum of risk encompassing both classifications. Under stable endemic 
conditions, the prevalence of infection is relatively high and persistent. 
Transmission remains relatively insensitive to environmental changes and there is 
little year-to-year variability although seasonal fluctuations can occur. Unstable 
areas conversely are characterised by great variability in transmission over time.
A number of measures have been used to estimate the intensity of transmission. A 
widely used measure is the prevalence of peripheral blood stage infections among a 
community, or the parasite rate or more accurately parasite ratio. Parasite ratios do 
not provide a direct quantitative estimate of new infections unless the survey is 
restricted to infants, in which case the age-related acquisition of parasitaemia can 
give a direct measure of transmission, they can vary widely from season to season 
within the same year and variation over small distances has been recorded (Smith, 
Charlwood et al. 1995). Nonetheless, the parasite ratio does give a measure of 
intensity of transmission and has thus been used to define endemicity in classical 
malaria epidemiology. Both parasite and spleen ratios (the proportion of a 
population that exhibit splenomegaly) were used to define classes of endemicity as 
outlined in table 1.1 (Metselaar and Van Theil 1959). Although widely used this 
classification creates artificial groups from a natural continuous spectrum and hides 
important differences between localities, for example an area where an individual
22
may experience five infective bites per year would be classified in the same bracket 
as an area where an individual may receive five hundred infective bites in a year.
23
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Using malariometric indices such as parasite rate in endemic areas may imply that 
this can give us some information about malaria illness and death. However this is 
not straightforward. During the critical period when children are most at risk of 
severe disease, they spend most of their time asymptomatically parasitised. In fact 
the prevalence of parasitaemia continues to rise during the period when the incidence 
of clinical malaria and the risk of death falls, (figure 1.3) (Marsh, Otoo et al. 1989). 
Parasite rates reach saturation and remain at this level throughout older childhood 
and adolescence and only begin to fall again in adulthood. The level at which 
saturation occurs correlates with transmission intensity, as measured by the 
entomological inoculation rate (EIR), although even at low transmission levels, the 
prevalence at which parasite rates saturate is high (Beier, Killeen et al. 1999). 
Saturation is maintained by chronic infection and re-infection. Although in areas of 
high transmission, a greater proportion of the population is parasitised at any one 
point, this does not reflect the incidence of clinical disease in a straightforward 
manner. Indeed, a study investigating the burden of severe malaria in five sites with 
differing transmission intensities demonstrated that population rates for severe 
malaria at first rose with increasing transmission intensity, then reached a plateau 
after which, at very high levels of transmission they fell (Snow, Omumbo et al. 
1997). A finding subsequently reproduced by others(Modiano, Sirima et al. 1999) 
(Reybum, Mbatia et al. 2005).
The EIR is a measure of the number of infective bites an individual receives over a 
particular unit of time. Usually the EIR is expressed per year in order to take into 
account the seasonality of transmission in many areas. The EIR is subject to many
25
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ecological and climatic constraints and varies widely across sub-Saharan Africa both 
in space and time (Hay, Rogers et al. 2000).
The relationship between transmission, age and distribution of disease
In non-immune individuals of any age, infection with P. falciparum parasites will 
almost always result in clinical disease. In stable endemic areas acquired immunity 
results in young children bearing the brunt of the morbidity and mortality. Up until 
the age of 6 months, infection and clinical disease are rare, producing only mild 
symptoms, and parasitaemias are usually low (Snow, Nahlen et al. 1998). This 
resistance is a result of passive transfer of maternal antibodies, persistence of 
haemoglobin F and other factors such as avoidance of vectors by the mother (Sehgal, 
Siddjiqui et al. 1989; Hogh, Marbiah et al. 1995). From around 6 months of age, 
children become susceptible to severe disease and death. Under high transmission 
pressure, disease incidence peaks in the first year of life and as a result of the 
development of functional immunity, by year four children have few clinical 
episodes and these are usually mild (Snow, Omumbo et al. 1997; Bloland, Boriga et 
al. 1999; Reybum, Mbatia et al. 2005). In areas with lower transmission 
characteristics the disease-incidence curve is flattened and the peak occurs at a later 
age, (figure 1.3)(Snow, Bastos de Azevedo et al. 1994; Snow, Omumbo et al. 1997; 
Modiano, Sirima et al. 1999; Rogier, Tall et al. 1999; Reybum, Mbatia et al. 2005). 
Clinical manifestations of severe malarial disease differ with age, with severe 
malarial anaemia occurring at a consistently younger age across the transmission 
spectrum (Snow, Bastos de Azevedo et al. 1994; Marsh, Forster et al. 1995; Snow, 
Omumbo et al. 1997; Reybum, Mbatia et al. 2005). It is not surprising then that in
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areas of high transmission severe malarial anaemia dominates the spectrum of 
disease with cerebral malaria becoming increasingly more important as transmission 
levels drop.
Clinical spectrum of disease
P. falciparum malaria causes a spectrum of clinical presentations from asymptomatic 
parasitisation, through a mild febrile illness to severe disease and death. The 
outcome of any sporozoite inoculation is dependant upon a multitude of factors 
including host genetic susceptibility, host acquired immunity, host nutrition, parasite 
virulence factors and access to prompt and effective treatment. It is estimated that 
between 0.1 and 0.5% of all malarial infections result in severe life-threatening 
disease (Greenwood, Marsh et al. 1991). Although a small proportion, the fact that 
the overall numbers of clinical attacks is so large, this results in a high number of 
cases of life-threatening infection (Snow, Guerra et al. 2005) (Figure 1.4).
The first clinical symptoms of infection with P. falciparum are non-specific. In 
common with many infectious diseases, high fever, muscle aches and headaches 
predominate. Specific to synchronised experimental malaria infections is the 
characteristic cyclical nature of the fevers, recurring every 48 to 72 hours coinciding 
with the erythrocytic growth phase of the life cycle and eventual erythrocyte rupture; 
in nature, individuals seldom exhibit such tightly synchronous infections 
(Kwiatkowski and Greenwood 1989). In those individuals resident in malaria 
endemic areas, over time, frequent exposure results in the development of non-sterile 
acquired immunity that protects against moderate to severe disease but not infection 
per se. In infants, young children and pregnant women in endemic areas, non-
28
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Age (years)
Figure 1.3
Relative risks of infection (triangles), morbidity (squares), severe disease (circles) 
and death (diamonds) among a population aged 0-15 years located in a stable 
endemic area on the Kenyan coast.
(Adapted from (Snow and Gilles 2002))
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exposed travellers to endemic areas, those resident in unstable epidemic-prone areas 
and those with impaired immunity, malaria infection can result in severe disease and 
possibly death.
Severe malaria in African children has been classified into three overlapping 
syndromes: cerebral malaria, severe anaemia and respiratory distress (Marsh, Forster 
etal. 1995)(Figure 1.5).
Cerebral malaria is characterised by impaired consciousness with or without seizures. 
The mortality rate varies from 15-33% in different settings, although comparison can 
be made difficult by variability in the definition of cerebral malaria (White, Warrell 
et al. 1985; Molyneux, Taylor et al. 1989; Kwiatkowski, Molyneux et al. 1993; 
Marsh, Forster et al. 1995). Outcome is associated with depth of coma, (Taylor, 
Molyneux et al. 1988; Molyneux, Taylor et al. 1989; Marsh, Forster et al. 1995), but 
for those who recover the return to consciousness can be rapid (Turner 1997). 
Approximately 11% of those who survive cerebral malaria have neurological 
sequelae (Newton and Krishna 1998). Factors associated with sequelae include 
protracted seizures, prolonged and deep coma and hypoglycaemia (Bondi 1992; 
Walker, Salako et al. 1992; van Hensbroek, Palmer et al. 1997) as well as the 
development of raised intracranial pressure (Newton, Crawley et al. 1997) As not all 
cerebral malaria patients suffer neurological sequelae, it must be that in the majority 
of cases the pathological processes underlying coma do not involve extensive 
irreversible destruction of the host’s cells
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Severe malaria anaemia (SMA) is defined as haemoglobin of 5g/dl or less in the 
presence of P. falciparum parasites with or without respiratory distress (WHO 2000). 
Around 25% of all malaria admissions met these criteria in a stable endemic
Malaria with impaired
consciousness
(332) /"■
Malaria with severe 
respiratory distress (132)
27.8%
(36)
23.8%
(21)7.3%
(219)
35.7% / \
(36) /  16.3% 
V /  (49)5.9%
(51)
1.3%
(380)
Malaria with severe 
anaemia (506)Malaria without 
impaired consciousness, 
severe respiratory distress 
or severe anaemia
0.6% (1027)
Figure 1.5
Total numbers are given in parenthesis and mortality is given as a percentage. 
(Adapted from (Marsh, Forster et al. 1995))
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area on the coast of Kenya (Marsh, Forster et al. 1995). Those children who were 
otherwise well did considerably better than those children with co-existent 
respiratory distress, with a mortality rate of only 1.3% compared to 16.3%, (figure 
1.5). Traditionally respiratory distress had been thought to be a manifestation of 
cardiac failure, reviewed in (English 2000). However, more recently studies have 
highlighted the contribution to respiratory distress of lactic acidosis and 
hypoperfusion secondary to both hypovolaemia and poorly deformable erythrocytes 
(English, Waruiru et al. 1997; Dondorp, Kager et al. 2000; Maitland, Levin et al. 
2003; Maitland, Pamba et al. 2003). It is clear from figure 1.5 that the burden of 
mortality within severe malaria as a syndrome falls with those children displaying 
respiratory distress either alone or in combination with severe anaemia or impaired 
consciousness.
Other prognostic indicators of a poor outcome in severe malaria include pulmonary 
oedema (Deaton 1970; Marsh, Forster et al. 1995), hypoglycaemia (Taylor, 
Molyneux et al. 1988; Molyneux, Taylor et al. 1989; Marsh, Forster et al. 1995), 
cerebral oedema (Newton, Kirkham et al. 1991; Newton, Crawley et al. 1997) and 
renal failure (Warrell 1989)
Immunology of malaria
The well-described age-related protection against severe disease and death due to P. 
falciparum malaria in stable endemic areas is a result of acquired malaria-specific 
immunity. This is not to say innate mechanisms of immunity do not play an 
important additional role. Even in those individuals exposed to malaria for the first 
time, it is not necessarily the case that severe disease will be the eventual outcome. 
Rather a spectrum of resolutions is possible from death at one extreme to those who
33
remain resistant even to mild clinical disease and infection. This spectrum is a result 
of innate mechanisms of protection and these include genetic polymorphisms 
affecting the ability of the parasite to infect and or replicate in host cells the immune 
response and molecules involved in pathogenesis.
Genetic resistance to malaria
When discussing genetic mechanisms of resistance to malarial disease of particular 
note are conditions affecting the structure of the P-globin chain of haemoglobin such 
as sickle cell trait (HbAS), haemoglobin C (HbC) and haemoglobin E (HbE), 
conditions affecting the rate of synthesis of globin chains such as the thalassaemia 
syndromes, the level of glucose-6-phospate dehydrogenase (G-6PD) as well as 
abnormalities of the red cell cytoskeleton such as ovalocytosis. A summary of 
evidence illustrating the effect of the haemoglobinopathies on incidence of clinical 
malaria is given in table 1.2.
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Although the relationship between the malaria parasite and the erythrocyte has led to 
most study on the interaction of genetic polymorphisms and susceptibility to or 
protection from malaria disease, many other genes in different systems and affecting 
alternative stages of the lifecycle are equally important. As an example of these 
associations, a large case-control study of malaria in West African children identified 
a human leucocyte class I antigen (HLA-Bw53) and an HLA class II haplotype 
(DRB1*1302-DQB1*0501), common in West Africans but rare elsewhere, which 
were independently associated with protection from severe malaria (Hill, Allsopp et 
al. 1991). Of considerable interest also, are polymorphisms affecting host molecules 
involved in the pathogenesis of malaria disease. Associations have been described 
with mutations in CD36, (Aitman, Cooper et al. 2000; Pain, Urban et al. 2001), albeit 
in opposite directions, intercellular adhesion molecule-1 (ICAM-1), with a specific 
mutation termed ICAM-1klllfl common in Kenya, yet predisposing to severe malaria 
(Femandez-Reyes, Craig et al. 1997) in some populations but not others (Grau, 
Taylor et al. 1989; Kwiatkowski 1990; Bellamy, Ruwende et al. 1999; Kun, 
Klabunde et al. 1999. Polymorphisms in the promoter region of TNF, increased in 
severe malaria, (Grau, et al. 1989 ) and implicated in the pathogenesis of murine 
cerebral malaria, (Grau, Fajardo et al. 1987), have been related to both susceptibility 
and protection (Knight, Udalova et al. 1999).
Innate immunity to malaria
Reanalysis of experimental P. falciparum infections induced in malaria-naive 
individuals between 1940 and 1963 as a treatment for neurosyphilis, revealed that 
the parasitaemia at which parasite growth is controlled is highly predictable within
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an individual between first and second infections and between infection with 
different species (Molineaux, Trauble et al. 2002). It was concluded that this is best 
explained by innate immune mechanisms employed by the host to limit maximum 
parasite density. It has been suggested that innate immune mechanisms are triggered 
by a pre-determined host-specific threshold of parasite density resulting in 
stimulation of immune effector cells in response to a parasite density in excess of 
this threshold (Kwiatkowski and Nowak 1991). Possible effector mechanisms 
include the production of pro-inflammatory cytokines interferon-y (IFN-y), TNF and 
various interleukin (IL) molecules including IL-8 and IL-12p70 by peripheral blood 
mononuclear cells (PBMC). Recent in vitro studies support this showing production 
of TNF, IL-12p70 and IFN-y by PBMC from naive donors within 12 hours of 
stimulation by P. falciparum infected erythrocytes (Scragg, Hensmann et al. 1999). 
Furthermore malaria-naive individuals experimentally infected with P. falciparum 
already had a detectable increase in the levels of INF-y, TNF and IL-8 at the first 
microscopically detectable appearance of parasites (Hermsen, Konijnenberg et al. 
2003).
A recent longitudinal study conducted in Papua New Guinea investigating parasite 
density regulation in semi-immune children demonstrated control of parasitaemia 
around a threshold. This threshold was maintained within individuals independent of 
species or genotype of infecting Plasmodium parasite (Bruce and Day 2003). These 
data and that obtained from the syphilis treatment records suggest the presence of 
host-specific density-dependent mechanisms irrespective of genotype or species of 
infecting parasite. The effector cells involved in such interactions and the 
determinants of their efficacy remain to be fully characterised.
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Acquired immunity to malaria
Important observations regarding the nature of acquired immunity to malaria can be 
gleaned from the epidemiological picture already outlined. In young infants, the 
resistance displayed towards clinical malaria can be attributed to the transfer of 
immunity, in the form of humoral factors, from mother to child. This important role 
for humoral mechanisms of protection is supported by the classical studies 
describing the passive transfer of antibodies from immune individuals to patients 
with acute clinical malaria and the resultant resolution of infection (Cohen, 
McGregor et al. 1961). Following this period of relative protection, children become 
susceptible to severe disease and death although it is likely that a degree of immunity 
to severe life-threatening episodes is apparent after only a few disease episodes 
(Gupta, Snow et al. 1999). In contrast the prevalence of asymptomatic parasitaemia 
continues to rise beyond the age at which immunity to severe malaria has developed. 
This and the observation that a seemingly well, asymptomatically parasitised child 
can be susceptible to severe disease have led to the hypothesis that acquired 
immunity must be directed, at least in part, against polymorphic targets with 
individuals gaining a repertoire of specificities over time.
The identification and characterisation of the host immune responses and the parasite 
antigenic targets underlying these epidemiological observations is essential in 
understanding the interaction of the host and the parasite, an understanding which 
would in turn better inform the development of an effective malaria vaccine. The 
studies described in this thesis concentrate on the intra-erythrocytic asexual stage of 
parasite development and specifically on humoral responses directed against the 
surface of parasite-infected erythrocytes. This area will form the bulk of the
38
literature review with a brief summary of immunity to the merozoite stage also 
discussed.
Immunity to the erythrocytic stage 
Effector mechanisms against merozoites
Invasion of erythrocytes by merozoites is an essential component of a patent P. 
falciparum infection. It involves an intricate progression of events linking both 
parasite proteins and receptors on the erythrocyte. Mediating the initial attachment 
of the merozoite to the erythrocyte surface are the antigens merozoite surface 
proteins 1-9 (MSP 1-9) (Holder 1994). Successful invasion requires processing of 
the whole MSP1 molecule until only a 19 kilodalton carboxyl terminus fragment 
(MSP 119) remains on the merozoite (Blackman and Holder 1992; Holder, Blackman 
et al. 1992). Following attachment the merozoite re-orients itself until the apical 
membrane is in contact with the erythrocyte membrane. This process is thought to 
be facilitated by apical membrane antigen 1 (AMA1), a protein also requiring 
proteolytic processing (Triglia, Healer et al. 2000; Mitchell, Thomas et al. 2004). 
Formation of a tight junction between the merozoite and the erythrocyte is then 
facilitated by the release of myriad antigens including the erythrocyte binding 
antigens (EBA175, EBA140, EBA180 and EBL-1), (Adams, Blair et al. 2001), and 
the reticulocyte binding homologues (P/RH1, 2a, 2b, 3 and 4) (Rayner, Galinski et al. 
2000; Taylor, Grainger et al. 2002), from organelles at the apical end of the 
merozoite. Due to the short time these antigens are potentially exposed to the host 
immune system, it is likely that antibodies are the predominant effector of anti- 
merozoite immunity. Antibodies could prevent invasion of the erythrocyte thus
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preventing the establishment of a symptomatic infection in many ways. These 
include opsonisation and resultant phagocytosis, complement-mediated damage of 
merozoites or blockage of erythrocyte-binding sites.
There have been contrasting results from studies investigating whether the presence 
of antibodies against the antigens listed are associated with protection from clinical 
malaria. Many studies have suggested that levels of anti-MSPl 19, anti-MSPl block 2, 
anti-MSP2, anti-MSP-3, anti-AMAl and anti-EBA175 may be associated with 
protection (Riley, Allen et al. 1992; al-Yaman, Genton et al. 1996; Egan, Morris et al. 
1996; Taylor, Allen et al. 1998; Conway, Cavanagh et al. 2000; Okenu, Riley et al. 
2000; Meraldi, Nebie et al. 2004; Polley, Mwangi et al. 2004), with yet others 
showing no association, (Dodoo, Theander et al. 1999; Corran, O'Donnell et al. 2004; 
Okech, Corran et al. 2004). It is unclear exactly why the disparity in results should 
exist. It may be they reflect genuine differences in ability of anti-merozoite antigens 
to protect in different settings or it may simply be a methodological issue 
highlighting the difficulties with assessing correlates of immunity.
Cellular immunity to the erythrocytic stage
The infected erythrocyte does not express major histocompatibilty complex (MHC) 
molecules and so is incapable of direct antigen presentation, as a result this stage in 
the life-cycle has generally been thought not to be a target for cell-mediated 
immunity. Recent data however challenge this. Naive individuals never previously 
exposed to P. falciparum infection were challenged with a low dose of blood stage 
parasites and then cured prior to the development of symptoms. It was shown that
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although these individuals were immune to subsequent challenge by the same strain 
of parasite, they developed no detectable antibody response (Pombo, Lawrence et al. 
2002). Rather, protected individuals had marked proliferative T-cell responses 
involving both CD4+ and CD8+ cells, a pro-inflammatory cytokine response 
involving INFy and high concentrations of inducible nitric oxide in PBMC’s. Given 
that naturally acquired immunity is associated with antibodies to erythrocyte surface 
variant antigens, (Marsh, Otoo et al. 1989), as will be discussed in some detail, and 
that cell-mediated immunity is not thought to contribute a great deal to immunity it is 
feasible that the parasite antigens involved in inducing these apparently protective 
responses will be under little immune pressure and therefore may not vary. It is 
interesting to speculate whether or not these mechanisms play in role in protecting 
young children in endemic areas and whether or not their manipulation could provide 
additive efficacy for a malaria vaccine targeting the erythrocytic stage. At present 
the parasite antigens responsible for this response are unknown.
Antibody responses to the infected erythrocyte surface
In 1917 Wagner von Jauregg inoculated tertiary syphilis patients with blood from 
individuals infected with Plasmodium vivax in an attempt to control their disease by 
raising their body temperature. A chance finding had demonstrated the susceptibility 
of Treponema pallidum to heat and malaria-induced fevers were employed as a 
means of eliciting this effect in vivo. Although much work was done using the non- 
falciparum strains of malaria, important information was acquired regarding the 
development of immunity to P. falciparum in humans, reviewed in (Desowitz 1991). 
By infecting patients with P. falciparum isolates from distinct geographical areas and 
by re-infecting using alternative species of malaria it became apparent that to a
degree, development of immunity was both species and, within P. falciparum, strain 
specific (Jeffery 1966; Collins and Jeffery 1999; Collins and Jeffery 1999).
It was the development of schizont-infected cell agglutination (SICA) in 1938 that 
allowed investigation of antibody responses directed at the infected erythrocyte 
surface during the asexual erythrocyte stage of the parasite life cycle (Eaton 1938). 
As discussed, malarial parasites have apparently evolved a perfect ecological niche. 
Their propensity to reside within the erythrocyte during the asexual growth phase of 
the parasite life cycle allowed them ostensible shelter from the host’s immune 
response. As mentioned, erythrocytes lack any surface MHC molecules and thus 
have no mechanism for antigen presentation. However, with the development of the 
SICA assay, Eaton showed that the actual situation was rather more complicated. 
When the asexual intraerythrocytic parasites of P. knowlesi had matured to the 
schizont stage, the infected erythrocytes could be agglutinated by sera from rhesus 
monkeys previously infected with P. knowlesi but not by sera from non-immune 
monkeys. In contrast, uninfected rhesus monkey erythrocytes or erythrocytes 
containing immature asexual parasites were not agglutinated by immune sera (Eaton 
1938). That this reaction only occurred with the more mature intraerythrocytic 
parasite stages implied the presence of stage-specific parasite-induced antigens on 
the surface of the red cell.
Over the ensuing decades the lack of ability to culture P. falciparum parasites in 
vitro necessitated the use of animal models in the attempt to elucidate the complex 
steps in the acquisition of anti-malarial immunity. In 1965, Brown and colleagues 
demonstrated elegantly the variant-specificity of the antibody response directed
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against the infected erythrocyte (Brown and Brown 1965). Utilising the SICA test 
with P. knowlesi parasites in rhesus monkeys, they showed that recrudescent 
parasites from a single inoculum differed in the antigens they expressed on the 
surface of the infected erythrocyte. Each wave of parasitaemia was subsequently 
followed by the presence of antibodies specific to the wave. In a series of influential 
papers this group demonstrated that chronic infections in P. knowlesi malaria were 
apparently maintained by the serial expression of different antigenic types. They 
subsequently showed that whilst protective immunity could not be inferred from the 
presence of SICA antibodies alone, suggesting that these antibodies were just a 
marker of exposure or a downstream marker of a protective response, protection was 
found to be correlated with the presence of variant-specific opsonising antibodies 
directed against the infected erythrocyte (Brown 1971; Brown 1973; Brown and 
Hills 1974).
As these initial experiments were not done with cloned parasite populations, it was 
conceivable that the appearance of different variants during the course of a chronic 
infection could be due to immune selection by sera of sub-populations of parasites 
present within the infecting parasite culture. In 1983, Barnwell and colleagues 
conclusively showed this was not the case when they performed similar experiments 
using a cloned line of P. knowlesi (Barnwell, Howard et al. 1983).
Together, data from experimental models and that inferred from the treatment of 
tertiary syphilis patients, pointed strongly to the development of anti-malarial 
immunity being predominantly variant-specific. However, it was also evident from 
these studies that the density of parasitaemia reduced and the period between
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recrudesences became more prolonged with the appearance of each new variant 
throughout the course of a chronic infection. This was not a result of a reduction in 
parasite virulence as the infection progressed, as, when a new variant was transferred 
into a naive host, they demonstrated the same degree of virulence in terms of 
maximum parasitaemia, pre-patent period and clinical symptoms as the original 
inoculating parasite had in the original host. This observation suggests some degree 
of variant-transcending immunity may exist. This may be due to the induction of 
cross-reactive antibodies to as yet undetermined targets, the development of humoral 
responses against conserved non-variant antigens or even improved variant-specific 
responses perhaps through increased T-cell help.
Human antibody responses to P. falciparum-infected erythrocytes
Studies on the human antibody response to the infected erythrocyte surface were 
made possible by two scientific advances: the first being the successful culturing of 
P. falciparum parasites in vitro, (Trager and Jensen 1976), and the second, the 
development of assays directly measuring antibodies from human sera reacting 
against the infected erythrocyte. These assays included antibody-mediated 
microagglutination similar to the SICA test already described, indirect surface- 
labelled immunofluorescence and adhesion-inhibition on endothelial cells 
(Sherwood, Marsh et al. 1985) (Marsh, Sherwood et al. 1986) (Udeinya, Miller et al. 
1983). As with the SICA test, it was demonstrated that microagglutination of P. 
falciparum-infected erythrocytes only occurred with mature infected erythrocytes, 
specifically late trophozoite and schizont stages. Agglutination occurred in a 
predominantly strain-specific manner and was only mediated by sera from malaria- 
exposed donors (Marsh, Sherwood et al. 1986; Forsyth, Philip et al. 1989; Marsh,
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Otoo et al. 1989; Southwell, Brown et al. 1989; Newbold, Pinches et al. 1992; Smith, 
Chitnis et al. 1995). Adhesion inhibition to endothelial cells also occurs in a strain- 
specific manner and as with agglutination only occurred with sera from malaria- 
exposed donors (Udeinya, Miller et al. 1983). In a direct comparison there was good 
correlation demonstrated between indirect surface-labelled immunofluorescence and 
agglutination (Marsh, Sherwood et al. 1986). Although the agglutination reaction is 
still widely used as a means of assessing antibody reactivity towards the infected 
erythrocyte, more recently flow cytometry has been employed as a means of 
measuring the anti-infected erythrocyte surface antibody response (Piper, Roberts et 
al. 1999; Staalsoe, Giha et al. 1999; Williams and Newbold 2003). As with 
agglutination, sera from malaria-exposed but not naive donors label the infected 
erythrocyte surface. In addition, sera from donors resident within endemic areas only 
label mature infected erythrocytes but not uninfected erythrocytes or erythrocytes 
infected with immature parasites. When individual parasite isolates were used to 
deplete sera of isolate-specific antibodies, reactivity against the isolate used for 
depletion was reduced whereas reactivity against other isolates remained unaltered, 
demonstrating the strain-specificity of the reactivity measured (Staalsoe, Giha et al.
1999). It is important to note however that both for agglutination and flow 
cytometry the precise antigenic target on the surface of the infected red blood cell is 
unknown. Although likely, it is not absolutely certain that both assays are measuring 
responses to the same antigen.
The ability of humans to mount an antibody response to the infected erythrocyte was 
demonstrated in 1986 (Marsh and Howard 1986). Children resident in The Gambia 
naturally infected with P. falciparum, developed isolate-specific agglutinating
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antibody responses against the surface of their own infected erythrocytes during 
convalescence, antibodies absent at the time of the acute infection. Sera from 
uninfected adults from the same area agglutinated a panel of parasite isolates in a 
non-specific manner. These results raised the possibility that if anti-infected 
erythrocyte antibody responses are important in the development of anti-malarial 
immunity, then perhaps adults develop variant-specific immunity towards the 
erythrocyte surface through being exposed to multiple isolates over the course of 
their childhood and adolescence, so-called ‘piecemeal’ acquisition of antibody 
responses. Equally it is possible that some degree of cross-reactivity exists between 
anti-surface responses, allowing adults recognition of conserved, less immunogenic 
epitopes present on the infected-erythrocyte surface.
In an attempt to answer this question, serum from a Gambian adult was used to elute 
antibodies from the surface of infected erythrocytes, obtained from a 
symptomatically infected child. These isolate-specific antibodies agglutinated a 
panel of isolates from children. Serum adsorbed against the same isolate, did not 
agglutinate any of the panel (Marsh and Howard 1986). Although these results 
suggested an element of cross-reactivity within the adult’s antibody response or 
recognition of more conserved epitopes, it must be recognised that while one variant 
may predominate within a natural infection, the likelihood is that there will be many 
variants present in one single inoculum (Marsh and Howard 1986).
Newbold and colleagues questioned the possibility of the presence of cross-reactive 
or conserved epitopes on the surface of the infected erythrocyte in 1992, (Newbold, 
Pinches et al. 1992). Using a differential staining technique, they demonstrated that a
46
mixture of field and laboratory-cultured isolates very rarely formed mixed 
agglutinates when incubated with immune serum. This suggested that the antibody 
response was predominantly variant-specific.
As illustrated in the earlier studies involving P.knowlesi-infected rhesus monkeys, 
(Brown and Brown 1965; Brown, Brown et al. 1968), and as can be inferred from the 
epidemiology of malaria infection and disease in humans, an element of both 
variant-specific and transcending responses must co-exist. In those resident in 
malaria-endemic areas, the observation of the apparently healthy, asymptomatically 
parasitised child who subsequently dies from severe malaria can be satisfactorily 
explained by the presence of variant-specific immunity playing a role in protection, 
with the child becoming infected with a ‘new variant’ or heterologous genotype 
previously not encountered (Collins and Jeffery 1999). Conversely, variant- 
transcending immunity, whether against the infected-erythrocyte surface or to 
another non-variant antigen, is suggested by the severity of clinical disease reducing 
with time and exposure.
In addition to the studies by Marsh and Newbold, variant-specific ‘piecemeal’ 
acquisition of antibody responses has been illustrated in several different 
epidemiological settings (Jeffery 1966; Hommel, David et al. 1982; Bull, Lowe et al. 
1998; Giha, Theander et al. 1998; Giha, Staalsoe et al. 1999; Giha, Staalsoe et al.
2000). As mentioned, deliberate human infections resulted in immunity to both 
homologous and heterologous P. falciparum secondary infections, however, a 
current patent infection did not prevent the development of a clinically symptomatic 
response following infection with a heterologous strain of P. falciparum (Collins and
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Jeffery 1999). In fact, individuals infected with heterologous secondary infections 
displayed less clinical immunity, as measured by duration and extent of fever, than 
they did in response to recrudescent parasitaemia during a chronic infection (Collins
and Jeffery 1999). In 1982, Hommel and colleagues demonstrated that convalescent
\
sera from squirrel monkeys experimentally infected with P. falciparum recognised 
the infecting homologous parasite only (Hommel, David et al. 1982). Furthermore 
antibodies that blocked the cytoadherence of P. falciparum-Qrythrocytes to 
amelanotic melanoma cells were shown to be isolate-specific (Udeinya, Miller et al. 
1983). In Papua New Guinea, children developed variant-specific antibodies 
specific to the infecting parasite isolate during convalescence, with both the 
proportion of isolates recognised and the intensity of recognition increasing with age 
(Forsyth, Philip et al. 1989). Adults in the same study agglutinated a significantly 
wider range of isolates than did children. In Pakistan, only three out of fifteen acute 
sera from infected children agglutinated their infecting isolate. In contrast all fifteen 
convalescent sera agglutinated the corresponding infecting isolate. A panel of 10 
hyperimmune adults from the same region not only recognised the majority of the 
isolates tested but recognised them to a greater degree (Iqbal, Perlmann et al. 1993). 
However, in the studies from Papua New Guinea and from Pakistan, none of the 
adult sera recognised all of the isolates tested, suggesting that rather than recognition 
of conserved epitopes on the infected erythrocyte surface adults developed immunity 
through successive exposures to multiple parasite variants, and, that although it is 
possible that cross-reactivity exists, responses are not pan-specific.
More recently in Kenya, a longitudinal study demonstrated that homologous serum 
taken before the disease episode, rarely agglutinated parasite isolates taken from
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malaria cases at the time of acute disease. In contrast isolates not involved in the 
disease-causing episode were readily recognised (Bull, Lowe et al. 1998). This 
implied that only parasite isolates to which the host does not already possess a 
specific antibody response could cause disease, supporting the notion of a gradual 
acquisition of variant-specific immunity.
In an area of low endemicity in Sudan, agglutinating antibody responses displayed 
marked seasonal variation (Giha, Theander et al. 1998) (Giha, Staalsoe et al. 1999). 
An individual’s ability to agglutinate a panel of isolates at the end of a high 
transmission season was not affected by that individual’s preceding malaria history. 
Those individuals apparently not suffering clinical malaria during the season 
exhibited the same increase in recognition following exposure during the high 
transmission period (Giha, Theander et al. 1998). Furthermore, individuals followed 
over many years for their ability to recognise the infected erythrocyte surface, 
displayed marked variation over time. Clinical disease resulted in a marked and 
specific antibody response that decayed over some months with overall neither the 
disease history of any individual nor the number of episodes of asymptomatic 
parasitaemia showing any relationship with the number of isolates recognised (Giha, 
Staalsoe et al. 1999). This suggests that either the target antigens are extremely 
polymorphic from one high transmission season to the next, or the seasonal 
component of the agglutinating antibody response is of short duration and targets 
relatively conserved epitopes. A recent longitudinal study in Kenya describing the 
kinetics of antibody responses to infecting isolates amongst young children 
demonstrated considerable variation in the ability of an individual to make an 
adequate humoral response and maintain it (Kinyanjui, Bull et al. 2003). Whether
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this variability in response is due to specific innate host factors or is a consequence 
of the particular infecting isolate is unknown.
Thus perhaps this well-illustrated diversity of serological responses to the infected 
red blood cell is not limitless. The adsorption and elution experiments described 
from the Gambia, (Marsh and Howard 1986), identified antibodies from a selection 
of adults which recognised all isolates tested, suggesting a conserved red cell surface 
expressed antigen. Moreover immune sera from adults from East and West Africa, 
South America and South-east Asia agglutinated to varying degrees, erythrocytes 
infected with parasites from East and West Africa (Aguiar, Albrecht et al. 1992). 
This result is somewhat similar to the classical passive transfer experiments whereby 
immunoglobulin from immune African adults dramatically reduced parasitaemia in 
distant regions (Cohen, McGregor et al. 1961) (Edozien, Gilles et al. 1962; 
Sabchareon, Burnouf et al. 1991). A more recent study likewise documented that 
antibody reactivity towards the infected red blood cell surface depended 
predominantly on the transmission characteristics of the site of plasma collection but 
was completely independent of the geographical origin of the parasites (Nielsen, 
Vestergaard et al. 2004). The serological variability of pRBC surface expressed 
antigens may thus be finite.
The induction of antibodies during an acute episode to parasite isolates apparently 
not involved in that episode has been suggested as evidence for cross-reactivity of 
responses against the pRBC surface (Giha, Theander et al. 1998; Chattopadhyay, 
Sharma et al. 2003). Chattopadhyay and colleagues in India, demonstrated using the 
mixed agglutination assay that 20-30% of agglutinates between different wild
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isolates were of mixed colour and from this concluded that there must be common 
epitopes or cross-reactivity of responses (Chattopadhyay, Sharma et al. 2003). 
Although this supports earlier findings by Marsh and Howard, (Marsh and Howard 
1986), caution in interpretation must be advised. As Roberts alluded to in a related 
editorial, the chance of heterologous recognition of different variant types is directly 
related to the proportion of minor variant types within each parasite population 
expressed through antigenic switching. Thus even a low degree of cross-reactivity 
between isolates could result in a high proportion of mixed agglutinates (Smith, 
Chitnis et al. 1995; Roberts 2003). In addition, although one variant may dominate 
in an acute infection, several other variants may well be present; this could lead to 
induction of antibodies to apparently heterologous isolates. Furthermore it may be 
that in both India and in Sudan, where these studies were done, the extent of variant 
surface antigen variability is more limited than that seen in other areas in sub- 
Saharan Africa where transmission is higher. Certainly this cross-induction of 
responses was not seen to the same extent in other areas with higher transmission 
characteristics (Marsh and Howard 1986; Iqbal, Perlmann et al. 1993; Reeder, 
Rogerson et al. 1994; Bull, Lowe et al. 1999).
Several studies have suggested that there may be a subset of serologically distinct 
variant isolates (Bull, Lowe et al. 1999; Bull, Kortok et al. 2000; Nielsen, Staalsoe et 
al. 2002). Initial studies in Kenya indicated that parasites varied considerably in 
their frequency of recognition by antibodies from children. A proportion of isolates 
displayed high frequency of recognition by children and this was independently 
associated with more severe disease and younger host age (Bull, Lowe et al. 1999; 
Bull, Kortok et al. 2000). This association has been confirmed in other areas
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(Nielsen, Staalsoe et al. 2002; Lindenthal, Kremsner et al. 2003). Those parasites 
less frequently recognised tended to come from older children with uncomplicated, 
milder disease. It would appear that the antigenic determinants of recognition 
amongst the frequently recognised parasites represent a less diverse group of variant 
surface antigens, with the size of the agglutinate formed being positively correlated 
with the degree of recognition (Bull, Kortok et al. 2000). The degree of recognition 
of an isolate on the other hand is not related to the number of parasite genotypes 
present in the infection (Bull, Kortok et al. 2000). More recently it has been shown 
that the more frequent recognition of parasites causing severe disease cannot be 
explained in terms of the antibody repertoire at the time of disease. In a recent 
analysis of data from Kenya, there was no significant difference between those 
children with non-severe disease and those with severe disease in terms of their anti­
erythrocyte surface antibody repertoire at the time of acute disease (Bull P.C. in 
press), a finding also seen amongst children in The Gambia (Erunkulu, Hill et al. 
1992). Thus if children who suffer an episode of severe disease are in some way less 
immune than those who don’t it is not reflected in their heterologous anti-variant 
surface antigen antibody repertoire at the time of acute disease.
Anti-infected erythrocyte antibodies and protection from malaria
Studies investigating which immune responses to the infected erythrocyte confer 
protection against clinical malaria are problematic. Children residing in malaria- 
endemic areas are constantly challenged by P. falciparum and are thus frequently 
infected. Because of the ubiquity of infection children develop antibody responses 
to a wide range of parasite antigens, the range of which increases with age. 
Differentiating those responses that are protective from those simply reflecting
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exposure has proven difficult. The first study to definitively show an association 
between antibodies to the infected erythrocyte and protection from clinical disease 
was carried out by Marsh and colleagues in 1989 (Marsh, Otoo et al. 1989). 
Agglutinating antibodies directed against the surface of a randomly selected wild 
isolate was the only immunological assay associated with protection from 
subsequent clinical malaria. Since then studies examining humoral responses against 
the erythrocyte-surface and their association with protection from clinical disease 
have yielded conflicting results. It is clear that following infection individuals 
develop antibodies specific to the infecting isolate (Bull, Lowe et al. 1998; Giha, 
Staalsoe et al. 2000; Chattopadhyay, Sharma et al. 2003). What is less clear is how 
relatively cross-reactive responses, assessed using heterologous isolates, are involved 
in protection from disease. In Kenya, the ability of sera to agglutinate a randomly 
selected isolate was not associated with protection (Bull, Lowe et al. 1998; Bull, 
Lowe et al. 2002). However in Sudan, antibodies directed against an isolate from 
Ghana were associated with protection while antibodies to six Sudanese isolates 
were not. Similarly, in Ghana responses to a Sudanese isolate and to a Ghanaian 
isolate demonstrated an association with protection but responses to another 
Ghanaian isolate did not (Giha, Staalsoe et al. 2000; Dodoo, Staalsoe et al. 2001). 
This data together with the results from the Gambia already mentioned (Marsh, Otoo 
et al. 1989); suggest that responses to some isolates but not others are associated 
with protection. It may be that antibodies directed against these isolates are 
genuinely more protective or that these isolates are in some way different in the 
antigens expressed. They may express to a greater degree a cross-reactive or 
conserved sub-set of variant antigens. Alternatively, these results may simply reflect
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differences in prevalence and the ability of these measured responses to act as 
surrogate markers of protection.
It should be noted however that in none of these studies was asymptomatic 
parasitaemia taken into account at the time the sera were assayed. Several studies 
have demonstrated an association between P. falciparum infection and enhanced 
anti-pRBC antibody responses to heterologous isolates (Iqbal, Perlmann et al. 1993; 
Giha, Staalsoe et al. 1999; Giha, Staalsoe et al. 1999; Ofori, Dodoo et al. 2002) In 
support of this, more recent data from Kenya demonstrated that the proportion of 
heterologous isolates agglutinated was strikingly higher amongst children with a 
microscopically detectable parasitaemia at the time of assay compared to those 
without and that this association was not just due to cumulative exposure (Bull, 
Lowe et al. 2002). As the sera in this study were assayed at the end of a dry season 
these asymptomatic parasite infections will have most likely been sustained as 
chronic infections since the preceding rainy season. It can be conjectured that a 
degree of cross reactivity may exist within the antibody repertoire induced by such 
infections, with the constant presence of a range of antigenic variants over time 
serving to continuously boost the otherwise rapidly decaying antibody response. 
Alternatively, it may be that these chronic infections have had longer to switch 
antigenic variants displayed thus inducing a broader range of antibody specificities.
A subsequent study using flow cytometry again demonstrated an enlarged repertoire 
of anti-infected red blood cell surface antibodies amongst those children with a 
microscopically detectable parasitaemia (Kinyanjui, Mwangi et al. 2004). 
Furthermore the presence of asymptomatic parasitaemia and anti-infected
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erythrocyte antibodies directed at heterologous isolates together was associated with 
protection against subsequent clinical malaria compared to either alone (Kinyanjui, 
Mwangi et al. 2004), a finding also seen with severe malaria (Bull, Lowe et al. 2002). 
Independently both the presence of heterologous anti-surface antibodies in the 
absence of parasites and the presence of parasites with no concurrent heterologous 
antibody response were associated with susceptibility to clinical malaria during the 
subsequent six months. The mechanisms underlying these associations are presently 
unknown. It may be that the development of immunity against clinical malaria is 
associated with the ability to maintain chronic asymptomatic infections. This 
hypothesis is supported by the observation that, with age, disease incidence 
decreases at a time when the prevalence of parasitaemia increases (Marsh 1992). 
The increased susceptibility observed in those with parasites and poor concomitant 
heterologous antibody responses might reflect a poor inherent ability to respond 
appropriately. Such children have been reported in a number of studies (Giha, 
Staalsoe et al. 1999; Ofori, Dodoo et al. 2002; Kinyanjui, Bull et al. 2003) although 
on individual basis it is not known if these children are actually more susceptible to 
clinical malaria. Having antibodies in the absence of detectable parasitaemia may 
simply indicate a recently treated symptomatic infection and may thus be reflective 
of a sub-population of individuals at increased risk in terms of either challenge or 
inherent host susceptibility factors. Of course these differences in susceptibility may 
simply be highlighting differences in exposure and thus risk between the groups. 
Those with parasites at the time of sampling have a defined exposure, whereas those 
without parasites will be a more heterogeneous group in terms of likelihood of risk 
and thus any difference in protection or susceptibility may be more difficult to 
disentangle.
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It seems clear that following repeated challenge individuals become progressively 
better equipped to handle a larger proportion of the possible variants they are 
exposed to. This process is undoubtedly complex and the resultant functional 
immunity will consist of many components. It would appear though, from 
epidemiological and modelling data that the development of anti-disease immunity 
occurs faster than would be expected if it purely depended on encountering all 
possible locally relevant variants (Gupta, Snow et al. 1999). It is likely that 
responses to different stages of the life-cycle will be additionally and simultaneously 
relevant and that as well as a strong and protective variant-specific response there 
will be both an element of cross-protection amongst selected antigens and possibly a 
slower to develop but functionally extremely important response against less 
immunogenic conserved targets.
Antigenic targets on the P. falciparum -infected red blood cell surface
The isolate-specific agglutination of infected erythrocytes by sera from malaria- 
immune hosts along with the observation that immune sera did not agglutinate 
uninfected or immature-infected erythrocytes, led to the hypothesis that there must 
be new, malaria-specific antigens expressed on the surface of infected erythrocytes 
(Eaton 1938). This finding as well as the observation that only young ring-stage 
infected-erythrocytes were present in the peripheral blood of individuals infected 
with P. falciparum led to the understanding that the parasite must modify the surface 
of the erythrocyte it invades. Since this became apparent, the challenge to identify, 
sequence and understand the function of these surface-exposed molecules has proven 
not only demanding but also important. Many parasite-induced proteins and altered
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host proteins have been identified on the surface of P. falciparum infected 
erythrocytes including RIFIN, STEVOR, SURFIN and altered band 3 (Cheng, 
Cloonan et al. 1998; Kyes, Rowe et al. 1999) (Crandall, Collins et al. 1993; Winter, 
Kawai et al. 2005). However, the best characterised and most studied of these 
proteins is Plasmodium falciparum erythrocyte membrane protein-1 (P/EMP1).
iyEMPi
In 1984, Leech and colleagues identified a high molecular weight, strain-specific 
protein present on the surface of P. falciparum-infected erythrocytes(Leech, 
Barnwell et al. 1984). Using Camp and St Lucia strains of parasites, a 200-250kDa 
weight protein was specifically immuno-precipitated by immune sera from Aotus 
monkeys infected with the homologous strain of parasites. Sera from monkeys 
infected with a heterologous strain did not immuno-precipitate the same protein. 
These surface-exposed proteins were sensitive to low concentrations of trypsin and 
the antibodies which resulted in their immuno-precipitation blocked binding of 
infected erythrocytes to melanoma cells in a strain-specific manner (Leech, Barnwell 
et al. 1984; Howard, Barnwell et al. 1988). The protein was not extracted from 
infected erythrocytes by a non-ionic detergent such as Triton X-100 but was 
extracted with sodium dodecyl sulphate (SDS), suggesting linkage to the erythrocyte 
cytoskeleton (Aley, Sherwood et al. 1984). This family of proteins became known 
as Plasmodium falciparum erythrocyte membrane protein 1(P/EMP1).
P/EMP1 has been implicated in two key phenomena responsible for much of the 
pathology associated with P. falciparum infections: cytoadherence of pRBC, 
including rosetting of uninfected erythrocytes and immunoregulatory effects on host
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immune effector cells through binding to other host effector molecules and antigenic 
variation with resultant immune evasion
Erythrocytes infected with the mature forms of P. falciparum disappear from the 
peripheral circulation, a phenomenon known as sequestration (Bignami and 
Bastianeli 1889). Sequestration results from the cytoadherence of infected 
erythrocytes to a variety of host receptors situated on endothelial cells in most organs 
of the human body (Miller 1969; Luse and Miller 1971; Gilks, Walliker et al. 1990). 
P/EMP1 is associated temporally with the appearance of knob-like protrusions on 
the pRBC surface, (Leech, Barnwell et al. 1984), knobs themselves being associated 
with the expression of i^EMPl (Aley, Sherwood et al. 1984; Leech, Barnwell et al. 
1984). Erythrocytes bearing more mature parasites attach themselves to endothelial 
cells via these knobs (Luse and Miller 1971; Kilejian 1979; MacPherson, Warrell et 
al. 1985). However it must be noted that knobless laboratory cloned isolates have 
also been shown to bind to endothelial cell receptors and a protein with the 
characteristics of P/EMP1 has been immunoprecipitated from the surface of these 
knobless clones (Biggs, Gooze et al. 1990). In fact recent data has highlighted that 
in the absence of knobs P/EMP1 clusters in a similar way although around 50% less 
is expressed on the surface of infected erythrocytes (Horrocks, Pinches et al. 2005). 
This finding supports earlier work showing that although adherence to CD36 (a 
characteristic attributable to P/EMP1) is maintained in the absence of knobs, the 
attachment is much weaker and more easily disrupted under flow (Crabb, Cooke et al.
1997).
There is now overwhelming evidence that P/EMP1 is the principal parasite receptor 
mediating cytoadherence. In 1996 Gardner and colleagues described the abrogation
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of binding of various parasite clones to a number of previously described endothelial 
cell receptors through pre-treatment of mature pRBC with trypsin, thus 
demonstrating that the parasite receptor mediating cytoadhesion had characteristics 
similar to those of PyEMPl (Gardner, Pinches et al. 1996). Conclusive evidence for 
the role of P/EMP1 in sequestration came when affinity purification of detergent 
extracts of radio-iodinated infected cells using known host endothelial cell receptors, 
ICAM-1, CD36 and TSP, yielded proteins with all the properties of P/EMP1 (Baruch, 
Gormely et al. 1996).
Simian malaria models were the first to provide evidence for antigenic variation 
(Brown and Brown 1965; Brown, Brown et al. 1968; Brown 1973; Barnwell, 
Howard et al. 1983; Handunnetti, Mendis et al. 1987). The first direct evidence that 
P. falciparum also underwent antigenic variation came in 1983 by Hommel and 
colleagues (Hommel, David et al. 1983). By infecting Saimiri monkeys with P. 
falciparum and serotyping the resultant peaks of parasitaemia using indirect surface 
immunofluorescence, they demonstrated that each wave of parasitaemia was 
associated with antigenically distinct determinants present on the surface of the P. 
falciparum-infected red blood cells. Studies with cloned parasites demonstrated that 
antigenic variants arose with extraordinary frequency, switching away from an 
existing antigenic and adhesive phenotype at a rate of up to 2% per generation in the 
absence of immune selection (Roberts, Craig et al. 1992).
A subsequent series of experiments linked the antigenic and adhesive properties of P. 
falciparum-infected erythrocytes with the modulation of PfPMPl. In a family of 
sub-clones derived from a parental clone that displayed binding to ICAM-1, changes 
in the capacity to bind to ICAM-1 within the daughter clones were always associated
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with a change in antigenic type (Roberts, Craig et al. 1992). In a separate set of 
experiments, parasites derived from a single clone were selected for their capacity to 
bind to endothelial cells. These selected parasite lines reacted with agglutinating 
antiserum that failed to react with the parental clone. Immunoprecipitation with this 
agglutinating serum demonstrated that the selected daughter clones expressed a 
larger and antigenically discrete variant of P/EMP1 that was cross-reactive amongst 
the daughter clones but distinct from that expressed by the parental clone (Biggs, 
Anders et al. 1992). A fuller understanding of these pathogenic processes requires 
an in depth understanding of the genetic control mechanisms underlying 
transcription and expression of this family of proteins.
Var genes
P/EMP1 is encoded by a family of genes called var (Baruch, Pasloske et al. 1995; 
Smith, Chitnis et al. 1995; Su, Heatwole et al. 1995). The finding that within each 
haploid P. falciparum genome there are around 60 copies of these genes, that 
dramatic sequence variation exists among the gene copies, and that the encoded 
protein domains all exhibited receptor binding properties firmly established the var 
genes and their products as the major determinants of cytoadherence and antigenic 
variation within the P. falciparum genome (Baruch, Pasloske et al. 1995; Smith, 
Chitnis et al. 1995; Su, Heatwole et al. 1995).
The resultant encoded proteins are mostly extracellular. They exhibit a domain 
structure and the domains bear homology to the cysteine-rich binding domains of 
varied Plasmodium molecules involved in the binding to and invasion of 
erythrocytes. These include EBA-175, the P. falciparum glycophorin A receptor and
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the Plasmodium vivax and Plasmodium knowlesi ligands that allow invasion of 
Duffy blood-group positive erythrocytes (Adams, Sim et al. 1992; Chitnis and Miller 
1994; Sim, Chitnis et al. 1994). It was for this latter reason these P/EMP1 domains 
were termed Duffy-binding like domains (DBL). They are interspersed with regions 
containing multiple cysteine residues termed the cysteine-rich interdomain regions 
(CIDR).
Var genes are encoded in two exons, (figure 1.6). The first exon encodes the 
exposed extracellular region and the transmembrane domain. It is highly variable 
both in length and sequence and encodes between 2 and 7 DBL domains and, in the 
majority of cases, at least one CIDR domain. The second exon, in contrast, is 
relatively short, highly conserved and encodes the intracellular domain or acidic 
terminal segment. This segment is hypothesized to anchor the protein to the infected 
erythrocyte cytoskeleton (Oh, Voigt et al. 2000; Waller, Nunomura et al. 2002). In a 
recent study investigating the relatedness of DBL domains within different PyEMPl, 
sequences from 20 R/EMP1 variants were analysed and 65 DBL domains identified 
(Smith, Subramanian et al. 2000). A phylogenetic tree was constructed using the 
sequences of these DBL domains along with the DBL domains of EBA-175 of P. 
falciparum, P.knowlesi and P. vivax. Within this analysis the DBL domains of the 
EBA proteins grouped closely together, with the DBL domains of P. knowlesi and P. 
vivax EBA being very closely related. By comparison the P/EMP1 DBL domains 
have diverged significantly from their probable ancestral origin and within 
themselves grouped into five statistically diverse sequence groups. These groups 
were named a, (3, y, 8 and s. Using a similar methodology, three classes of CIDR 
were identified, a, (3 and y (Smith, Subramanian et al. 2000). A small number of
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domains present within the genome studied, P. falciparum clone 3D7, did not fit well 
into the existing classification and as a result these were termed DBL-x or CIDR-x 
(Gardner, Hall et al. 2002). Despite the sequence signatures allowing each domain 
type to be classified, there was little sequence homology even amongst domains of 
the same type. In fact, the sequence similarity overall of the var genes encoded 
within the 3D7 genome ranges from 24-98% (Flick and Chen 2004). Var genes are 
present on all 14 chromosomes of the genome of P. falciparum clone 3D7. 24 are 
situated at the telomere and with two exceptions all the sub-telomeric var genes are 
transcribed towards the centromere. The two exceptions, situated on chromosomes 7 
and 11 are oriented towards the telomere. Also oriented towards the telomere is a 
var pseudo-gene situated on chromosome 5 (Gardner, Hall et al. 2002). This gene, 
known as 3D7chr5var2, consists of a truncated exon 1 with a deletion at the end of 
DBL7s and no intron or exon 2 intracellular sequences making it unlikely that this 
particular var gene will encode a functional protein. Despite this, it caused 
considerable interest subsequent to the publication of the genome. The 5’ end of this 
var pseudogene was shown to be highly expressed amongst CSA-binding isolates 
and within wild isolates taken from children suffering from malaria (Rowe, Kyes et 
al. 2002; Winter, Chen et al. 2003). Such an observation might suggest it has an 
important function although precisely what this is is currently unknown. It would 
seem that as not all isolates have such a var homologue, it must not be essential for 
survival (Winter, Chen et al. 2003).
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A further 12 var genes are located near the telomere with the remainder forming 
internal clusters on chromosomes 4, 6, 7, 8 and 12. Analysis of sequences 1.5kb 
upstream of the var genes has revealed three distinct and conserved flanking regions 
of sequences, nominally ups A, B and C (Gardner, Hall et al. 2002; Kraemer and 
Smith 2003; Lavstsen, Salanti et al. 2003). These regions show preferential 
association with different var genes, upsA associated var genes are always sub- 
telomeric, upsC var genes are always chromosome-internal and upsB var genes can 
be situated in either location (Voss, Thompson et al. 2000). Additionally, 
transcription of upsA var genes is always towards the telomere and upsB associated 
var genes away from the telomere. Internal upsB and C associated vars are arranged 
in head to tail clusters and within the 3D7 genome there are single copies of separate 
upsD and E promoters associated with unusually conserved single-copy var genes.
More recently a classification of var genes was proposed taking into account 
chromosomal location, transcriptional direction, domain structure of the encoded 
proteins and sequence similarity among coding and non-coding regions (Lavstsen, 
Salanti et al. 2003). They were divided into three discrete groups, A, B and C with a 
farther two groups B/A and B/C, representing those genes whose characteristics fall 
between the three groups.
Those genes in group A represent var genes encoding large and complex E/EMP1 
proteins. The var genes in groups B and C bind to CD36 via CIDR, whereas 
recombinant CIDR proteins originating from group A var gene sequences do not 
bind CD36 (Robinson, Welch et al. 2003). The largest var group in 3D7 constitute
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the group B genes. These comprise 22 genes all but one of which are situated in the 
telomeric region. They all share a conserved 5’ upsB region. The 13 genes of group 
C are all located internally.
The var gene repertoire of around 60 copies per haploid genome is relatively small 
compared to multigene families of other eukaryotic protozoa involved in antigenic 
variation (Rudenko 1999). It is therefore not surprising that large sequence diversity 
exists between different P. falciparum isolates (Su, Heatwole et al. 1995). Using in- 
situ hybridisation techniques it was demonstrated that genetically diverse parasites 
contained essentially, although not completely, non-overlapping var gene repertoires 
(Freitas-Junior, Bottius et al. 2000). This proposed discrete strain structure of var 
gene repertoires, whilst indicative of the extreme diversity of var genes, is in 
accordance with modelling work whereby immune pressure results in genomic 
organisation into stable antigenic types (Gupta and Anderson 1999). The small 
extent of overlap that exists, blocks of between 20 and 80 amino acids, between 
sequences of both laboratory-strains and wild isolates suggests that recombinational 
reshuffling of var genes also exists (Ward, Clottey et al. 1999; Taylor, Kyes et al. 
2000). As has been described, the majority of var genes are located at the telomeric 
ends of chromosomes, (Gardner, Hall et al. 2002). It has also been demonstrated, 
using fluorescence in situ hybridisation, that within the P. falciparum nuclei the 
chromosome ends cluster at the periphery (Freitas-Junior, Bottius et al. 2000). This 
alignment of chromosome ends will physically position non-homologous 
chromosomes in close proximity with one another so providing a structural set-up for 
recombination events in this area. This proposed telomere-mediated enhancement of
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recombination would have the effect of increasing the relatively modest var gene 
repertoire available to the parasite.
Regulation of var gene expression
Using clonal parasite lines selected for specific phenotypes and thus specific 
expressed P/EMP1 proteins, a number of important findings regarding var gene 
expression and control were elucidated. Firstly, expression of var genes is 
temporally regulated during parasite development. Secondly, telomeric as well as 
internal var genes located on different chromosomes can be selected for expression. 
Thirdly, the expression of var genes is mutually exclusive, i.e. only one member of 
the var gene family is expressed on the surface of an individual infected erythrocyte 
(Chen, Fernandez et al. 1998; Scherf, Hemandez-Rivas et al. 1998; Kyes, Pinches et 
al. 2000).
The expression of P/EMP1 is developmentally regulated with the protein appearing 
on the surface of the infected erythrocyte around 16-18 hours post-invasion 
coincident with cytoadhesion (Gardner, Pinches et al. 1996). It would appear that 
the control of var gene transcription is also tightly regulated and stage-specific. Two 
different experimental approaches investigating this issue have led to two opposing 
hypotheses. Using Northern blot analysis it was shown that the major var mRNA 
transcript encoding the P/EMP1 destined for expression on the erythrocyte surface 
was present at maximum amounts in late-ring stages declining until barely detectable 
by the trophozoite stage (Kyes, Pinches et al. 2000). No other var transcripts were 
detectable by Northern blot leading to the supposition that control of var gene 
expression is maintained at the level of transcription initiation. This contrasts with
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data whereby reverse transcriptase and polymerase chain reaction (RT-PCR) has 
been employed as a means of detecting mRNA transcripts within a single infected 
erythrocyte. Results from these experiments would suggest that multiple var 
transcripts are present in ring stages with one dominant transcript present by the 
trophozoites stage (Chen, Fernandez et al. 1998; Scherf, Hemandez-Rivas et al.
1998). These results imply a post-transcriptional mechanism of control. It is 
interesting to note that RT-PCR picks up transcription of sporozoite and gametocyte 
stage-specific genes during the asexual cycle as well as multiple var transcripts. 
Perhaps then, RT-PCR is too sensitive a tool in detecting short transcripts and as a 
result is unable to distinguish between background low levels of transcription and 
meaningful specific activation.
Interestingly repression of var gene transcription during intraerythrocytic 
development of the parasite occurs at different times depending on the location of 
the var gene. Inhibition of subtelomeric var gene transcription occurred between 4 
and 8 hours before that of centrally located vars. This illustrates that the structural 
differences of the three types of promoter reflect functional and regulatory 
differences in transcriptional repression (Voss, Kaestli et al. 2003). Whether these 
differences in control reflect differences in function and virulence with regards the 
different subsets of var gene remains to be seen. It is interesting to note however 
that var genes located subtelomerically are subject to frequent ectopic recombinant 
events compared to the more stable internally located var genes (Freitas-Junior, 
Bottius et al. 2000). Also of note is the finding that upsA-associated var genes, i.e. 
those situated subtelomerically, were more commonly expressed by parasites 
selected to express a phenotype (high frequency of recognition) similar to that found
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in parasites isolated from cases of severe malaria (Jensen, Magistrado et al. 2004). 
This is consistent with the observation that var genes expressed from cases of severe 
malaria in Brazil, were more likely to have less cysteines present within the DBL la  
domain, a feature more common in var genes associated with the upsA promoter, 
(Kirchgatter and Portillo Hdel 2002), and also from work describing the expression 
of longer PfEMP 1 molecules being more common in parasites from cases of severe 
malaria (Bian, Wang et al. 1999).
Excitingly very recent data has given more weight to the differential regulation of 
expression of var genes from different genomic locations. A homologue to the yeast 
protein SIR2 (silent information regulator 2), known to have a role in silencing 
telomerically situated genes through alterations in chromatin compaction, called 
PySIR2, was found to have a similar role in P. falciparum. Parasites with this gene 
knocked-out showed increased transcription of a sub-group of sub-telomerically 
situated var genes. It was also demonstrated that within the nucleus changes in 
spatial location of the telomeres was associated with active transcription of 
telomerically situated genes (Duraisingh, Voss et al. 2005; Freitas-Junior, 
Hemandez-Rivas et al. 2005). This has been demonstrated in trypanosomes where 
movement of a gene into a specific nuclear compartment allowed full transcription of 
this locus to the exclusion of all others (Navarro and Gull 2001). Whether a similar 
mechanism exists in P. falciparum remains to be seen.
The presence of the previously mentioned 5’ flanking regions, specific to the 
different var types (upsA, B and C) and strongly correlated with chromosomal 
location as described, implies that regulation of transcription does not rely on the
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presence of generalised var gene-specific transcription factors but rather every var 
gene represents a single transcriptional unit capable of in situ activation (Deitsch, del 
Pinal et al. 1999; Voss, Thompson et al. 2000). Removal of the promoter from its 
chromosomal location abrogates the silencing of the corresponding var gene 
(Deitsch, del Pinal et al. 1999). This finding was extended by the observation that 
silencing of var gene transcription requires cooperative interaction between the 
specific promoter and conserved sequences within the var gene intron (Deitsch, 
Calderwood et al. 2001). This finding is especially interesting when considering the 
previously described conserved var pseudogene 3D7chr5var2. It is known that this 
gene is missing a substantial portion of its intron and that it is constitutively 
transcribed in around 60% of field isolates as well as many laboratory-adapted 
isolates (Kyes, Christodoulou et al. 2003; Winter, Chen et al. 2003). It may be that 
this pseudogene has lost the ability to silence itself.
Despite this inherent capability for activation, var gene expression occurs in a 
mutually exclusive way. It was observed that neither the chromosomal location nor 
the DNA sequence altered when comparing those var genes in the active state with 
those silenced, not only implying transcriptional control but also epigenetic 
mechanisms at work. It would appear from work undertaken in other organisms, 
that histone modification including acetylation, phosphorylation and methylation 
plays an important role in epigenetic regulation of gene expression. It is of interest 
that the P. falciparum genome identified an extensive range of genes involved in 
chromatin assembly and histone modification (Aravind, Iyer et al. 2003). This is 
supported by data showing repression of subsets of var genes through inhibition of
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histone acetylation: a function of the P/SIR2 protein as described previously 
(Duraisingh, Voss et al. 2005; Freitas-Junior, Hemandez-Rivas et al. 2005).
Despite the data supporting a transcriptional and epigenetic level of gene control 
there is a growing body of thought postulating that post-transcriptional gene 
silencing (PTGS), may indeed be the predominant mechanism by which one var 
gene is ultimately selected for expression (Borst, Bitter et al. 1995). In P. knowlesi, 
the homologues of the var genes are called SICAvar and these share many of the 
same biochemical and variant properties of the var genes (al-Khedery, Barnwell et al.
1999). Many transcripts relating to the 3’ end of SICAvar genes are detectable at 
both the ring and trophozoite stages of development. This observation led some 
groups to hypothesize that PTGS may be functioning in P. knowlesi perhaps through 
an RNAi-mediated route (Galinski and Corredor 2004). In support of this viewpoint, 
antisense spliced SICAvar RNA is present throughout the intraerythrocytic 
development of the parasite, which may represent the products of RNA dependent 
RNA polymerase functioning to create double stranded RNA as would occur in a 
functioning RNAi system (Denli and Hannon 2003). Furthermore Plasmodia spp. 
have recently been shown to posses the ability to process double-stranded RNA into 
small 25 nucleotide RNA packets, an intrinsic quality of RNAi mediated PTGS 
(Malhotra, Dasaradhi et al. 2002). Despite this result however, it seems unlikely this 
is the predominant mechanism operating in P. falciparum as the necessary genes are 
not identifiable within the P. falciparum genome {C. Newbold personal 
communication}.
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Other P. falciparum polymorphic gene families
The publication of the P. falciparum genome in 2002 highlighted the significant 
proportion of the genome devoted to multigene families, suggesting the importance 
of immune evasion to the parasite (Gardner, Hall et al. 2002). In addition to the var 
genes, are the families r if stevor, pf60 and surf (Weber 1988; Carey, Bonnefoy et al. 
1994; Cheng, Cloonan et al. 1998; Winter, Kawai et al. 2005).
The r if  (repetitive interspersed family) family of genes was discovered in 1988 when 
interspersed repetitive DNA was isolated from a genomic library of P. falciparum. 
Northern blot analysis identified that this sequence was transcribed during late 
asexual growth stages within the erythrocyte, however no protein translation 
initiation codon could be located and protein products were not detected (Weber 
1988). Subsequent analysis of the P. falciparum genome revealed not only that there 
were an extremely high copy number of these genes, 149 in the 3D7 genome, but 
also that 300bp upstream of each r if  gene was a sequence encoding a translational 
start and a putative signal sequence (Gardner, Hall et al. 2002). The r if  genes have 
a two exon structure and are located subtelomerically on all 14 chromosomes. The 
first exon encodes a signal peptide and the second, a putative transmembrane region 
and a polymorphic extracellular domain, which includes conserved cysteine residues 
and a highly variable region (Cheng, Cloonan et al. 1998). A further 
transmembrane region follows the extracellular domain with a short, conserved 
cytoplasmic tail. The proteins encoded by these genes (RIFINS) are expressed in the 
late ring or early trophozoite stage and are located on the surface of the infected red 
blood cell temporally associated with the expressed var gene product (Fernandez, 
Hommel et al. 1999; Kyes, Rowe et al. 1999; Kyes, Pinches et al. 2000). Each
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RIFIN protein is around 30-40kDa in size, undergoes antigenic variation and is a 
target for naturally occurring antibodies in sera from adults in endemic areas (Abdel- 
Latif, Khattab et al. 2002). The precise function of the expressed r if  genes is 
presently unknown however their co-localisation on the surface of infected red blood 
cells with P/EMP1 as well as their close proximity with var genes at the telomeres, 
have led to speculation that they are involved in either trafficking of PJEMP1 or 
regulation of expression of var genes.
A third multigene family, stevor (subtelomeric variable open-reading frame), closely 
related in terms of structure and chromosomal location, to the r if  gene family was 
identified in 1990 (Limpaiboon, Taylor et al. 1990). Each stevor gene encodes a 30- 
40kDa protein and like the r if  genes have a two exon structure. A short first exon 
similar in both families encodes a start codon and predicted signal sequence. The 
second exon is shorter than that found in the r if genes, lkb compared to 1.3kb, and 
encodes a hypervariable area flanked by transmembrane domains (Cheng, Cloonan 
et al. 1998). The genome-sequencing project highlighted that all 28 stevor genes 
present within the 3D7 genome share this domain pattern. The r if  genes display a far 
less uniform structure as a family (Gardner, Hall et al. 2002). As with the r if  genes, 
stevor genes are located subtelomerically on all 14 chromosomes. Multiple stevor 
transcripts have been detected within a single parasite, with peak transcription 
occurring at around 28 hours post invasion of the red cell, coinciding with the mid­
trophozoite stage, later than expression of both the r if  and var gene families 
(Kaviratne, Khan et al. 2002). It is unclear presently, whether the presence of 
multiple transcripts is correlated with the expression of more than one expressed 
STEVOR product. Immunofluoresence experiments using monoclonal and
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polyclonal antibodies raised against STEVOR proteins have demonstrated that the 
expressed protein does not localise to the red cell membrane but rather migrates to 
the Maurer’s clefts (Kaviratne, Khan et al. 2002). Maurer’s clefts are membranous 
structures situated just beneath the red cell membrane, which have been implicated 
in the transport of parasite products to the surface of the red cell. At the time of 
STEVOR expression, late trophozoites and schizonts are already sequestered and 
have expressed on their surface both P/EMP1 and RIFIN proteins. It would seem 
thus that the function of STEVOR is clearly distinct from that of the RIFIN proteins 
despite being extremely similar gene families in terms of structure and location 
within the genome. More recently expression of STEVOR proteins has been 
observed in sporozoites and gametocytes. In gametocytes, stevor transcripts appear 
transiently early in development but STEVOR proteins persist for several days and 
are transported out of the parasite, travel through the host cell cytoplasm, and 
localize to the erythrocyte plasma membrane. In contrast to asexual parasites, 
gametocytes move STEVOR to the periphery via a trafficking pathway independent 
of Maurer's clefts. In sporozoites, STEVOR proteins appear dispersed throughout the 
cytoplasm in vesicle-like structures. It is likely that STEVOR variants perform 
different functions in each stage of the parasites life cycle in which they occur 
(McRobert, Preiser et al. 2004).
The Pf60 family, which shares a high degree of homology with the second exon of 
the var genes, is composed of approximately 90 copies per haploid genome (Carey, 
Bonnefoy et al. 1994). It is clear from the genome project that the majority of these 
genes are pseudogenes as they contain frameshifts or internal stop codons (Gardner, 
Hall et al. 2002). However one member of this family has been fully characterised 
and unusually a mature protein is expressed through the presence of additional 5’
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exons allowing a translational frameshift (Bischoff, Guillotte et al. 2000). The 
mature protein is located in the nucleus. How many other mature proteins are 
similarly expressed or whether or not this mechanism of translational frameshifting 
is employed in the expression of other P. falciparum proteins is unknown.
The most recently discovered family of polymorphic antigens are the SURFINS 
(Winter, Kawai et al. 2005). At present 10 copies of this family of genes, denoted 
surf have been described within the 3D7 genome, and located on five chromosomes 
at or near the telomere. Structural and sequence similarity has been described to 
PfEMPl as well as to other surface-exposed proteins of different Plasmodium 
species, PvSTPl, PkSICAvar, PvVIR, Pf332 (Winter, Kawai et al. 2005).
Antigenic variation
Organisms that rely on an insect vector to complete their life cycle or exist in an 
ecological niche where transmission can be sporadic or seasonal have evolved tactics 
to ensure their survival through maintenance of infection within the mammalian host. 
These include Trypanosoma spp., Borelia spp. and Neisseria spp as well as 
Plasmodia spp. These pathogens all undergo clonal antigenic variation. Surface 
molecules exposed to the host immune response, are encoded in the genome as 
multi-copy gene families. Antigenic variation occurs by the successive switching of 
members of these families, each variant having little or no immunological cross­
reactivity. The precise signals involved in promoting a switch and the molecular 
mechanisms that underpin antigenic variation are complex and difficult to 
disentangle.
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Chronic infection is characterised by successive peaks of parasitaemia associated 
with the development of antibodies specific to each peak. As discussed each P. 
falciparum parasite has a var gene repertoire of around 60 and in vitro cloning 
studies show that switching away from a parental variant type can occur at a rate of 
up to 2% per generation in the absence of immune pressure (Roberts, Craig et al. 
1992). If this switching rate occurred to the same degree in vivo, the parasite would 
rapidly exhaust its variant repertoire. Instead, as well as new repertoires of variant 
antigens becoming available for selection through telomeric mitotic recombination 
events, it is likely that there is a wide range of switch rates, with expression of some 
variants occurring more frequently than others. This could potentially result in a 
hierarchy of expression determined by different switch rates. This is certainly the 
case with P. fragile infections in the toque monkey (Handunnetti, Mendis et al. 
1987), and has been predicted from modelling work to occur in P. falciparum 
(Molineaux and Dietz 1999; Molineaux, Diebner et al. 2001). Indeed, mosquito- 
induced experimental infections in human volunteers highlighted a switching rate 
away from the initial dominant expressed var gene of 16% per generation, much 
higher than the 2% described in vitro. Subsequent switching occurred at a slower 
rate (Peters, Fowler et al. 2002). The composition and frequency of var transcripts 
in the parasites isolated from the human volunteers were dramatically different from 
the parent parasite used to infect the mosquito. There would thus seem to be a 
complete changeover in var gene expression after parasites pass through the 
mosquito vector. The pattern of subsequent transcription, at least early on in the 
infection seemed to be an intrinsic property of the set of var genes present within the 
infecting parasite as the same switch to an alternative expressed var was seen in 
more than one human volunteer (Peters, Fowler et al. 2002), although as this work
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was done using PCR and no actual protein expression or changes in antigenic 
phenotype were identified, it is possible that lack of specificity may have led to 
multiple var transcripts being detected thus caution in interpretation of these data is 
advised. Similarly, in vitro, switching rates were variable within a panel of parasite 
clones and between parasites expressing the same variant, switching rates were 
identical (Horrocks, Pinches et al. 2004), implying the rate of switching is an 
intrinsic property of individual var genes.
The signals controlling regulation and initiation of switching within the parasite are 
as yet unknown. There is some evidence suggesting communication between the host 
and the parasite can occur. In 1973 Brown and colleagues immunised rhesus 
monkeys with P. knowlesi bearing a particular phenotype resulting in the production 
of high titres of variant-specific antibodies (Brown 1973). They then went on to 
infect both immunised and naive monkeys with 10, 100 or 1000 P. knowlesi 
parasites expressing the same SICA antigen to which the immunised monkeys had 
already been sensitised. The resulting infections in both the immunised and naive 
monkeys were almost identical in terms of the pre-patent period and subsequent 
parasitaemia. However the infections in the sensitised monkeys contained parasites 
expressing a different SICA antigen on the surface of the erythrocyte. It was argued 
that the difference in phenotype could not have occurred through selection of 
subpopulations of parasites expressing different variants because of the limited 
inocula used and the kinetics of appearance of a patent parasitaemia. It was 
concluded that homologous anti-variant antibody acted as a signal, from the host to 
the parasite, inducing switching. This hypothesis would suggest that switching away 
from a given variant would not occur until after the appearance of a specific anti­
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variant antibody, so protecting the variant repertoire from rapid exhaustion. 
However in the recent study examining switching in naive human volunteers, there 
was evidence of rapid switching away from the parental dominant expressed var 
gene on establishment of initial blood stage infection (Peters, Fowler et al. 2002). 
Furthermore attempts to show evidence of a similar phenomenon in vitro, using 
hyper immune sera from adults resident in Kilifi, Kenya and a monoclonal antibody 
directed against a specific P/EMP1, A4 var, proved inconclusive {P.Horrocks 
personal communication}. Thus perhaps the initial interpretation was wrong, 
perhaps antibody subclass is important or it may be that signals in addition to 
specific antibody are necessary to induce switching.
Further evidence supporting host-parasite signalling comes from data illustrating the 
role of the spleen in determining the surface characteristics of P. knowlesi infected 
erythrocytes. Passage of P. knowlesi parasites through splenectomised rhesus 
monkeys resulted in infected erythrocytes no longer displaying on their surface 
SICA variants. They were not agglutinated by immune sera or indeed specific anti­
sera from monkeys previously infected with the homologous parasite. Surface- 
iodinated SICA antigens could no longer be immunoprecipitated from these 
populations of infected erythrocytes. Furthermore these SICA negative parasites 
were less lethal than the SICA positive variants suggesting a link between these 
surface variant antigens and virulence. If these SICA negative parasites were 
passaged again through a spleen-intact monkey the SICA antigens once again 
appeared on the surface of the infected red cell (Barnwell, Howard et al. 1982; 
Barnwell, Howard et al. 1983). These observations give further support to the 
premise that the in vivo environment may provide signals that influence the
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expression and switching of variant antigens and consequently the phenotype of the 
infected red cells.
The erythrocyte is apparently the perfect ecological niche for the malaria parasite: it 
does not differentiate, has no internal protein trafficking or synthesis capability and 
does not posses any MHC molecules. As a result there is considerable speculation as 
to why the parasite has evolved mechanisms whereby parasite-derived proteins are 
transported to the surface of the infected red cell and expressed on its surface in full 
view of the host’s immune response. As a consequence of this action considerable 
effort is expended by the parasite to evade recognition by the host through antigenic 
variation. It must be crucial to the parasite that these proteins are inserted into the 
membrane and thus they must perform a critical function. The fact that 
cytoadherence to endothelial cells removes mature forms of the intraerythrocytic 
parasite from the circulation, so preventing removal of pRBCs by the spleen, would 
seem a compelling reason to insert these proteins into the surface membrane. 
However, variant surface antigens have been detected in all species of malaria and 
yet only a minority of these, as far as we know, display any cytoadherent properties. 
This would thus argue that perhaps expression of these surface-bound variant 
proteins predates, in evolutionary terms, cytoadherence.
Another possible reason for the evolution of antigenic variation is that perhaps it is in 
the parasite’s favour to expose themselves to the host in order to allow control of 
parasite numbers. In naive humans, the initial growth rate of P. falciparum is 
extremely high and if it were left to continue unabated would result in complete 
erythrocyte destruction and death of the host before transmission occurred (Cheng,
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Lawrence et al. 1997). Thus by the inability to cytoadhere, it is conceivable that in 
the absence of variant antigen expression, parasites would multiply and quickly 
overcome the host, thus abrogating their chance of transmission (Saul 1999). 
However, data does not support this hypothesis. Lines of both P. falciparum and P. 
knowlesi which are temporarily unable to express variant antigens on the surface of 
red cells are less virulent and achieve lower parasitaemias than their wild-type 
counterparts (Barnwell, Howard et al. 1983; Langreth and Peterson 1985).
It is clear from experimental evidence, that parasites that don’t express on their 
surface variant proteins are both less virulent and more immunogenic (Barnwell, 
Howard et al. 1983; Langreth and Peterson 1985). i^EMPl has been shown to 
inhibit the maturation and activation of dendritic cells (Urban, Ferguson et al. 1999), 
so leading to an impaired host immune response and thus potentially prolonging the 
life and, as a result, transmissibility of the parasite: a possible alternative reason for 
the development of antigenic variation as a consequence of displaying these surface- 
exposed proteins.
iyEM Pl and pathogenesis 
Cytoadherence
Unique amongst human malarias, P. falciparum can avoid removal by the spleen by 
sequestering its mature forms within the vasculature. Post-mortem examinations of 
people who have died from P. falciparum infection show accumulation of infected 
erythrocytes within the small vessels of many tissues (MacPherson, Warrell et al. 
1985; Turner, Morrison et al. 1994). This phenomenon is likely to be important by 
contributing to high total body parasitaemia and focusing pathology in distinct sites.
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As an example, several post-mortem studies have demonstrated greater infected 
erythrocyte sequestration in the brain compared with other organs in individuals 
dying of cerebral malaria as defined clinically (MacPherson, Warrell et al. 1985; Oo, 
Aikawa et al. 1987).
The observed sequestration of infected erythrocytes and the possible associations 
with clinical presentation of P. falciparum infection has led to intense interest in the 
molecular mechanisms of cytoadherence and the ligands involved both host and 
parasite derived. Although it is mainly the more mature forms of the intra- 
erythrocytic P. falciparum stages that sequester this is not exclusively so. Recent 
evidence suggests that ring-stages, as early as 4 hours post-erythrocyte invasion were 
capable of binding to several cultured cell types in vitro, albeit to a much lesser 
degree than trophozoites (Pouvelle, Buffet et al. 2000). In addition there is some 
histopathological evidence in support of this although whether the accumulation of 
ring-stages seen is due to specific receptor binding or simply reflects the passive 
accumulation of early parasitised red cells is unknown (Silamut, Phu et al. 1999). 
Within the placenta 90% of parasitised erythrocytes are of the mature trophozoite 
and schizont stage with the proportion of ring-forms in the placental and peripheral 
circulations not significantly different, results consistent with a prominent role for 
mature asexual parasites in placental malaria (Beeson, Amin et al. 2002).
It is clear that infected erythrocytes display multiple adhesive properties and that 
these vary between clones (Roberts, Craig et al. 1992) (Biggs, Anders et al. 1992). It 
is also clear that, to a large extent, iyEMPl is responsible for the variability of the 
adhesive characteristics of different parasite clones. In vitro studies have identified
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several cell-surface molecules as potential receptors for infected erythrocyte binding, 
including thrombospondin (TSP), CD36, intercellular adhesion molecule 1 (ICAM- 
1), vascular cell adhesion molecule, E-selectin, chondroitin sulphate A (CSA), CD31, 
complement receptor-1 (CR1), heparin sulphate and hyaluronic acid (HA) (Roberts, 
Sherwood et al. 1985; Barnwell, Asch et al. 1989; Berendt, Simmons et al. 1989; 
Ockenhouse, Tegoshi et al. 1992; Rogerson, Chaiyaroj et al. 1995; Rowe, Moulds et 
al. 1997; Treutiger, Heddini et al. 1997; Beeson, Rogerson et al. 2000; Vogt, 
Barragan et al. 2003). In addition to adhering to endothelial cells and 
syncytiotrophoblasts, mature-stage pRBCs can also adhere to non-infected 
erythrocytes (Handunnetti, David et al. 1989), forming rosettes, and to other infected 
erythrocytes, forming clumps (with platelets) or autoagglutinates (Roberts, Pain et al. 
2000; Pain, Ferguson et al. 2001).
Establishing a direct cause and effect relationship between sequestration and severe 
malaria has proven difficult. This in part is likely to be due to the heterogeneity of 
pathogenic processes that can lead to the end point of severe disease, as indicated in 
clinical studies, (Marsh, Forster et al. 1995), and recently supported by detailed 
histological studies in Malawian children where out of 31 patients with clinically 
defined cerebral malaria, 7 had alternative non-malaria causes of death identified at 
post-mortem (Taylor, Fu et al. 2004). During pregnancy, infected erythrocytes 
typically sequester in the placenta, and maternal malaria is associated with intra­
uterine growth retardation and premature delivery resulting in excess neonatal 
mortality (Steketee, Nahlen et al. 2001; Shulman and Dorman 2003). Maternal 
health also suffers through the development of maternal anaemia and the resultant 
increased likelihood of maternal death (Shulman and Dorman 2003).
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The consequences of sequestration to the host are thus variable and can be severe. 
Although the link between sequestration and clinical disease in humans remains 
indirect, in vasculature where this phenomenon occurs a degree of obstruction to 
blood flow will occur. This could lead to hypoxia, reduction of metabolite exchange 
and the release of inflammatory mediators. In the brain it could contribute directly 
to cerebral oedema and raised intracranial pressure (Newton, Peshu et al. 1994).
Host receptors
Many host receptors have been associated with a role in the adhesion of infected 
erythrocytes but individually their specific role in pathogenesis is unclear. Organ- 
specific sequestration undoubtedly involves multiple receptors and the different 
combinations afforded by expression of particular P/EMP1 variants with the possible 
combinations of host receptors may determine the principal site of sequestration and 
thus the resultant clinical features.
CD36
CD36 is an 88-kDa glycoprotein found on the surface of platelets, monocytes, 
dendritic cells and micro vascular endothelial cells. In a histo-pathological study of 
post-mortem material from individuals dying of cerebral malaria, very little CD36 
expression was found on cerebral endothelium but it was present ubiquitously on 
lung, liver, kidney, skin and muscle vasculature (Turner, Morrison et al. 1994; 
Turner, Ly et al. 1998).
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In vitro, mature parasitised erythrocytes can bind to CD36 (Barnwell, Asch et al. 
1989; Oquendo, Hundt et al. 1989). The majority of clinical isolates causing disease 
in non-pregnant individuals also bind to CD36 (Ockenhouse, Klotz et al. 1991; 
Newbold, Warn et al. 1997; Rogerson, Tembenu et al. 1999). The relationship 
between CD3 6-binding and pathogenesis however, is not clear. In a large study in 
Kenya the ability of 200 isolates to bind to a range of endothelial cell receptors 
including CD36, was assessed quantitatively (Newbold, Warn et al. 1997). There 
was no difference in CD36 binding between isolates from well, asymptomatically 
parasitised children and those with cerebral malaria. There was, however 
significantly higher binding to CD36 in children with non-severe symptomatic 
malaria. These results are in accord with a study from Malawi where an inverse 
relationship was found between binding to CD36 and disease severity (Rogerson, 
Tembenu etal. 1999).
In support of this, in malarious areas of the Western Pacific, Southeast Asian 
ovalocytosis (SAO) is a genetic trait, which occurs at high frequencies and provides 
some protection against severe disease especially cerebral malaria (Allen, O'Donnell 
et al. 1999). SAO is caused by a deletion of 27 base pairs of the erythrocyte 
membrane band 3 gene on chromosome 17 (Jarolim, Palek et al. 1991). It has been 
reported that under flow conditions, SAO infected red cells bind at significantly 
higher levels to CD36 compared to non-SAO infected red cells (Cortes, Benet et al. 
2004). This suggests that the protection afforded to SAO individuals against 
cerebral malaria may be due to an altered distribution of sequestered parasite mass, 
with infected red cells preferentially binding to CD36 and thus avoiding cerebral 
vasculature.
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Two studies examining the effects of a CD36 mutation, present at high frequencies 
in some African populations and resulting in a deficiency of CD36, on susceptibility 
to or protection from clinical malaria, have found conflicting results. In one study an 
association with susceptibility to severe, in particular cerebral malaria was described, 
(Aitman, Cooper et al. 2000), and in the other association with protection against 
some forms of severe malarial disease was found (Pain, Urban et al. 2001).
ICAM-1
ICAM-1 is member of the immunoglobulin super-family and supports parasite 
adhesion both in vitro and in vivo (Berendt, Simmons et al. 1989; Ho, Hickey et al.
2000). A good case can be made for ICAM-1 being a key host receptor in the 
causation of cerebral malaria. It is widely expressed on cerebral endothelium, is 
upregulated in the presence of pro-inflammatory cytokines such as tumour necrosis 
factor (TNF) and in a histo-pathological study was co-localised with infected 
erythrocytes in the brains of patients dying from cerebral malaria (Turner, Morrison 
et al. 1994).
Looking quantitatively at binding to ICAM-1 and relating this to disease severity, the 
same study previously described found in Kenya a positive association with binding 
to ICAM-1 in vitro and severe malaria (Newbold, Warn et al. 1997). However in 
Malawi the opposite association was observed (Rogerson, Tembenu et al. 1999).
Sequencing of ICAM-1 has revealed a high frequency mutation, termed ICAM-1klllfi, 
present in individuals from East and West Africa but absent in Europeans
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(Femandez-Reyes, Craig et al. 1997). Using a case-control framework, the effect of 
this mutation on susceptibility to severe malarial disease was examined amongst 
children resident in a malaria-endemic area of Kenya. Homozygotes for this 
mutation were found to be at a two-fold higher risk of cerebral malaria than controls. 
In West Africa, one study showed the opposite association, (Kun, Klabunde et al.
1999), with yet another study demonstrating no association (Bellamy, Kwiatkowski 
et al. 1998). It is possible that this mutation was selected for another reason within 
these populations. It is of note that a positive association with protection from non- 
malarial infectious disease in Kenya has been demonstrated with ICAM-1klllfl 
(Jenkins, Mwangi et al. 2005)
CSA
Parasite adhesion to CSA has been implicated as a key pathological step in the 
development of placental malaria (Fried and Duffy 1996; Beeson, Brown et al. 1999). 
Several studies have shown that parasites accumulated in the placenta typically 
adhere to CSA and in vitro, infected erythrocytes adhere to placental vascular tissue 
in a CSA-dependent manner (Fried and Duffy 1996; Beeson, Brown et al. 1999; 
Gysin, Pouvelle et al. 1999). This contrasts with parasites isolated from children or 
non-pregnant adults, which show little or no adherence to CSA (Fried and Duffy 
1996; Beeson, Brown et al. 1999) (Chaiyaroj, Angkasekwinai et al. 1996; Rogerson, 
Tembenu et al. 1999). Placental isolates show little binding to receptors such as 
CD36 or ICAM-1, and if parasites are selected for binding to CSA, they lose the 
ability to bind to these receptors (Rogerson, Chaiyaroj et al. 1995; Gamain, Smith et 
al. 2001). However parasites isolated from the peripheral blood of pregnant women 
show binding to both CSA and CD36 suggesting these circulating ring-stage
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parasites have arisen from both placentally-bound parasites and parasites sequestered 
elsewhere in the vasculature (Fried and Duffy 1996; Beeson, Brown et al. 1999). 
Interestingly there was no binding to ICAM-1 amongst parasites isolated from the 
placenta or peripheral blood of pregnant women, a finding in stark contrast to the 
binding patterns seen in parasites infecting children. ICAM-1 is present on the 
surface of syncytiotrophoblasts as well as being ubiquitous throughout the vascular 
system, it may be that immune responses against ICAM-1 binding parasite strains 
acquired during previous infections may be the reason behind this finding (Beeson, 
Brown et al. 1999).
Rosetting
Rosetting, involving infected and uninfected erythrocytes, is observed with some, 
but not all parasite isolates. It appears to involve several erythrocyte ligands 
including heparan sulphate (HS), complement receptor 1 (CR1) and blood group 
antigens A and B (Rowe, Moulds et al. 1997; Chen, Barragan et al. 1998; Barragan, 
Kremsner et al. 2000).
Several, (Carlson, Helmby et al. 1990; Rowe, Obeiro et al. 1995), but not all, (al- 
Yaman, Genton et al. 1995), studies have demonstrated an association between the 
rosetting phenotype and disease severity in that parasites displaying the rosetting 
phenotype occur more often in children with severe disease. It has also been shown, 
again in some but not all studies, that antibodies that disrupt rosettes are less 
common in individuals with clinical disease (Carlson, Helmby et al. 1990; Reeder, 
Davem et al. 1997). Further support for an association between rosetting and disease
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severity comes from recent work from Papua New Guinea. As mentioned CR1 has 
been shown to mediate the formation of rosettes and erythrocytes displaying CR1 
deficiency show reduced rosetting (Rowe, Moulds et al. 1997). In Melanesian 
populations CR1 deficiency is common and in Papua New Guinea this deficiency 
was associated with protection from severe malaria (Cockbum, Mackinnon et al. 
2004). Furthermore, indirect evidence linking rosetting to disease severity was 
established when it was shown that individuals of blood group A antigen are more 
likely to suffer severe malarial disease than those with any combinations involving 
blood groups B or O (Fischer and Boone 1998). Blood group A antigen was found 
to mediate rosetting in both laboratory-adapted and wild isolates (Carlson and 
Wahlgren 1992; Udomsangpetch, Todd et al. 1993).
Immunomodulation
Dendritic cells represent a vital link between the innate and adaptive immune 
response to infection, and are responsible for presenting antigen, activating naive T- 
cells and enhancing antibody production (Liu 2001). Immature dendritic cells are 
highly phagocytic, internalising antigens by various pathways including those 
involving CD36 (Albert, Pearce et al. 1998). Antigen uptake then induces dendritic 
cell maturation, characterised by increased expression of MHC class II molecules, 
costimulatory molecules (CD40, CD80, CD86) antigen processing and presentation, 
and secretion of cytokines that activate effector immune cells.
Parasitised erythrocytes that bind to monocyte-derived dendritic cells via CD36 
modulate the maturation of dendritic cells in vitro. Human dendritic cells 
interacting with erythrocytes infected with parasites selected for CD36 binding did
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not mature on stimulation with lipopolysaccharide (LPS) or TNF (Urban, Ferguson 
et al. 1999; Urban, Willcox et al. 2001). This inhibition of maturation of dendritic 
cell function was dependent on the affinity of the infected erythrocytes for CD36 
(Urban, Ferguson et al. 1999). In accordance with this, the percentage of circulating 
mature dendritic cells in children with malaria, both mild and severe, was 
significantly reduced compared to healthy aparasitaemic children (Urban, Mwangi et 
al. 2001)
/yEM Pl as the adhesive parasite ligand
Adhesion to many endothelial cell receptors has been attributed to PJBMVl. These 
include CD36, ICAM-1, HS, CSA and CR1 (Baruch, Ma et al. 1997; Rowe, Moulds 
et al. 1997; Chen, Barragan et al. 1998; Reeder, Cowman et al. 1999; Smith, Craig et 
al. 2000). Infected erythrocytes are able to bind to a range of host receptors with 
each parasite having the ability to bind to a subset of them only.
The sequencing of the var genes has enabled the mapping of specific receptor 
binding sites to motifs within /yEMPl. There are binding sites for several molecules 
at the N-terminal head of the extracellular domain of P/EMP1. In vitro data 
identified that three i^EMPl domains, DBLla, CIDRla and DBL25 mediated 
binding independently to a number of host receptors (Chen, Heddini et al. 2000). 
These interactions included the identification of D B Lla as the parasite ligand 
binding to CR1 thus mediating rosetting and also CIDR1 a  as the domain mediating 
binding to CD36. It is important to stress that not all expressed var genes have the 
same binding properties and domain-specific binding varies considerably between 
var s.
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Binding of infected erythrocytes to CD36 is especially interesting as it is a feature of 
many parasite isolates (Ockenhouse, Ho et al. 1991; Newbold, Warn et al. 1997; 
Rogerson, Tembenu et al. 1999). Antibodies raised against a recombinant protein 
corresponding to a portion of the CIDRla domain of two var genes present within 
the Malayan Camp parasite isolate, blocked adherence of this strain to immobilised 
CD36 (Baruch, Pasloske et al. 1995). Furthermore these antibodies 
immunoprecipitated the same fragment of CIDRla as purified CD36 (Baruch, 
Gormely et al. 1996) and, when anti-CD36 monoclonal antibodies were shown to 
block adherence of parasitised erythrocytes to CD36 this occurred regardless of 
differences in the expressed P/EMP1 protein (Barnwell, Asch et al. 1989; Hasler, 
Albrecht et al. 1993). This suggests that most variants of iyEMPl bind to the same 
region of CD36 and as such the CD3 6-binding domain of P/EMP1 may have some 
conserved sequence and structure. Analysis of the sequences corresponding from 
diverse parasites to the CD36 binding region of P/EMP1, located within the CIDRla 
domain, demonstrated that these sequences were not identical but did display some 
homology. This was most apparent by conservation of cysteine residues at either 
end of the fragment resulting in a highly conserved predicted three-dimensional 
structure (Baruch, Ma et al. 1997). It is thought that this structure is maintained 
regardless of differences in amino acid sequence and that it is the conformation of 
the protein fragment rather than the sequence itself that is essential for function.
Exceptions to CIDRla mediating binding to CD36 are CSA-binding parasite isolates. 
P/EMP1 was discovered to be a parasite ligand mediating binding to CSA in 1999 
(Reeder, Cowman et al. 1999). Selection of infected erythrocytes on CSA in vitro
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leads to a loss of CD36 and ICAM-1 binding and the ability to form rosettes 
(Rogerson, Chaiyaroj et al. 1995; Gamain, Smith et al. 2001; Beeson and Brown 
2004). As a consequence of binding to CSA via CIDRla, CSA and CD36-binding 
are mutually exclusive phenotypes (Gamain, Gratepanche et al. 2002). Selection of 
a laboratory isolate for binding to CSA initiated a switch in the var gene expressed 
coinciding with a change in antigenic type. A specific var gene was transcribed in 
these CSA-selected parasites, different to the dominant var transcribed in the 
parental non-selected clone (Reeder, Cowman et al. 1999). This var gene was called 
CS2. The direct association of this PfEMP1 variant and CSA binding was 
demonstrated by almost complete reduction in adhesion in the presence of antibodies 
raised against some of the domains of this protein, specifically anti-DBL3y and anti- 
CIDRla antibodies. Interestingly the inhibitory effect of anti-DBL3y antibodies was 
specific to CSA binding but the anti-CIDRla antibodies also abrogated binding of 
other non-CSA selected parasite lines to CD36. In fact it has become clear that 
although the ZyEMPl variants expressed on the surface of CSA-binding parasites 
contain CIDRla domains they do not bind to CD36 (Buffet, Gamain et al. 1999; 
Reeder, Cowman et al. 1999). This suggests that the DBLy-type and the CID Rla 
domains of parasites displaying binding to CSA may combine to form the CSA- 
binding region. Further work suggested that recombinant CIDRla domains on their 
own might be able to mediate binding to CSA in the absence of DBLy-type domains 
(Degen, Weiss et al. 2000). However, the expressed CID Rla protein in this 
particular case was isolated from a parasite line unable to bind CSA and so this 
adhesion characteristic is unlikely to represent a mechanism utilised in vivo.
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Although binding to CSA has been largely attributed to the DBLy domains of 
PfEMP1, many expressed DBLy domains do not bind CSA (Gamain, Smith et al. 
2004). There are varying amounts of homology and diversity in sequence amongst 
DBLy domains without any clear conserved areas among those domains that do bind 
CSA (Gamain, Smith et al. 2004). An analysis of 5 DBLy sequences from placental 
isolates revealed a homology ranging from 39 to 55% (Khattab, Kun et al. 2001).
The suggestion from serological studies, (Fried, Nosten et al. 1998), that a conserved 
ligand may be responsible for placental binding and may thus be amenable to 
targeting in a pregnancy-associated-malaria specific vaccine was given support by 
the finding that one var gene was the dominant transcript in many placental isolates 
as well as many isolates selected for adhesion to CSA (Duffy MF 2003; Salanti, 
Staalsoe et al. 2003). This gene, called var2csa, has an atypical structure lacking 
both DBLy and CIDRla domains instead possessing three DBLX-type and three 
DBL-e-type domains (Salanti, Staalsoe et al. 2003). Until recently a CSA-binding 
domain had not been identified for this gene although substantial homology existed 
between the third DBL domain of var2csa and the minimal-binding region of the 
DBLy domain of another commonly expressed CSA-binding var gene, FCR3varCSA 
(Gamain, Smith et al. 2004). Recent work, however, has led to the identification of 
multiple CSA-binding domains within both 3D7 and A4 var2csa genes, including 
DBL2-X and DBL6- s. Of note though the third DBL domain, which as described 
showed homology to the CSA binding region of FCR3varCSA, did not bind to CSA 
(Gamain, Trimnell et al. 2005). Despite these encouraging results, the role of 
var2csa remains controversial. Analysis of expression of membrane proteins in 
placental and CSA-binding isolates showed that neither var2csa nor FCR3varCSA
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were preferentially expressed on the surface of the infected erythrocyte (Fried, 
Wendler et al. 2004).
As described, another major receptor for infected erythrocytes is ICAM-1 (Berendt, 
Simmons et al. 1989). The binding site for ICAM-1 on P/EMP1 has been mapped to 
the DBL2p-c2 region (Smith, Craig et al. 2000). This region shares only low 
homology with the same area in other ICAM-1 binding parasites, indeed showing the 
same degree of homology with DBLp domains from non-ICAM-1 binding parasites 
(Smith, Subramanian et al. 2000). The domain CIDRla has exhibited weak affinity 
for ICAM-1 although the relative importance of this interaction in vivo remains to be 
seen (Chen, Heddini et al. 2000).
Rosetting has been linked to the D B Lla domain (Rowe, Moulds et al. 1997; Chen, 
Barragan et al. 1998). A recombinant fusion protein expressing D B Lla was found to 
adhere directly to normal erythrocytes, disrupt naturally formed rosettes and block 
rosette reformation. However, although the majority of var genes appear to possess 
a DBLa-type domain, 58 out of the 59 sequenced in P. falciparum genome project, 
not all parasite isolates form rosettes or adhere to the receptors involved. A 
summary of the known binding characteristics of P/EMP1 is given in figure 1.7.
Other adhesive ligands
Other molecules present on the surface of infected erythrocytes have been proposed 
to act as adhesive ligands. Using an anti-idiotype antibody raised against a CD36 
monoclonal antibody, a large molecular weight protein was identified and called 
sequestrin (Ockenhouse, Klotz et al. 1991). This protein is around 270-kDa in size,
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is specific to parasite-infected erythrocytes and is surface-labelled with radioiodine. 
To date a direct interaction between sequestrin and CD36 has not been reported nor 
has this protein been implicated in adhesion to other receptors.
It has been thought that clag9 {cy to adherence-linked asexual gene 9) may be 
involved either directly or indirectly, in the binding of infected red blood cells to 
CD36. Targeted gene disruption of clag9 resulted in the loss of binding to CD36, 
and antibodies against clag9 protein have been found to inhibit binding to CD36 
(Trenholme, Gardiner et al. 2000). By profiling expression of clag9 in both CD36 
and CSA binding parasites, it has been shown that expression of this protein, 
comparable in both parasite lines, is limited to rhoptries and young ring-stage 
parasites but is not present in trophozoites, the phase in the P. falciparum growth 
cycle when parasite-infected red blood cells sequester (Chaorattanakawe, Davis et al. 
2004). It may be then that clag9 has an indirect role in adhesion perhaps in 
trafficking of PfEMPl or other surface-expressed proteins.
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Figure 1.7
Schematic representation of the binding properties of the parasite-encoded 
RBC surface protein /yEM Pl.
The intracellular acidic terminal sequence (ATS) is highly conserved and anchors the 
protein to parasite-derived knobs on the RBC surface. The highly variable 
extracellular region is assembled from three blocks of sequence which share 
homology; DBL, CIDR and C2. A representation is illustrated. The arrows indicate 
the known binding specificities of each PfEMPI region with the downstream effects 
illustrated. The binding specificities of domains vary among different var genes. Any 
single domain from a particular var gene may not bind to all of the receptors shown.
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Peptides derived from parasite-modified band 3, an intrinsic red cell anion-transport 
protein, inhibited adhesion to CD36 (Crandall, Collins et al. 1993). Band 3 has also 
been mooted as the parasite adhesion molecule responsible for binding to 
thrombospondin (TSP) (Lucas and Sherman 1998). Involvement in binding to other 
receptors has not been described.
Is iyEM Pl a major target for naturally acquired antibodies?
As described before, antibodies directed against the surface of P. falciparum-infQctQd 
erythrocytes measured either through agglutination or flow cytometry, may well be 
targeting iyEMPl. The evidence existing currently, although compelling remains 
indirect. Considering agglutination assays against the infected erythrocyte surface, 
only sera from malaria-exposed individuals resulted in agglutination and only 
infected erythrocytes were agglutinated. Furthermore, both for agglutination and 
indirect surface immunofluorescence, positive results were only obtained from 16 
hours post-erythrocyte invasion onwards, in other words only when the parasites 
were mature trophozoites or schizonts. Also both agglutination and surface 
immunofluorescence were abrogated by trypsin treatment of the infected 
erythrocytes but not by neuraminidase (Marsh, Sherwood et al. 1986). By using a 
differential staining technique, Newbold and colleagues also showed the 
agglutination reaction was variant-specific as described before (Newbold, Pinches et 
al. 1992). Many subsequent studies assessing the human agglutinating antibody 
response against the infected erythrocyte have also demonstrated the variant- 
specificity of this response (Forsyth, Philip et al. 1989; Iqbal, Perlmann et al. 1993; 
Reeder, Rogerson et al. 1994; Bull, Lowe et al. 1998). Thus antigens targeted by
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agglutinating antibodies would seem to have properties known to be associated with 
P/EMP1.
Flow cytometry was introduced as a means of measuring antibody reactivity against 
the infected erythrocyte surface because it allowed for automated analysis of a large 
number of samples, both sera and parasites. By using a parasite line selected with a 
known deletion at the 5’ end of chromosome nine, Piper and colleagues concluded 
that the target for antibodies directed at the infected erythrocyte surface measured by 
flow cytometry was i^EMPl (Piper, Roberts et al. 1999). Parasites missing a 
portion of chromosome nine had previously been shown to lack the ability to bind to 
CD36, they were not agglutinated by immune sera and a protein of a similar size to 
P/EMP1 was not precipitated from the surface of erythrocytes infected with these 
parasites by immune sera (Day, Karamalis et al. 1993). From this it was concluded 
that these mutant parasites did not express P/EMP1 on the surface of the erythrocyte. 
When antibody reactivity against the surface of the erythrocyte infected with the 
mutant parasite was compared to that of wild-type parasites, a marked reduction in 
fluorescence intensity was observed (Piper, Roberts et al. 1999). Similarly a 
different group showed that antibody responses measured by flow cytometry were 
stage-specific, occurring only in late trophozoite and early schizont stages and were 
variant-specific in that depletion from sera of antibodies recognising one particular 
variant did not reduce its ability to label other parasite variants (Staalsoe, Giha et al. 
1999). In addition trypsinisation of infected erythrocytes resulted in reduced surface 
antibody binding by 96% (Williams and Newbold 2003). In a landmark paper in 
1995, Smith and colleagues demonstrated elegantly that switches of var gene 
expression within cloned parasite lines correlated well changes in the specificity of
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agglutination and also that flow cytometry using a monoclonal antibody (BC6) 
specific for one particular expressed var product, A4 i^EM Pl, revealed a specificity 
of recognition which correlated closely with expression of A4 var (Smith, Chitnis et 
al. 1995).
Thus convincing if circumstantial evidence exists for antibodies in human immune 
sera recognising on the surface of P. falciparum-infected erythrocytes, P/EMP1 by 
both agglutination and flow cytometry.
Very few studies have looked specifically at antibodies present in the sera of 
individuals in malaria-endemic areas against defined epitopes of iyEM Pl. In 1998 
Staalso and colleagues described antibody responses, measured by ELISA, against 
three conserved peptides from a laboratory strain of PFEMPI (Staalso, Khalil et al. 
1998). These peptides corresponded to the relatively conserved N-terminal sequence 
containing the binding site for CD36 and the C-terminal sequence making up the 
intracellular portion of the integral membrane protein. The reactivity against the 
peptides increased with age and was also significantly greater in those individuals 
with an asymptomatic infection compared to those with symptoms of acute malaria. 
This result led to the tentative conclusion that the presence of peptide-specific 
antibodies was associated with asymptomatic parasitaemia and therefore protection. 
However it must be noted that in this study those asymptomatically parasitised were 
significantly older than those with symptoms.
A further study described antibody responses to recombinant D B Lla domains from 
nine wild isolates from Gabon. These were compared to responses against three
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conserved peptides from D BLla (Oguariri, Borrmann et al. 2001). Again there was 
evidence of acquisition of responses with age against all the D B Lla domains and 
also higher reactivity against the variable, intact domains compared to the conserved 
peptides.
Less directly, anti-rosetting antibodies in individuals from two malaria-endemic 
areas with different transmission characteristics showed evidence of exposure-related 
acquisition with regards age and transmission (Barragan, Kremsner et al. 1998). 
Their precise target however is open to conjecture. Interestingly anti-rosetting 
activity and agglutination correlated poorly is this and another study, suggesting 
antibodies targeting diverse epitopes (Rogerson, Beck et al. 1996). Both sets of 
antibodies may be targeting different epitopes of the same antigen, P/EMP1, 
however again this remains purely speculative.
P/EMP1 as a vaccine candidate
As must be apparent, there are many problems with the feasibility of P/EMP1 as a 
vaccine candidate, not least of which is its immense variability. However it is 
undoubtedly the case that these antigens are targets for naturally acquired protection 
and furthermore this family of proteins underpins much of the virulence of P. 
falciparum infections via cytoadherence, antigenic variation and immunomodulation 
as described and it is for these reasons that any prospective vaccine involving 
P/EMP1 is potentially attractive.
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The aim of a blood-stage vaccine will be to decrease mortality. This may happen by 
reducing the sequestered parasite biomass or possibly by extending the sub-clinical 
period, perhaps through increased splenic destruction of infected erythrocytes. 
Despite the immense variability of the nucleotide sequence, there is conservation in 
the overall domain architecture of this protein with evidence of functional constraints 
within individual domains. For example, there is, in the majority of cases, a semi­
conserved head structure comprising D B Lla and CIDRla, which mediate binding 
to a range of endothelial cell receptors (Chen, Heddini et al. 2000). In addition, the 
structuring of var genes into types and the tentative but inconclusive observation that 
sub-telomerically situated var genes form a distinct group possible over-represented 
amongst cases of severe malaria has led to renewed interest in the possibility of a 
vaccine (Bian, Wang et al. 1999; Kirchgatter and Portillo Hdel 2002; Jensen, 
Magistrado et al. 2004).
There are a number of P/EMP1-based vaccines in varying stages of development. 
Using recombinant proteins corresponding to D B Lla of ten parasite isolates, rats 
were immunised and the subsequent sera assessed for cross-reactivity (Oguariri, 
Mattei et al. 2003). While these rat antibodies recognised synthetic peptides derived 
from conserved regions of DBLla, they failed to recognise the surface of the 
homologously infected erythrocyte. There are potential reasons for this failure of 
recognition, including the possibility that the fusion proteins do not reflect the 
correct conformation of the intact D B Lla domain and thus the rat antibodies would 
predominantly be directed against linear as opposed to conformational epitopes. 
More encouraging recent work using a prime-boost immunisation regime resulted in 
rat antibodies, which not only recognised the surface of the homologously infected
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erythrocyte, but also disrupted pre-formed rosettes (Chen, Pettersson et al. 2004). 
This method, involved initially recombinant Semliki forest virus (SFV)- mini-var 
constructs, designed to allow the proteins DBLla, CIDRla and DBL2J3 to be 
expressed extracellularly but anchored to the cell membrane thus allowing them to 
fold in a similar way as in the parasite, followed by a boost using a linear 
recombinant fusion protein expressing DBLla.
Possibly the most promising P/EMP1 vaccine candidate with the exception of 
pregnancy-associated malaria vaccines, is CIDRla. Gamain and colleagues 
demonstrated the cross reactivity of antibody responses against this region using 
monoclonal antibodies prepared against the CD36-binding region of CID Rla from a 
laboratory strain of parasite. This antibody recognised 9 of 10 heterologous 
recombinant CIDRla proteins expressed on the surface of Chinese hamster ovary 
(CHO) cells (Gamain, Miller et al. 2001). In 2002 vaccination of Aotus monkeys 
with one copy of CIDRla from MC parasites protected them from homologous 
challenge with the otherwise lethal MC parasite line, but offered no protection 
against challenge with an alternative parasite line, FVO (Baruch, Gamain et al. 2002). 
Using a prime-boost regime, Gratepanche and colleagues established cross-reactivity 
of the antibody response elicited following vaccination of mice with three variants of 
CIDRla (Gratepanche, Gamain et al. 2003). The cross-reactive antibodies were 
measured using flow cytometry against CHO cells expressing heterologous CID Rla 
variants on their surface although whether or not these responses would lead to 
cross-reactivity when challenged against intact heterologously infected erythrocytes 
remains to be seen.
100
Pregnancy-associated malaria provides a syndrome-specific example of the 
feasibility of vaccination based on i^EM Pl. Indirect observation suggests the 
placenta can affect R/EMP1 expression by selecting those variants expressing CSA- 
binding characteristics ensuring sequestration within the placental vasculature. Of 
obvious interest is which i^EMPl proteins are expressed by placental binding 
isolates and do these reflect a more conserved sub-group of antigens more amenable 
to exploitation in a vaccine? Recently some encouraging results suggest that this 
may indeed be the case. Sera from pregnant women resident in Africa inhibit 
adhesion onto CSA of parasites taken from pregnant women in Asia and vice versa 
(Fried, Nosten et al. 1998) also antibody reactivity in sera from pregnant women 
correlates strongly between multiple CSA-binding parasites from diverse regions 
(Fried, Nosten et al. 1998; Khattab, Reinhardt et al. 2004) A genome-wide 
transcriptional screen has led to the identification of a distinct var gene upregulated. 
in a CSA-binding parasite line (Salanti, Staalsoe et al. 2003). As mentioned 
previously, this var gene, var2csa, is not only present within the genome of most 
parasite isolates, (Rowe and Kyes 2004), but is expressed on the surface of 
erythrocytes infected with CSA-adherent parasite lines from diverse geographical 
areas and may be an important target of protective antibodies in pregnant women 
(Salanti, Dahlback et al. 2004).
As already outlined, there is currently no reliable surrogate in vitro correlate of 
protective immunity against P. falciparum. The studies in this thesis aim to measure 
heterologous or presumed cross-reactive immune responses amongst a cohort of 
individuals resident within two areas of differing transmission intensity on the coast
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of Kenya. These responses were related to the presence of asymptomatic parasite 
carriage and any association with protection from subsequent clinical malaria was 
assessed. An attempt was made to identify the target of these responses on the 
surface of infected erythrocytes through expression of recombinant proteins 
corresponding to domains of A4 P/EMP1.
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Chapter 2
Materials and methods
Study Site
Description of areas under study
The studies outlined in this thesis were carried out at the Kenya Medical Research 
Institute Centre for Geographic Medicine Research Coast (KEMRI-CGMRC) 
situated within the grounds of Kilifi District Hospital in Kilifi, 50 km north of 
Mombasa on the coast of Kenya (figure 2.1). The hospital serves around 300,000 
people living north and south of an ocean creek. Individuals whose immune 
responses were investigated throughout these studies were resident in two sites 
within Kilifi District within 20 km of each other, Chonyi and Ngerenya. Both areas 
experience perennial transmission with the most intense transmission occurring 
between May and July and December and January each year. Inhabitants of these 
areas are predominantly from the Mijikenda ethnic group and have similar beliefs 
and customs. Residents of Ngerenya have, on average 10 infective bites/person/year, 
(Mbogo, Snow et al. 1995) whereas residents of Chonyi have an estimated 50 
bites/person/year (Mbogo, Mwangangi et al. 2003). The difference in transmission 
between the two areas is reflected in the parasite rate in each area and the proportion 
of individuals suffering an attack of clinical malaria during the period of follow up 
(figure 2.2 and figure 2.3). Within the individuals sampled in this study, in Chonyi 
in children aged 1 - 1 0  years, the parasite prevalence was 43.2% (95% Cl 37.2 -  
49.3%) and in Ngerenya over the same age range 23.6% (95% Cl 18.9 -  28.9%). A 
study examining the clinical epidemiology of malaria under different transmission
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conditions determined the incidence of clinical malaria in the two areas under study 
as being in Ngerenya 0.84 episodes/person/year and in Chonyi 0.55 
episodes/person/year, evidence for lower incidence of malaria in the higher 
transmission area (incidence rate ratio - 0.66 (95% Cl 0.61 -  0.72) p<0.001) 
(Mwangi, Ross et al. 2005). There was higher bed-net use amongst children less 
than 10 years in Ngerenya compared with that in Chonyi (69% vs. 6%) (Mwangi 
2003). This is possibly because of a previous trial of bed-net usage undertaken in 
Ngerenya in the mid-1990s (Nevill, Some et al. 1996).
Sample collection
Sera collection and active surveillance were conducted as part of a study examining 
the clinical epidemiology of malaria under differing transmission conditions 
(Mwangi 2003). In brief, serum was collected in October 2000 from individuals of 
all ages in both areas and the cohorts were followed for evidence of malaria by 
active and passive case detection for the subsequent 30 weeks. Malaria was defined 
as a febrile episode with an axillary temperature greater than 37.5°C and a 
parasitaemia of greater than 2500 parasites/pl except in children less than 1 year 
when fever (again >37.5°C) plus any parasitaemia counted as an episode. These 
have been determined to be optimal definitions for malaria among the different age 
groups in this area (Mwangi, Ross et al. 2005). A blood slide was prepared for every 
individual in the cohort at the time of serum collection in order to categorise him or 
her as parasite positive or negative by microscopy at the pre-transmission bleed. 20 
non-malaria exposed control sera were collected from Oxford, United Kingdom.
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Map of study area
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Figure 2.2
Proportion of individuals in each age group in each area with microscopically 
detectable parasitaemia at serum collection.
Serum collection occurred at the end of a low transmission period in October 2000.
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defined in the text.
Shown are overall proportions and upper 95% confidence intervals
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Laboratory methods
Each section of this thesis has a particular design and experimental outline, however 
a number of laboratory techniques are used throughout and these are outlined here 
for future reference.
Amplification and cloning of DNA sequences 
PCR amplification of specific DNA sequences
Target domain and interdomain regions of the sequenced A4var gene were amplified 
for cloning using the polymerase chain reaction (PCR). Forward and reverse primers 
were designed around domain boundaries previously described, (Smith, 
Subramanian et al. 2000). Primers were designed to include a restriction site at each 
end of the resultant product. Each region to be cloned had a blunt-ended 5’ site 
created by using Xmn-1 restriction enzyme or its isochizomer Smal, and a staggered 
3’ end to allow directed cloning. Each different PCR reaction was optimised by 
varying cycle times, annealing temperature and magnesium chloride concentration. 
Individual conditions are given below. Approximately lOOng of A4 genomic DNA 
(gDNA) was mixed with PCR buffer (lOmM tris pH 8.3, 50mM potassium chloride), 
0.3mM each of dATP, dCTP, dGTP, and dTTP, 1.5-3.5 mM magnesium chloride, 
lpM  of each primer and 1.25 Units of Taq polymerase. Reactions were performed 
in 50pl volumes.
Separation of DNA fragments
Plasmid DNA extracted from bacterial cells or DNA fragments amplified from 
genomic DNA were separated and sized by agarose gel electrophoresis. Gels were
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poured using between 1-2.5% weight/volume (w/v) agarose in 0.5 x TBE (1 x TBE -  
6g TRIS, 5.5g orthoboric acid and 4ml 0.5M EDTA pH 8.0 made up to 1 litre with 
deionised water (dH20)). Samples were mixed with equal volumes of loading buffer 
(30% volume/volume (v/v) glycerol, lOmM EDTA pH 8.0, 0.25% (w/v) xylene 
cyanol and 0.25% (w/v) bromophenol blue) immediately prior to loading. Gels were 
run in 0.5x TBE for approximately 1 hour until the first dye front was within 2-3cm 
of the end. On completion, gels were stained for 20 minutes in 0.5pg/ml ethidium 
bromide in dH20 before ultraviolet (UV) visualisation. Fragment sizes were 
estimated by comparison to appropriate molecular weight markers run in adjacent 
lanes.
Quantification of DNA
DNA concentration was estimated by agarose gel electrophoresis. Samples were run 
against a DNA mass ladder consisting of known band sizes, each containing known 
amounts of DNA. Quantification of DNA in each experimental sample was then 
estimated by comparison to the appropriately sized band.
Post PCR purification of DNA
To purify the full-length PCR products, a PCR purification kit (Qiagen, Hilden, 
Germany) was used according to the manufacturer instructions. This technique 
utilised a silica-gel membrane allowing selective binding of DNA and removal of 
contaminants.
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Gel Purification of DNA
To purify specific DNA fragments from restriction digests, samples were 
electrophoresed on agarose gel (1% w/v) in TAE buffer, (40mM Tris-Acetate, ImM 
EDTA). Because of concerns regarding the effect of UV light exposure and 
ethidium bromide on the integrity of the DNA purified the following method was 
used. 50pl samples were split into 5pi and 45 pi aliquots and prepared as described 
previously, samples were mixed with equal volumes of loading buffer (30% (v/v) 
glycerol, lOmM EDTA pH 8.0, 0.25% (w/v) xylene cyanol and 0.25% (w/v) 
bromophenol blue) immediately prior to loading. The 5pi aliquots were loaded into 
a well adjacent to a 1 kb DNA mass ladder with the 45pi sample loaded adjacent 
again (figure 2.4). The gel was run until the dye front was approximately 2-3cm 
from the end and then cut with a scalpel as shown by the dashed line. The gel 
containing the DNA ladder and the 5pi sample was stained as before in 0.5 pg/ml 
ethidium bromide in dH20 and then read next to a ruler under UV visualisation 
(figure 2.5). Using the ruler to measure the distance from the well travelled by the 
5pl sample, the unstained 45pi sample, which had not been exposed to UV 
transillumination, was excised from the gel using a sterile scalpel and transferred to 
an eppendorf tube. The DNA fragment was then recovered from the agarose gel 
using QIAquick Gel Extraction Kit (Qiagen, Hilden Germany).
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45 pi sample loaded 5pl sample loaded
lkb DNA ladder
Gel purified Ethidium bromide stained
UV transilluminated
Figure 2.4
Agarose gel showing layout of samples.
Dashed line indicates where gel was cut.
I l l
Figure 2.5
U.V. visualisation of the ethidium bromide-stained DNA.
The ruler was used to measure the distance travelled by the non-stained DNA and 
thus inform as to the correct position to excise the DNA from the gel.
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Restriction Digests
Purified vector DNA and PCR products were prepared for ligation by restriction 
digestion. Vector DNA was additionally treated with phosphatase to prevent self­
ligation. Table 2.1 shows the enzymes used and the buffer compositions. When 
required, double digests using two restriction enzymes followed manufacturer 
recommendations regarding the choice of a common buffer.
Table 2.1 Restriction enzymes and buffers used
Restriction Enzyme Buffer constituents
BamH 1 50 mM Tris-HCl, pH 8.0, 10 mM MgCl2, 100 mM NaCl
Hind III 
Pst 1 
Xba 1 50 mM Tris-HCl, pH 8.0, 10 mM MgCl2, 50 mM NaCl
Sma 1 20 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 50 mM KC1
Xmn 1 10 mM Tris-HCl, pH 7.9, 10 mM MgCl2, 50 mM NaCl
The amount of enzyme used was based on the number of restriction sites per jug of 
DNA and the empirically found efficiency of cleavage. Depending on the enzyme, 
between 0.13 and 1 unit enzyme per jug DNA when digesting PCR products and 
between 1 and 5 unit enzyme per pg DNA when digesting plasmid vector DNA was 
used at temperatures either 25°C (Sma 1) or 37°C (all other enzymes) for between 4 
and 16 hours. For phosphatase treatment 0.03 units of calf intestinal phosphatase 
(CIP) were added per jug of DNA for the last hour of restriction digest treatment. 
DNA was purified by gel electrophoresis and purification as previously described.
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Ligation
Plasmid and PCR insert DNA were prepared by restriction digestion with the 
appropriate restriction enzyme and then gel purified as described. lOng of vector 
DNA was incubated with a 1:1 and 1:3 molar ratio of vectoninsert DNA . Ligation 
reaction buffer was 60mM Tris-HCl, pH 7.5, 60mM MgCk, 50mM NaCl, 1 mg/ml 
bovine serum albumin, 70mM p-mercaptoethanol, ImM ATP, 20mM dithiothreitol, 
lOmM spermidine and 4 units of T4 DNA ligase. Samples were incubated overnight 
at 16°C.
Bacterial transformation and expression of DNA constructs 
Bacteriological Media
Routine culturing of bacterial cells was performed using Luria-Bertani (LB) medium 
(lOg tryptone, 5g yeast extract and 5g sodium chloride in 1 litre of distilled water, 
pH 7.0 with sodium hydroxide) and LB-agarose plates (LB medium supplemented 
with 15g agarose per litre). All media was autoclaved immediately and liquid media 
was stored at room temperature for up to 1 month, while agarose plates were stored 
at 4°C. In all experiments utilising the p-Malc2x series of plasmids, ampicillin was 
added to a final concentration of 100pg/ml from a 50mg/ml stock in d ^ O . In all 
experiments using BL21-CodonPlus-Ril competent cells for final expression 
chloramphenicol was also added to a final concentration of 50 pg/ml from a stock of 
50mg/ml in methanol. All cultures were grown in a shaking incubator at 140 rpm 
and 37°C unless otherwise stated.
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Bacterial Strains Used
There were three strains of E.coli bacteria used in these experiments. Strain DH5a 
was used for cloning and all transformations and initial expression experiments. 
Initially strain TB1 was used for final expression of the recombinant protein, 
however after poor results with expression and purification, BL21-CodonPlus-Ril 
bacteria cells were used. BL21-CodonPlus-Ril cells contain extra copies of the argU, 
ileY andleuW tRNA genes in the form of a pACYC plasmid. These genes encode 
tRNAs that recognise the arginine codons AGA and AGG, the isoleucine codon 
AUA and the leucine codon CUA, together the tRNAs that most frequently restrict 
translation of heterologous proteins from organisms with AT-rich genomes. The 
BL21 expression strains of E. coli naturally lack the Lon protease, which can 
degrade recombinant proteins. They are also engineered to be deficient for a second 
protease, the OmpT protein. The extra plasmid, pACYC, also has chloramphenicol 
resistance to maintain the plasmid. The genotypes of these three strains of E.coli are 
outlined in table 2.2.
Table 2.2 Bacterial genotypes used
Strain
Genotype
DH5a SupE44 hsdR17 recAl gyrA96 endAl thi-1 relAl deoR
B121 -CodonPlus-Ril E.coli B F'ompT hsdS(rB‘mB') dcm+Tetr gal endA Hte [argU ileY leuW Camr]
TB1 F' araA(lac-proAB)[<D80dlacA(lacZ)M15]rpsL(StrR)thi hsdR
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Transformation of competent bacterial cells
DH5a cells were used for initial transformation and replication of recombinant 
plasmids with TB1 and then BL21-CodonPlus-Ril cells used for final expression. 
The latter two strains were not used for initial transformations because of poor 
transformation efficiency. Transformation was performed as follows. 50pl of 
competent cells were thawed on ice, when using BL21-CodonPlus-Ril cells 2pl of a 
1:10 dilution of p-mercaptoethanol was added to the competent cells and mixed 
gently. This increases the transformation efficiency of these cells. Approximately 
20ng of expression plasmid DNA containing the gene of interest was added to each 
transformation reaction and mixed gently. The reactions were then incubated on ice 
for 30 minutes. Each transformation reaction was heat pulsed in a 42°C water bath 
for precisely 20 seconds before being transferred onto ice again for 2 minutes. 500pl 
of pre-heated LB medium was added to each reaction before incubating them at 37°C 
for 1 hour while shaking at 225rpm. Using a sterile spreader lOOpl of transformed 
cells were plated onto LB-agarose plates containing ampicillin only when 
transforming DH5a cells and ampicillin and chloramphenicol when plating out 
transformed BL21-CodonPlus-Ril cells. Transformants appeared as colonies 
following overnight incubation at 37°C.
Storage of Transformed Bacterial Cells
For immediate use, bacteria were grown overnight in LB medium at 37°C before 
being plated on LB-agarose. These plates were grown overnight at 37°C and then
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stored for up to 1 month at 4°C. For longer-term storage, glycerol was added (20% 
v/v), to overnight cultures and the cultures were then stored at -20°C.
Plasmid Isolation and Purification
Single clones of transformed bacterial were picked from LB-agarose plates and 
inoculated into 5ml of LB medium containing ampicillin alone or in combination 
with chloramphenicol depending on the cell type growing. The culture was grown 
overnight at 37°C. The culture was then harvested by centrifugation for 5 minutes at 
10,000 x g  in a tabletop centrifuge. The supernatant was aspirated and excess media 
blotted with a paper towel. 250pl of cell resuspension solution (50mM Tris-HCl, pH 
7.5, lOmM EDTA, lOOpg/ml RNAse A) was added to the pellet and the cells 
resuspended by vortexing. 250pl of cell lysis solution was added (0.2M NaOH, 1% 
SDS) and the solution mixed by inversion of the tube. The lysate was incubated at 
room temperature and observed to clear. In order to inactivate endonucleases 
released during cell lysis, lOjal of alkaline protease was added and the solution 
mixed by inversion. A neutralisation solution was added (4.09M guanidine 
hydrochloride, 0.759M potassium acetate, 2.12M glacial acetic acid) and again the 
solution inverted. The bacterial lysate was then centrifuged for 10 minutes at 14,000 
x g  at room temperature. The cleared lysate is then transferred to a silica membrane 
based minicolumn (Promega, MA, USA) and centrifuged for 1 minute at 14,000 x g, 
the flow-through is then discarded and the minicolumn reinserted into the collection 
tube. 750pl of column wash solution (162.8mM potassium acetate, 22.6mM Tris- 
HCl, pH 7.5, 0.109mM EDTA, 95% Ethanol) was added to the column and 
centrifugation was repeated. Adding lOOpl nuclease-free water to the column and
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centrifuging at maximum speed for 1 minute eluted the plasmid DNA. The purified 
DNA was stored at -20°C.
Sequencing
Sequencing by automatic sequencer was carried out in order to verify the reading 
frame and insert boundaries of the DNA constructs produced. Sequencing reactions 
were prepared using an ABI Prism Dye Terminator Cycle Sequencing kit, following 
recommended procedures. 500ng of plasmid DNA was mixed with reaction buffer 
and 3.2pmol primer specific to the insert boundaries spanning the 5’and 3’ end of the 
inserted construct. Reactions were cycle sequenced using a PCR machine. 
Extension products were purified by ethanol precipitation, with the addition of 
sodium acetate to 0.3M and 2 volumes ethanol. Tubes were incubated at 0°C for 10 
minutes before centrifugation at 20,000 x g for 15 minutes. Pellets were washed 
once with 70% (v/v) ethanol before being resuspended in loading buffer and 
separated on an automated sequencing gel.
Sequence reactions were repeated by the Department of Biochemistry, University of 
Oxford.
Expression of Recombinant Proteins 
Maltose-Binding Protein Expression System
First devised in 1988, (di Guan, Li et al. 1988; Maina, Riggs et al. 1988), the pMAl-2 
vector system, (figure 4.1), provides a novel method for expressing and purifying a 
protein derived from a cloned gene or open reading frame. The cloned gene is
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inserted downstream from the malE gene of E.coli, which encodes maltose-binding 
protein (MBP), producing a recombinant protein fused to MBP. This vector system 
utilises the tac promoter and the malE translation initiation signals to give high-level 
expression of the fusion protein,(Duplay, Bedouelle et al. 1984; Amann and Brosius 
1985) as well as allowing simple purification through the affinity of MBP for 
maltose,(Kellermann and Ferenci 1982). The vector carries the laclq gene, which 
codes for the lac repressor. This keeps expression low in the absence of isopropyl-p- 
D-thiogalactopyranoside (IPTG) induction. The inclusion of an ampicillin resistance 
gene allowed for selection of transformed bacteria.
Expression of recombinant proteins
The basic protocol for these experiments was as follows. The bacterial cell cultures 
consisting of the transformed bacteria were grown to logarithmic phase by shaking at 
37°C. IPTG was then added to induce transcription of the recombinant DNA and 
subsequent translation of the protein of interest. Sufficient time was allowed for the 
proteins to reach maximal intracellular levels and cells were then harvested, lysed 
and the recombinant protein of interest purified through use of a maltose column.
Initially small-scale experiments were performed to allow screening of transformed 
bacterial cells for expression. Once this was established larger scale experiments 
were performed with the recombinant protein harvested in large quantities. Maltose 
immobilised on amylose resin was used to purify the recombinant protein.
To screen for expression, LB medium, supplemented with ampicillin and 
chloramphenicol, was inoculated with transformed bacterial clones and the bacteria
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were grown to stationary phase overnight. Following 1:100 dilution with LB 
medium, bacterial growth was monitored by periodic measurement of the absorbance 
at 600nm. When the OD6oo was between 0.4 and 0.6, IPTG was added to O.lmM, 
after collecting a sample of uninduced bacteria for comparison, and the cultures were 
incubated for a further 3 hours. 1ml of each culture was then pelleted in a microfuge 
and lOOpl of loading buffer added (2% (w/v) SDS, 0.1M Tris 10% (v/v) glycerol, 
10% (v/v) P-mercaptoethanol). The pellets were then boiled for 5 minutes and 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) assessed 
expression (figure 2.6). Conditions for optimum expression were established for 
each construct and are outlined in chapter 4.
Figure 2.6
Expression of three individual clones containing construct CIDRla. Uninduced (-) 
and induced (+) lanes are shown.
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Once expression had been optimised larger scale purification was* commenced. 
Overnight cultures were seeded with bacterial clones, grown overnight and then 
diluted 1:100 with fresh LB medium supplemented with 0.2% (w/v) glucose, 
ampicillin and chloramphenicol and grown in a shaking incubator at varying 
temperatures until the OD6oowas between 0.3 and 0.6. IPTG to 0.1 mM was added 
and the cultures incubated for the optimal period of time as established. The cells 
were then pelleted at 6000 x g  for 10 minutes. Cell pellets were resuspended in 50ml 
lysis buffer per 1 litre of culture (2ml 1M Tris-HCl, pH 8.0, 10ml 5M NaCl, 0.5ml 
Tween 20, 0.2ml 0.5M EDTA, 100p,g/ml lysozyme, 0.1% Na azide, ljag PMSF to a 
volume of 100ml with d ^ O ) and stirred on ice for 1 hour. Sonication was 
performed using a 10mm diameter probe with a total sonication exposure time of 6 
minutes. The lysate was then centrifuged at 16,000 x g  for 30 minutes at 4°C. The 
supernatant was collected and run down a pre-poured amylose resin. Amylose resin 
is an affinity matrix used for the isolation of fusion proteins with maltose-binding 
protein. It is poured into a 2.5 x 10 cm column and as it comes pre-swollen in 20% 
ethanol it is washed with 5 x column volumes of column buffer (lOmMTris-HCl, pH 
7.4, 0.2M NaCl, lOmM p-mercaptoethanol, ImM EDTA). The resin is reported to 
bind 3mg/ml protein bed volume and so a 5ml column was sufficient for a yield of 
around 15mg fusion protein / litre of culture. The crude extract supernatant was 
poured into the column to affect a flow rate of around 1 ml/minute. After the extract 
had ran through, the column was washed with 10 column volumes of column buffer 
with the fusion protein then eluted by addition of lOOmM maltose to the column 
buffer. The purified protein was collected in 10 x 1ml fractions and each fraction 
was analysed for presence of the fusion protein by SDS-PAGE. Those fractions
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containing the purified fusion protein were aliquoted and snap frozen before being 
stored at -80°C.
Separation and Analysis of Proteins
Protein mixtures were routinely separated on the basis of size by SDS-PAGE, using 
a modified Laemmli approach. (Laemmli 1970). Acrylamide gels were poured 
which, when set, allowed migration of proteins differentially, according to size, 
when a constant voltage was applied. Gels were run under reducing, denaturing 
conditions to ensure all polypeptides were linearised and secondary structure 
removed. Bio-Rad mini-protean II cells were used for all experiments.
Solution A Solution B Solution C
48ml HCL 48ml HC1 30% (w/v) Acrylamide / 0.8% (w/v) Bisacrylamide
36.3g Tris 5.98g Tris
0.23ml TEMED 0.48ml TEMED
dH20  to 100ml dH20  to 100ml
Table 2.3
Composition of buffers used to cast polyacrylamide gels for SDS-PAGE
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5% Running Gel 10% Running Gel Stacking Gel
Solution A 2.5ml 2.5ml —
Solution B — — 0.95ml
Solution C 1.7ml 3.3ml 1.25ml
10% (w/v) SDS 0.1ml 0.1ml 0.075ml
10% (w/v) APS 0.1ml 0.1ml 0.075ml
dH20 5.7ml 4.0ml 5.0ml
Table 2.4
Composition of gels for SDS-PAGE
Running gels were layered under 50% (v/v) isopropanol until polymerisation was 
complete. Isopropanol was then removed and the stacking gel was overlaid followed 
by insertion of the sample comb. Protein samples were mixed with equal volumes 
loading buffer (2% (w/v) SDS, 0.1M Tris, 10% (v/v) glycerol, 10% (v/v) P- 
mercaptoethanol) and boiled for 5 minutes before loading. Electrophoresis cells 
were then filled with running buffer (3g Tris, 14.4g glycine, lOmls 10% SDS, ddEhO 
to 1 litre) and the gels were run for approximately 1 hour at 200V.
Gels were fixed and stained for 30 minutes in stain solution (20% (v/v) methanol, 
10% (v/v) acetic acid, 0.05% (v/v) coomassie blue). De-staining was performed in 
the same buffer without the dye.
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Quantification of Protein
Estimates of concentration were obtained by two methods: electrophoresis and a 
soluble phase protein assay.
For crude estimates of concentration, samples of protein purified as above were 
compared on an SDS-Page gel to known amounts of bovine serum albumin (BSA). 
The relative intensity of the coomassie stained bands gave an approximate value for 
the protein concentration of the sample.
For more accurate quantification, a soluble phase protein assay was carried out using 
a Protein Assay kit (Bio-Rad). Coomassie Blue was used to stain proteins in 
aqueous solution with results being read by spectrophotometry at 595nm. BSA was 
used as a standard. Briefly, protein samples were diluted in PBS and proprietary dye 
reagent added at a 1:5 dilution. Standard dilutions of BSA were prepared in parallel 
in PBS. Samples were incubated for 20 minutes before absorbance was read and 
sample concentrations were calculated from standard curves.
Enzyme Linked Immunosorbant Assay (ELISA)
Introduction
Solid phase assays, in which one reactant has been immobilised to a solid support, 
such as a polystyrene or polypropylene 96 well plate, are highly versatile. They 
allow both the qualitative and quantitative determination of antigen or antibody, and 
are the basis for a wide range of accurate and sensitive measurement tools (Engvall, 
Jonsson et al. 1971; Engvall and Perlman 1971). There are certain requirements of
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the solid-phase system necessary for optimal binding to occur. These include; 
preservation as much as possible, of the native structure and biological activity of the 
immobilised antigen, stability of bonding to the plastic surface to enable as little as 
possible loss of the protein coated and inertness of the solid support such that little 
non-specific binding occurs.
There are many materials available for the solid-phase support in an ELISA. The 
most widely used are plastics, most commonly polystyrene. The protein-surface 
adsorption process is complex with the major driving force behind the interface 
being hydrophobic interaction. Careful consideration of the buffer used to 
immobilise the antigen on the plastic is important. Protein stability is influenced by 
alterations in pH, which can lead to charge neutralisation resulting in denaturation 
and decreased solubility. Popular coating buffers include 50mM bicarbonate, pH 9.6, 
PBS, pH 7.2, and Tris-saline pH 8.5. Coating buffers usually do not contain 
detergent, which can compete with the protein for hydrophobic binding sites on the 
plastic surface.
Once the antigen has been immobilised it is necessary to reduce as much as possible 
any non-specific binding. The sensitivity of the assay can be greatly compromised if 
non-specific binding is substantial. Sources of non-specific binding can include 
impurities in the protein immobilised, proteins and lipids in the serum sample or 
contamination during the assay. Secondary antibody can also stick to exposed 
surface areas on the microwell plate. Minimising non-specific binding can be done 
in a number of ways. One such way is using a blocking agent such as a solution of
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BSA, gelatin or milk. It is worth noting that in some cases, in addition to masking 
non-specific sites on the plate, blocking agents can also contribute to new sites. For 
example, albumin is known to adsorb basic immunoglobulins. Previous studies have 
examined various blocking agents for inhibition of non-specific binding. Vogt et al 
looked at the adsorption of gelatin, non-fat dry bovine milk, casein and BSA onto the 
surface of polystyrene 96 well plates and scored each in terms of their inhibition of 
non-specific binding. This was measured by the binding of an antibody-peroxidase 
conjugate to the surface of the plate. It was found all proteins were able to block at 
high concentrations but whereas with non-fat bovine milk and casein, blocking was 
maintained throughout a 10,000-fold dilution, BSA and gelatin exhibited a rapid 
drop off (Vogt, Phillips et al. 1987).
Another important consideration is the use of detergents. Detergents serve two 
purposes; they can remove non-specifically bound molecules from the surface of the 
plate by disruption of hydrophobic bonds formed between the two and they can bind 
to the surface itself and serve as a blocking agent. For these reasons detergent is 
included in wash buffers.
Selection of plate and coating buffer
In order to optimise coating of the protein to the plate, the effect of binding to 
different 96-well micro titre plates from differing manufacturers and coating in two 
alternative coating buffers at different pH was assessed. The recombinant fusion 
protein CIDRla-MBP was coated at a concentration of 400ng/well in both 
bicarbonate buffer, (15mM Na2C0 3 , 35mM NaHCCb, pH 9.3) and phosphate-
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buffered saline (PBS), pH 7.2. Each was assessed using three different types of 96- 
well plate: U-bottom tissue culture grade plates, (Falcon), flat-bottom tissue culture 
grade plates, (Coming) and flat bottom polystyrene plates, (Nunc). The primary 
antibody used was mouse monoclonal anti-MBP IgG2a (Dako Ltd.), at a dilution of 
1:10,000 with detection being horseradish peroxidase (HRP)-conjugated anti mouse 
IgG2a at a dilution of 1:5000. Each combination of plate and coating buffer was 
performed in triplicate and the average OD, read at 492nm, taken after controlling 
for background binding using PBS or bicarbonate buffer only. Results are shown in 
figure 2.7. Significantly increased OD values were obtained using PBS as a coating 
buffer for both the Nunc plates and the Coming plates (p=0.0487 and p<0.0001, 
using a paired t-test, respectively). Considering only those wells coated with 
recombinant protein in PBS, the Nunc plates gave rise to significantly greater OD 
values than either the Coming or the Falcon plates (p=0.0362 and p=0.0167 
respectively). The same analysis was performed with each recombinant protein in 
turn and consistently coating in PBS using Nunc flat-bottomed 96-well plates give 
the highest OD values after controlling for background non-specific binding.
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Figure 2.7
Graph showing reactivity using different solid-phase supports, coating with 2 
different buffers.
Each condition was done in triplicate and the average taken. Shown are mean values 
with upper 95% confidence limits. Plates were coated overnight at 4°C and ELISA 
done according to the method described. The legend at the right-hand side refers to 
the different types of plate used.
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Concentration of antigen to coat
The assay is ideally designed if an antigen, in the correct conformation to optimally 
bind antibody, takes up the maximum numbers of binding sites on the solid phase. 
However, as the concentration of antigen in the coating buffer increases, so does the 
rate of desorption of antigen from the matrix, during the assay. The steric 
conformation of the antigen may also be altered at high concentrations, thus reducing 
antibody binding. The optimal concentration of antigen in order to achieve an excess 
of antigen compared to antibody was determined through the use of a chequerboard 
titration of diluted protein against a range of positive and negative reference sera. 
Figure 2.8 outlines the results obtained. Essentially, ELISA’s were performed 
against a range of coating concentrations of each recombinant protein (expressed as 
ng/well). Reactivity was assessed using a panel of high reacting sera obtained from 
adults resident within Kilifi District and a panel of sera from non-malaria exposed 
donors. All sera were measured at a concentration of 1:100. All responses were 
assessed in triplicate and the average taken. Results are expressed as the mean 
reactivity for the panel of high reacting serum and the mean plus 3 standard 
deviations for the non-exposed serum donors. The selection of coating concentration 
to use for each protein was based on achieving a clear separation in reactivity 
between the high reacting sera and the non-malaria exposed donor sera and 
limitations on the amount of protein available. In summary, concentrations used 
were as follows: D BLla - 400ng/well, CIDRla - 400ng/well, DBL2p - 200ng/well, 
DBL4y - 200ng/well and DBL5p - 400ng/well, (figure 2.8).
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ELISA Protocol
An optimal coating concentration, experimentally defined, of each recombinant 
protein was coated onto individual wells on Nunc transparent, flat-bottomed 96 well 
plates (Nunc technology) in lOOpl PBS. An equivalent molar concentration of MBP 
alone was coated in exactly the same way as a control. The plates were incubated 
overnight at 4°C, washed in PBS with 0.05% Tween 20 and blocked with 200pl 
blocking buffer (10% skimmed milk in PBS with 0.5% Tween 20) for 1 hour at 37°C. 
The plates were washed again as before and lOOpl of human sera (diluted 1:100 with 
blocking buffer) was incubated in duplicate for 1 hour at 37°C. The wells were again 
washed and lOOpl of HRP-conjugated rabbit anti-human IgG (Dako Ltd.), at a 
dilution of 1:5000 was added and the plates incubated again for 1 hour at 37°C. 
Detection was by the addition of O- phenylenediamine/LLC^ (Sigma) for 15 minutes 
in darkness. The mean absorbance, taken at 492nm, was calculated for each sample 
after correction for binding to MBP alone. A serum was scored as positive if the 
corrected absorbance was higher than the mean + 3 standard deviations of 20 
negative control sera from UK residents who had never been exposed to malaria.
130
a)
1.5000 
1.4X0 
1.3000 
13X0 
1.1000- 
1.0000 
Q9000- 
08000 
Q7000- 
Q0OOO 
O'5000
b)
0.9000
0.8000
0.7000
0.6000
0.5000
0.4000
0.3000
0.2000
0.1000
0.0000
20Qrg 400V 60Cng
c)
1.4000-
12000
1.0000-
Q8000
Q0OOO-
Q4000-
02000
Q000Q
-i »-
200^ 400^ 800^
d)
20000
1.8000
1.6000
1.4000
1.2000
1.0000
0.8000
0.6000
0.4000
0.2000
0.0000
 ■
2Q0ng 400ng
qxid
Q6DDD
cam
Q3000
Q3X0
otm
octro
2Xg 8Xg
Figure 2.8
Optimisation of recombinant protein coating concentration
Along the x-axis of each graph are the different coating concentrations of purified 
recombinant protein. Concentrations are expressed as ng/well on a 96-well plate. 
Along the y-axis is the absorbance measured at 492nm. The solid lines refer to the 
average absorbance obtained from 5 high reacting sera from Kilifi District, along 
with the standard deviations. The dashed lines refer to the average value plus 3 
standard deviations of 5 non-malaria exposed donors. All sera were used at a 
concentration of 1 TOO. a) DBLla, b) CIDRla, c) DBL2p, d) DBL4y, e) DBL5p.
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Affinity purification of PJEMF1 domain-specific antibodies
lml of purified recombinant protein at a concentration of between 0.5 and 1.5mg/ml 
was dialysed overnight at 4°C against 0.1M NaHCOs, 0.5M NaCl pH 8.3, with the 
medium changed twice using slide-a-lyser dialysis cassettes (Pierce). Using lg  of 
CNBr Sepharose beads (Amersham Biosciences) for every 5ml of purified protein, 
the beads were washed three times in 200ml ImM HC1 by gentle centrifugation for 
less than 2 seconds at lOOOg and then removal of supernatant. The dialysed protein 
and the washed sepharose beads were then mixed in an eppendorf tube and rotated 
for 1 hour at room temperature, before the excess ligand was removed by washing 
with 5 volumes of 0.1M NaHCOs, 0.5M NaCl pH 8.3. 0.1M Tris-HCl ph8.0 was 
added to the beads to a total volume of 1.5ml and the mixture allowed to stand for 2 
hours at room temperature. The beads were then again washed with 3 cycles of 5 
volumes of alternating buffers as follows: 0.1M Acetate, 0.5M NaCl pH 4.0, 0.1M 
Tris-HCl, 0.5M NaCl pH 8.0 as per the manufacturer instructions. Five volumes of 
each buffer were added to the beads and the beads gently rotated, each buffer was 
then removed by gentle centrifugation for 2 seconds and removal of supernatant as 
before. A slurry of beads to a final concentration of 75% PBS, 25% settled beads 
was prepared and to this lml of hyperimmune sera, diluted 5 times in PBS, was 
added. The serum and beads were rolled at room temperature for 1 hour. The mix 
was then spun for 2 seconds at 1 OOOg and the supernatant removed. The beads were 
washed 5 times with phosphate buffer comprising lOmM phosphate pH 7.2, 
immunoglobulins were then eluted using 200pl 0.1M Acetate pH 3.0 and the sample 
was spun immediately (lOOOg for 2 seconds). The supernatant was removed and the 
eluted antibody neutralised immediately with ImM Tris-HCl pH 8.0.
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Parasite Culture
Routine culture of P. falciparum parasites was performed according to the methods 
adapted from Trager and Jensen 1976 (Trager and Jensen 1976). All manipulations 
were conducted in a tissue culture laminar flow hood using sterile techniques. All 
surfaces were cleaned regularly with 70% methylated spirit and contaminated 
disposables rinsed with 1% Virkon.™
Culture Media
Routine culture of parasites was carried out in RPMI-1640 supplemented with 
37.5mM HEPES, 20mM glucose, IOOjliM hypoxanthine, 2mM glutamine, 25pg/ml 
gentamicin sulphate. The pH was adjusted to 7.2 by addition of sodium hydroxide to 
pH 7.2 and 10% (v/v) pooled human serum was added (called RPMI-S). For all 
washes medium without serum was used (denoted RPMI). Pre-sterilised RPMI-1640 
medium (Gibco, UK) was used while supplements and other solutions used during 
the manipulation of cultures, were sterilised either by autoclaving or by passage 
through a 0.2pm filter and stored at 4°C. Serum from individual donors was tested 
to ensure that it sustained parasite growth. Serum from 5-7 donors was then pooled, 
divided into 50ml aliquots and stored at -20°C until required.
Preparation of erythrocytes
Fresh, human erythrocytes of blood group 0  were obtained from a local blood donor 
and washed to remove leucocytes and serum. Whole blood was suspended in RPMI 
to 40% haematocrit. % volume of Lymphoprep was added and the suspension was 
centrifuged at 3000g for 15 minutes at 4°C. Erythrocytes were pelleted by this 
procedure, leaving leucocytes and serum in suspension and thus able to be aspirated
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off. The remaining erythrocytes were washed twice in 10 volumes of RPMI, 
centrifuging at 3000g for 5 minutes at 4°C after each wash. The final pellet was 
resuspended in RPMI to 25% haematocrit, and this suspension was stored at 4°C for 
up to 1 month.
Maintenance of parasites in culture
Parasitised erythrocytes (pRBC) were maintained in RPMI-S in sterile flasks under a 
modified gas mixture of 96% N2, 3% CO2 and 1% O2 and stored in an incubator at 
37°C. Cultures were routinely maintained at 1-10% parasitaemia in fresh 
erythrocytes assuming a fivefold rate of trophozoite reinvasion. Suitable culture 
flasks were chosen to ensure that the depth of medium did not exceed 1cm.
Medium was changed daily according to the following empirical formula:
packed cell volume (ml) x parasitaemia (%) x 5 = volume RPMI-S required (ml)
For washes cultured cells were centrifuged at 2000g for 5 minutes to pellet them 
without damaging the pRBC. Washes were performed in 10 volumes of RPMI. All 
RPMI and experimental materials were pre-warmed to 37°C before use.
Assessment of parasitaemia and growth stage
The routine assessment of the number and stage of parasitised cells in culture was by 
thin blood smear. Small samples of cultured cells suspended in culture medium were 
centrifuged briefly in a microfuge. The supernatant was aspirated to give a 
haematocrit of 25-50% and a drop of this cell suspension was placed on clean 
microscope slide. Using another clean slide the cell suspension was smeared across
134
the surface of the slide and left to dry. The slide was then fixed with methanol, dried 
and stained with Giemsa (10% (v/v) Giemsa stain, 2 ImM sodium hydrogen 
phosphate, 4.4mM potassium dihydrogen phosphate, pH 7.35). Slides were stained 
for 15 minutes before being washed, dried and examined under a light microscope 
set at lOOx magnification under oil immersion. Parasitaemia was determined by 
counting the number of parasites seen in at least 500 red blood cells. In addition the 
maturity of parasites was noted by comparison to standard charts (W.H.O. 1991).
Preservation and storage of pRBC
Long-term storage of parasitised cells was achieved by freezing samples in 
cryopreservative media as individual stabilates following the methods of Diggs and 
colleagues (Diggs, Joseph et al. 1975). The desired pRBC were centrifuged at 2000g 
for 5 minutes and the supernatant aspirated. The pellet was slowly resuspended in 
glycerolyte (57g glycerol, 1.6g sodium lactate, 30mg potassium chloride and 1.38g 
sodium dhydrogen phosphate made up to 100ml in dH20  and adjusted to pH 6.8 with 
sodium hydroxide) at a ratio of 3 volumes packed cell volume: 5 volumes 
glycerolyte. Once the first volume of glycerolyte was added, the suspension was 
incubated for 5 minutes at room temperature before further addition. On completion, 
the suspension was frozen at -80°C in 200pl aliquots in cryo tubes before being 
moved to liquid nitrogen (-196°C) for long-term storage.
Thawing frozen stabilates
Frozen stabilates were rapidly thawed at 37°C and then transferred to a sterile 
polypropylene centrifuge tube (Falcon™; 50 ml) and 0.2mls of 12% (w/v) sodium 
chloride solution was added drop wise with agitation over 5 minutes. Following
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incubation at room temperature for 5 minutes, 5 volumes of 1.8% NaCl (w/v) were 
added dropwise with agitation over 5 minutes and the cells were then pelleted by 
centrifugation at 2000g for 5 minutes. The supernatant was aspirated and 5 volumes 
of 0.9% (w/v) sodium chloride solution was added dropwise with agitation and the 
cells were spun as before. Finally the cells were washed with lOmls RPMI, 
centrifuged at 2000g for 5 minutes, the supernatant was aspirated and cells were re­
suspended in RPMI-S and put into culture as described.
Trypsin treatment of parasitised erythrocytes
Parasites were washed twice in 10 volumes of RPMI which had been adjusted to the 
correct pH by addition of sodium hydroxide solution. All trypsin dilutions were 
performed at pH 7.2. Cells were re-suspended in 10 volumes RPMI containing 
trypsin at a concentration of 1 mg/ml, 100pg/ml or lOpg/ml and incubated for 5 
minutes at room temperature. Control cells were incubated in 10 volumes RPMI 
containing no protease. Trypsin inhibitor was then added at a concentration of 
2mg/ml in an equal volume RPMI and the suspensions incubated for a further 5 
minutes at room temperature. Cells were then pelleted by centrifugation at 2000g for 
5 minutes and washed 3 times in 10 volumes fresh medium prior to use.
Parasites
In this thesis the term isolate will denote a parasite taken from a patient. Line will 
refer to an isolate established in culture and clone will denote a culture derived from 
a single cell of a line.
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The line A4 was derived from sequential cloning from the Brazilian line IT 4/25/5 
(figure 4.3). Two derivations of A4 were used: A4U and A4 40-cycle. A4U was 
derived by sequential selection for binding to the monoclonal antibody BC6, which 
is specific to the expressed A4 var gene, resulting in a population of infected 
erythrocytes expressing predominantly one specific T^EMPl variant on their surface, 
A4 PjEMP1 (Roberts, Craig et al. 1992; Smith, Chitnis et al. 1995). A4 40-cycle 
refers to parasites allowed to grow in culture for 40 cycles with no selection. More 
detail on both these parasite clones is given in chapter 3.
The line 3D7 was obtained by limiting dilution cloning of the isolate NF54, which 
was derived from a patient who acquired malaria in the airport area in Amsterdam, 
The Netherlands. It is the genome of this parasite which was sequenced in its 
entirety and recently published (Gardner, Hall et al. 2002).
The clinical isolate PI was obtained from a 5yr old child admitted to Kilifi District 
Hospital with a fever and moderately severe malaria. It was kindly obtained and 
cultured by Dr Margaret Mackinnon. After sample collection, the sample was 
centrifuged at 693g for 5 min and the red cell pellet obtained washed twice in RPMI 
1640 medium. The parasites were cultured until a parasitaemia of 5% was obtained 
and cryopreserved when the majority of the parasites were at the ring stage.
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Measurement of antibody responses against the surface of the 
infected erythrocyte
Assessment of the reactivity of human sera to the surface of the infected erythrocyte 
was performed using indirect immunofluoresence as measured by flow cytometry .
Flow cytometry
Mature trophozoite stage pRBC at between 1 and 5% parasitaemia were thawed, as 
described, or taken directly from culture. They were washed twice in RPMI and the 
pellet was resuspended at 1% haematocrit in 0.1% bovine serum albumin/phosphate- 
buffered saline (0.1 %BS A/PBS). 1 pi of primary antibody, either human sera or BC6 
monoclonal antibody, was pipetted into separate wells of a 96-well flat-bottomed 
plate (nunc) and 9pi of the infected pRBC cell suspension was added to each well 
giving a final test serum concentration of 1:10. The mixture was incubated at room 
temperature for 1 hour, following which the cells were washed three times with 
0.1 %BSA/PBS, spinning at 1500g between each wash to remove the wash buffer. 
The cells were then re-suspended in 25pl 0.1 %BSA/PBS containing the secondary 
antibody, either rabbit anti-human IgG if testing human sera or rabbit anti-mouse 
IgG for reactions involving BC6 monoclonal antibody, at a concentration of 1:50. 
Again the reaction mixture was incubated for 1 hour at room temperature after which 
a further three washes were performed as before. Finally 25pl of 0.1%BSA/PBS 
containing a 1:50 dilution of swine anti-rabbit IgG coupled to FITC and lOpg/ml of 
ethidium bromide was added to each well. A further incubation at room temperature 
in darkness, for 1 hour was carried out, after which, following a further series of
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washes, at least 1000 pRBC were counted on an EPIC/XL flow cytometer (Coulter- 
electronics, UK).
BC6 monoclonal antibody was isolated from hybridomas generated from mice 
immunised repeatedly with a triton X-100-insoluble extract from A4 infected 
erythrocytes (Smith, Chitnis et al. 1995). It is of isotype IgGl and 
immunoprecipitates a high molecular weight protein with the characteristics of 
P/EMP1 only from clones of the A4 antigenic type. It was used, in this work, to 
select for a population of infected erythrocytes expressing one dominant var gene on 
their surface, A4 var.
Reactivity against the erythrocyte surface was scored in two ways; as mean 
fluorescent intensity and as percentage of infected erythrocytes positive for FITC 
staining using the method of Williams et al (Williams and Newbold 2003). In detail, 
mean fluorescence of parasite-infected erythrocytes was determined using the 
formula:
(d-c)-(b-a)
a = the mean fluorescence intensity (MFI) of uninfected erythrocytes following 
incubation in control plasma or isotype control antibody; b = MFI parasitised 
erythrocytes following incubation in control plasma or isotype control antibody; c = 
MFI uninfected cells incubated in immune plasma or test antibody and d = MFI 
parasitised erythrocytes incubated in immune plasma or test antibody.
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The specific percentage of cells (either parasite infected or uninfected) 
demonstrating surface staining was calculated using the formula:
[count UR / (count UR + count UL) x 100] -  [count LR / (count LR + count LL) 
x 100]
Where UR, UL, LR and LL correspond to the upper right, upper left, lower right and 
lower left quadrants respectively.
Statistical analysis
Data was entered and stored in Microsoft Excel. FACS data was collected using 
Weasel Software (WEHI, Melbourne, Australia) and converted into Excel files. 
Databases were converted into Stata 8 files (State Corp, Ca. USA) and analysed in 
Stata. Detailed and specific statistical analysis is described in each results chapter.
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Chapter 3
Naturally-acquired antibody responses to erythrocyte 
surface-expressed antigens
Introduction
There is now a substantial body of evidence suggesting humoral responses to the 
surface of the infected erythrocyte are an important component of acquired anti­
malaria immunity (Marsh, Otoo et al. 1989; Bull, Lowe et al. 1998; Giha, Staalsoe et 
al. 2000). It is thought that individual responses to the surface of the infected 
erythrocyte are predominantly variant specific, with immunity gained through 
acquisition of a repertoire of variant-specific responses over time (Jeffery 1966; 
Hommel, David et al. 1982; Marsh and Howard 1986; Newbold, Pinches et al. 1992; 
Bull, Lowe et al. 1998; Giha, Theander et al. 1998). In support of this, children 
develop antibodies following infection that are specific to the infecting isolate, 
antibodies which were generally absent at the time of the disease episode (Bull, 
Lowe et al. 1998). However, it is possible that either the diversity in antigenic 
targets is not limitless or there exists cross-reactivity amongst antigenic targets. 
Immune sera from African adults resulted in dramatically reduced parasitaemia when 
given to children with acute malaria living in distant areas (Cohen, Me et al. 1961; 
Cohen, McGregor et al. 1961; Edozien, Gilles et al. 1962). Similarly, immune sera 
from adults from East and West Africa, South America and South-east Asia 
agglutinated erythrocytes infected with parasites from distant geographical regions 
(Aguiar, Albrecht et al. 1992). Taken together, these observations may suggest
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either the restriction worldwide in the targets of these responses or be an indication 
simply that certain antigenic determinants have a broad distribution or contain cross­
reactive epitopes.
Most studies investigating antibody responses directed against the surface of the 
infected erythrocyte have used agglutination to measure these responses (Marsh and 
Howard 1986; Forsyth, Philip et al. 1989; Southwell, Brown et al. 1989; Newbold, 
Pinches et al. 1992; Smith, Chitnis et al. 1995; Bull, Lowe et al. 1998). Only 
recently has flow cytometry been widely adopted as a means of evaluating the anti­
infected red cell surface response (Piper, Roberts et al. 1999; Staalsoe, Giha et al. 
1999; Williams and Newbold 2003). The precise antigenic targets for responses 
detected by both methods are currently unknown, although the most likely target is 
the polymorphic protein family P/EMP1 and while correlation between agglutination 
scores and antibody binding as measured through flow cytometry or surface 
immunofluorescence has been shown (Marsh and Howard 1986; Kinyanjui 2001), it 
is not absolutely certain that both methods are detecting the same response.
As already described, the intra-erythrocytic parasite modifies the surface of the host 
erythrocyte through insertion of parasite derived proteins into the surface membrane 
which drastically alter the morphology and behaviour of infected cells. They 
become highly immunogenic and as the parasite matures they adhere to other cells. 
There are a number of currently identified parasite derived surface proteins including 
the variant antigens RIFINS and i^EMPl and the recently discovered SURFIN as 
well as the modified host protein Band 3 (Leech, Barnwell et al. 1984; Sherman, 
Crandall et al. 1992; Kyes, Rowe et al. 1999; Winter, Kawai et al. 2005). The most
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likely candidate for infected-erythrocyte surface antibody responses and best 
characterised is a single family of diverse parasite proteins, P/EMP1, the features of 
which have been comprehensively reviewed in chapter 1.
Identifying the specific host immune responses and the molecular targets on the 
surface of the infected red cell that explain the variant-specific nature of responses 
and the possibly more conserved or cross-reactive response is of paramount 
importance, both in understanding host-parasite interactions and the development of 
a vaccine. In this chapter, heterologous antibody responses to both wild psarasite 
isolates and laboratory parasite lines, including a laboratory clone selected to express 
one particular variant of P/EMP1, are described for two populations resident under 
differing transmission characteristics on the coast of Kenya. Relationships between 
recognition of the isolates with age, asymptomatic parasitaemia and the effect of host 
genotype, specifically a-thalassaemia and the sickle cell trait (HbAS) are described. 
Investigation of the variant specificity of each measured response was performed and 
an attempt made to abrogate antibody binding to the infected red cell surface through 
protease treatment.
Aims
1. To describe antibody responses to a laboratory-adapted isolate highly selected for 
expression of one dominant var gene, in a community-based cohort of asymptomatic 
individuals.
a) To describe acquisition of antibody responses with age.
b) To examine the differences in acquisition between two areas of differing 
transmission characteristics.
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c) To examine what effect the presence of microscopically-detectable parasitaemia has 
on antibody responses.
2. To compare antibody responses to the same laboratory-adapted clone, although 
unselected, in the same cohort of individuals.
3. To compare antibody responses to two further isolates, the laboratory-adapted clone 
3D7 and a clinical isolate obtained from a symptomatic 5 year old child, PI.
4. To assess the specificity of individual antibody responses.
5. To assess the sensitivity of the measured antibody responses to protease treatment.
6. To examine what effect different host genetic markers of resistance to malaria
disease have on antibody responses to a laboratory-adapted isolate and a clinical
isolate obtained from a symptomatic child.
Methods
Study Population
After obtaining informed consent, sera from 290 asymptomatic individuals were 
obtained at a cross-sectional bleed in Chonyi and Ngerenya in October 2000 as part 
of an on-going study (Mwangi 2003). Written consent for the children’s 
participation was given by their parents or guardians. Baseline characteristics of the 
individuals tested are given in table 3.1.
Cross-sectional survey
A cross-sectional survey was performed in October 2000, when malaria transmission 
was low. Blood samples were obtained from children by venepuncture and plasma 
was separated by centrifugation and stored at -80°C. The children were examined 
for fever (axillary temperature was taken by use of an electronic thermometer), and
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their parasitological status was determined by use of a Giemsa-stained thin malaria 
smear. Individuals were followed up with weekly active malaria case detection and 
continuous passive case detection. A case of malaria was defined as:
Individuals aged less than 1 year -  fever > 37.5°C plus any parasitaemia 
Individuals aged over 1 year -  fever >37.5°C plus parasitaemia > 2500/pl (Mwangi 
2003)
In order to assess antibody binding in symptomatically unwell children, a separate 
cohort of 39 children were recruited at presentation with symptomatic non-severe 
malaria, and followed weekly thereafter for a further 5 weeks. They were examined 
for antibody recognition of A4U by flow cytometry at time of presentation and 
weekly thereafter. The methodology used was as for the asymptomatic community 
cohort with the same positive controls present. All children were aged between 7 
and 115 months and were resident in Kilifi district. Samples were collected as part 
of a study examining the kinetics of antibody response to the infecting isolate 
(Kinyanjui, Bull et al. 2003).
145
VOOs
- Q
3^"
O n
(NSOO (N Os r"
oo o <N
o
Ir,
o n rs i
o o  ON
o CnI
O<N
<N
CM
O O o
CMS O
CM
(N
CN
so
Parasites
In order to test heterologous antibody responses, three parasite lines were used; 
laboratory clones A4 and 3D7 and one clinical isolate denoted PI.
A4
The isolate A4 was derived from sequential cloning from the Brazilian line IT 4/25/5 
(figure 4.3). It was provided as a gift to Professor C. Newbold from Dr R.J. Howard. 
Two derivations of A4 were used: A4U and A4 40-cycle. A4U was derived by 
sequential selection for binding to the monoclonal antibody BC6, which is specific to 
the expressed A4 var gene. This results in a population of infected erythrocytes 
expressing predominantly one specific P/EMP1 variant on their surface, A4 P/EMP1 
(Smith, Chitnis et al. 1995). The extent of expression of this var gene can be 
measured using flow cytometry with BC6. A4 40-cycle, in contrast, was derived 
from A4 by being allowed to grow in culture with no selection for 40 intra- 
erythrocytic cycles. Measuring A4 P/EMP1 expression using flow cytometry 
revealed that between 72 and 86% of A4U-infected erythrocytes were displaying this 
protein on their surface compared to between 8 and 12% of A4 40-cycle-infected 
erythrocytes. Both these cloned parasite lines were a gift from Mr Bob Pinches.
3D7
The parasite 3D7 was obtained by limiting dilution cloning of the isolate NF54, 
which was derived from a patient who acquired malaria in the airport area in 
Amsterdam, The Netherlands. It is the genome of this parasite which was sequenced 
in its entirety and recently published (Gardner, Hall et al. 2002). Curiously, this
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particular isolate is not thought to express P/EMP1 on the surface of infected 
erythrocytes to the same degree as other isolates such as, for example, A4 {Sue Kyes, 
personal communication}. A recent paper by Jensen and colleagues describing 
antibody responses to 3D7 both unselected and selected by sera from children in 
malaria-endemic areas revealed low reactivity towards the unselected 3D7 as 
measured by flow cytometry (Jensen, Magistrado et al. 2004). Furthermore, 3D7 
displayed markedly less adhesion to CSA and ICAM-1, even following selection for 
these receptor-binding phenotypes, than isolates of the IT lineage and a range of 
clinical isolates although binding to CD36 occurred to a high level in both unselected 
and CSA-selected 3D7 (Beeson and Brown 2004) and {Beeson J.G. personal 
communication}.
Wild Isolate PI
PI was obtained from a 5yr old child admitted to Kilifi District Hospital with a fever. 
It was kindly obtained and cultured by Dr Margaret Mackinnon. After sample 
collection, the sample was centrifuged at 693g for 5 min and the red cell pellet 
obtained washed twice in RPMI 1640 medium. The parasites were cultured until a 
parasitaemia of 5% was obtained and cryopreserved when the majority of the 
parasites were at the ring stage. Culturing was done according to the methods 
outlined in chapter 2.
Assessment o f anti-infected erythrocyte antibody levels in plasma using flow  
cytometry
The serum obtained during the survey was assayed for antibodies to the surface of 
erythrocytes infected with each of the isolates described; A4U, A4 40-cycle, 3D7
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and PI, using flow cytometry. The flow cytometry was carried out as described in 
chapter 2. All individuals were assayed in duplicate and experiments involving a 
single isolate were all performed on the same day. Sera was assayed using 96-well 
U-bottomed plates (Nunc) and results were standardised relative to reactivity against 
previously screened high positive control sera, present in duplicate on each plate and 
20 sera from non-malaria exposed donors from Oxford U.K. Also present on each 
plate were two blank wells containing no serum sample, for assessment of 
background non-specific secondary antibody binding and two wells assaying 
responses of a known high responding serum sample to standard A4 in order to 
control for day to day variability. A proxy measure of the levels of anti-erythrocyte 
surface antibodies was taken as the mean fluorescence intensity (MFI) of infected 
erythrocytes after correction for background binding, as outlined in chapter 2.
Host genotype
To examine the effects host genotype may have on recognition of the parasites tested, 
a subgroup of individuals were genotyped with regards their sickle and a- 
thalassaemia status. Sickle cell status, whether HbAA (wild-type) or HbAS (sickle 
cell trait) was evaluated using electrophoresis and the common African 3.7kb a- 
globin deletion was identified using PCR on DNA extracted by standard methods 
(Chong, Boehm et al. 2000). All genotyping was performed as part of an ongoing 
study investigating the relationship between malaria disease and genetic mechanisms 
of resistance, (Dr Thomas Williams). Genotyping and electrophoresis were 
performed by Mr Alex Mwacharia, Mr Sammy Wambua and Ms Sophie Uyoga.
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Statistical analysis
All statistical analysis was performed using Stata8™ (StataCorp. Ca. USA). The 
relationship between parasite status at the time of blood sampling and reactivity to 
the surface of erythrocytes infected with each isolate was assessed using logistic 
regression. The outcome in every case was positivity for recognition of each isolate 
as classified using the cut-off of the mean response from 20 non-exposed donors plus 
3 standard deviations. Initially the data were explored for additional factors 
affecting the likelihood of recognising each isolate. In every case these were 
identified as age (in categories of 6 months duration), location of each individual 
(either Chonyi or Ngerenya) and previous exposure to malaria infection (estimated 
by responses to whole schizont extract). The likelihood of recognition of each 
isolate was then compared in those parasite positive and parasite negative at cross- 
sectional survey. When the relationship between host genotype and reactivity was 
assessed, again using logistic regression, parasite status, either positive or negative as 
determined by microscopy, was included in the model as a possible confounding 
variable.
When the relationship between parasitaemia and intensity of response was 
investigated, a multiple linear regression was performed after including the same 
confounding variables identified as for logistic regression. The outcome variable, 
MFI, was log transformed prior to inclusion in the linear regression model to 
normalise the distribution. When investigating the likelihood of recognising a 
greater number of isolates, an ordered logistic regression was used. Individuals were 
scored 0, 1, 2, 3 or 4 according to the number of isolates to which they scored 
positive, the resultant odds ratio obtained gives the likelihood of being in a higher
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recognition group comparing two groups of interest, either parasite status, positive or 
negative or host genotype. The same confounding variables were included as for the 
binomial logistic regression model. To investigate the relationship between 
responses to two isolates, again a multiple linear regression was performed after log 
transformation. To test if exposure alone could account for the positive correlation 
between responses to two isolates, age (again as a factor of 6 months duration), 
location, parasite status and responses to whole schizont extract were included as 
possible explanatory variables.
Where differences in two continuous variables were assessed, no assumptions of 
distribution were made and the Wilcoxon rank sum test was used to calculate 
significance. Where more than two variables were compared the Kruskal Wallis test 
was used. To assess all correlations the Spearman rank correlation coefficient was 
used.
Results
Sera from 290 individuals resident in both Chonyi and Ngerenya and aged between 6 
months and 85 years were tested for their ability to recognise the surface of 
erythrocytes parasitised with the P. falciparum line A4U.
Naturally acquired responses to laboratory isolate A4U
There is marked age-associated acquisition of antibody towards the surface of A4U- 
infected erythrocytes (figure 3.1). This is the case for those individuals resident 
within both the high and low transmission study areas (Chonyi and Ngerenya 
respectively). The chi-squared test for trend across the age groups shown gives a p-
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value of <0.0001 for both areas. As will be expanded upon in chapter 6, the risk of 
suffering an episode of clinical malaria by the definition described reduces 
significantly at different ages in the two areas. In Chonyi, the risk of experiencing 
an episode of clinical malaria is significantly less by the age of 5 years, whereas in 
Ngerenya the risk does not significantly lessen until the age of 10 years. If this test 
for trend is limited to those age-groups over which the risk of experiencing an attack 
of malaria becomes significantly less (0.5-5 years in Chonyi and 0.5-10 years in 
Ngerenya) then there remains a significant age-associated trend of antibody 
acquisition (p=0.0002 in Ngerenya and p=0.0057 in Chonyi). There is earlier 
acquisition of antibodies in Chonyi compared to Ngerenya, with responses reaching 
a plateau of between 80 and 100% of individuals reacting by the age group 6 -7 years. 
This contrasts with the pattern seen in Ngerenya where antibody prevalence 
continues rising until the age group 10-11 years. It is striking, that in both areas all 
individuals have antibodies to the surface of erythrocytes infected with this highly 
selected laboratory clone by late adolescence. If MFI is considered as a marker of 
the level of antibody binding then there is an increase with age in both areas with 
individuals in Chonyi recognising the surface of A4U-infected erythrocytes with a 
greater intensity than individuals in Ngerenya (p=0.0044 Wilcoxon ranksum) (figure
3.2).
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Figure 3.1
Proportion of individuals recognising A4U
Shown are proportion of individuals scoring positive for recognition of A4U as 
defined in the text within each age category shown. Shown are means and upper 
95% confidence intervals.
* p<0.05
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Responses to other isolates
Those individuals aged 10 years or less were subsequently tested for their 
recognition of three further parasite isolates: laboratory isolate 3D7, a wild isolate 
obtained from a symptomatically infected child, PI, and laboratory isolate A4 40- 
cycle (A4 parasites which have been allowed to grow in culture for 40 cycles with no 
selection).
There is evidence of acquisition of antibodies with age to all 4 isolates tested (figure
3.3). The chi-squared test for trend is highly significant for all isolates tested in each 
area, (p<0.005 for all isolates, both areas). For all isolates, there is evidence for 
earlier acquisition of antibodies in Chonyi. Figure 3.4 illustrates the MFI obtained 
against each isolate, split by location. As is obvious there is a greater intensity of 
response in the higher transmission area, Chonyi compared with responses from 
individuals resident in Ngerenya. This is true for all isolates tested. A greater 
proportion of individuals were positive for recognition of 3D7 overall than any of the 
other isolates. It was of interest to assess whether this was reflected in greater 
intensity of responses to 3D7. As is clear from figure 3.4 the median MFI obtained 
against 3D7 and the wild isolate PI is lower in most of the age groups tested 
compared to any of the A4 variants.
Interestingly, the pattern of antibody recognition of A4U was strikingly different 
amongst symptomatically infected children. Figure 3.5 shows an overview of the 
results. None of the children showed heterologous recognition of A4U at 
presentation and only 4 of the children showed any positive response and then only 
transiently.
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The effect o f asymptomatic parasitaemia on recognition o f the infected erythrocyte 
surface
A previous study from this area, analysing antibody reactivity to variant antigens 
exposed on the surface of infected erythrocytes, noted that the presence of 
asymptomatic parasitaemia at the time of serum collection resulted in a higher 
prevalence of antibodies, as measured by agglutination (Bull, Lowe et al. 2002). A 
subsequent study using flow cytometry demonstrated a strong association between 
being parasitaemic and scoring positive for recognition of a range of isolates 
including unselected A4 (Kinyanjui, Mwangi et al. 2004).
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Figure 3.2
Intensity of response to A4U amongst children under 10 years
Shown are median MFI plus upper and lower 95% confidence intervals after log 
transformation. The x-axis refers to the age category in years. The dashed 
horizontal line highlights the cut-off for positivity (the mean of the log transformed 
MFI from 20 non-exposed donors plus 3 standard deviations).
** p<0.005
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Figure 3.3 
Responses to all isolates tested
Shown are the proportion of individuals in each age category shown, scoring positive 
for each of the isolates tested. Positivity was scored as defined in the text and the 
absolute value differed for each isolate, a) refers to individuals resident in Chonyi 
and b) to individuals from Ngerenya.
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Figure 3.4
Intensity of responses to all 4 isolates tested
Shown are median log transformed MFI plus 95% confidence interval of responses t 
all 4 isolates by age. The key given at the bottom refers to the colours of the boxes,
a) individuals resident in Chonyi and b) individuals from Ngerenya
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Figure 3.6 illustrates the proportion of individuals in each age group reacting to the 
surface of A4U infected erythrocytes stratified by parasite status at the time of blood 
sampling. For those individuals aged less then 10 years, a greater proportion of 
those parasitaemic score positive (MFI greater than the average MFI plus 3 standard 
deviations of 20 non-exposed donors from the U.K.) for recognition of A4U. In 
those over 10 years, there is no difference between the groups due mainly to 
saturation of positivity. If the effect of parasite status on recognition to each isolate 
in turn was assessed by logistic regression, adjusting for the effects of age and 
location on acquisition of antibody responses and exposure as estimated by 
responses to whole schizont extract, then there is a significant increased likelihood of 
recognition of all isolates except the wild isolate PI, if an individual was 
asymptomatically parasitised at the time of cross-sectional survey, (figure 3.7). 
When MFI was considered as a continuous variable, in a linear regression model 
adjusting for age and location, (table 3.2), having detectable parasites at cross- 
sectional bleed resulted in significantly higher MFI against all isolates including PI, 
the wild isolate.
Correlation o f responses between isolates
In order to assess the specificity of each individual response, scatter diagrams of 
paired responses, normalised on a log scale, were plotted (figure 3.8). A distinct 
positive correlation between individual responses to each isolate in turn was 
observed. This was confirmed by Spearman’s rank correlation coefficient (table 3.3). 
Furthermore, the possibility that these relationships were entirely as a consequence 
of an individual’s exposure to malaria infection were shown to be unlikely by 
performing a multiple linear regression model examining the relationship between
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responses to each isolate controlling for age, categorised as a factor of six month 
duration, location, parasite status at cross-sectional bleed, location and responses to 
whole schizont extract as a proxy measure of exposure. From these results it was 
evident that exposure alone did not explain the very strong positive correlation in 
responses between the different isolates (table 3.4).
What is also evident from the scatter diagrams is that there are a proportion of 
individuals showing specificity for one isolate over another. The proportions of 
individuals in each area scoring positive for antibodies to 0, 1, 2, 3 or 4 isolates are 
outlined in table 3.5. Also shown are the odds of recognising 0, 1, 2, 3 or 4 isolates 
according to whether an individual was resident in Chonyi or Ngerenya after 
accounting for confounders, age, the presence of asymptomatic parasitaemia and 
exposure (estimated by response to whole schizont extract). It is clear that 
individuals not showing any antibody response to any isolate were significantly more 
likely to reside in the low transmission area and conversely those recognising all 4 
isolates were more likely to come from the high transmission area, Chonyi.
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Figure 3.6
Proportion of individuals recognising A4U stratified by presence of parasites
Each graph illustrates the proportion of individuals in each age category scoring 
positive for recognition of A4U. Shown are means and upper 95% confidence 
intervals. The solid grey bars refer to those individuals parasite positive by 
microscopy at cross-sectional survey and the cream bars to those parasite negative, a) 
Individuals resident in Chonyi, b) Individuals resident in Ngerenya.
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Figure 3.7
Odds ratio of being antibody positive against each isolate tested if parasite 
positive at cross-sectional survey
Odds ratio calculated using a logistic regression model controlling for location, age 
and exposure as estimated by responses to schizont extract. The horizontal line 
illustrates an odds ratio of one.
*=p<0.05 **=p<0.005
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T able 3.2
Increase in intensity of response as a result of the presence of parasites
Isolate Fold difference 
in M FI1
95% confidence 
interval
p-value
A4U 1.175 1.02-1.36 0.038
A4 40-cycle 1.274 1.16-1.40 0.003
3D7 1.198 1.07-1.35 <0.001
PI (clinical isolate) 1.073 1.01-1.146 0.031
The results of a multiple linear regression model examining the effect of having parasites on the resultant 
MFI obtained in response to each isolate in turn. Confounding variables included in the analysis were the 
age of the individual, the location and an individual’s exposure, as estimated by responses to schizont extract.
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Figure 3.8
Inter-isolate correlations
Scatter diagrams showing correlations of individual responses to pairs of isolates. All MFI scores 
have been log transformed. The best-fit line is shown.
a) A4U v A4 40-cycle
b) A4U v 3D7
c) A 4uvP l
d) A4 40-cycle v pi
e) A4 40-cycle v 3D7
f) PI v 3D7
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Table 3.3
Inter-isolate correlations
correlation Spearman’s rho p-value
A4U -  A4 40-cycle 0.8408 <0.0001
A4U -  3D7 0.6975 <0.0001
A4U -  PI (clinical isolate) 0.6203 <0.0001
A4 40-cycle -  3D7 0.8163 <0.0001
A4 40-cycle -  PI 0.7021 <0.0001
3D 7-P1 0.6711 <0.0001
Spearmans rank correlation coefficients for each pair o f comparisons. Shown are the coefficients and the
significance values.
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Table 3.4 Relationship between antibody responses to A4U and antibody 
responses to all other parasite lines
a) Univariate analysis with no adjustment for confounding variables
Isolate Coefficient1 95% C.I. p-value
A4 40-cycle 1.05 0.94 -1.17 <0.001
3D7 0.74 0.62 - 0.87 <0.001
Clinical isolate PI 1.38 1.09-1.68 <0.001
b) Multivariate analysis adjusted for age, location, parasite status and exposure
Isolate Coefficient2 95% C.I. p-value
A4 40-cycle 1.13 0.96 -1.30 <0.001
3D7 0.71 0.52 - 0.89 <0.001
Clinical isolate PI 0.99 0.64 -1.33 <0.001
'Coefficient calculated using univariate linear regression. The outcome of interest was MFI of 
antibody responses to A4U after log transformation. In each case the explanatory variable was MFI 
of antibody responses to each isolate in turn after log transformation.
Coefficient calculated using multivariate linear regression. The outcome of interest was MFI of 
antibody responses to A4U after log transformation as above. In each case the explanatory variable of 
interest was MFI of antibody responses to each isolate in turn after log transformation. The 
coefficient was adjusted for the effect of age (included as a categorical variable o f six months 
duration), parasite status (positive or negative for microscopically detected parasitaemia), location and 
exposure (as estimated by antibody responses to whole schizont extract after log transformation).
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Responses to protease-treated infected erythrocytes
All of the parasite-expressed antigens on the infected erythrocyte surface currently 
identified are trypsin-sensitive (Sherman, Crandall et al. 1992) (Leech, Barnwell et 
al. 1984) (Kyes, Rowe et al. 1999) (Winter, Kawai et al. 2005). P/EMP1 is 
classically thought to be exquisitely trypsin-sensitive with RIFINs less so (Leech, 
Barnwell et al. 1984) (Kyes, Rowe et al. 1999). In order to assess whether the 
antigenic targets binding IgG in this study were also sensitive to trypsin and if so to 
what extent, each of the four isolates tested were subjected to trypsin treatment. 
Initially infected erythrocytes were pre-treated with serial dilutions of trypsin with 
control aliquots of infected erythrocytes treated with RPMI only. All samples were 
then treated with trypsin inhibitor at the same concentration. Figure 3.9 outlines the 
results obtained. Whereas A4U appears extremely sensitive to trypsin even at 
concentrations as low as 10pg/ml, the other 3 isolates tested show less of a marked 
drop of in reactivity. Responses to all four isolates, however, do show evidence of 
trypsin sensitivity albeit to different degrees. It was decided to screen all individuals 
against all isolates pre-treated with trypsin at a concentration of lOpg/ml and repeat 
this at a concentration of 1 mg/ml. Experiments involving individual parasite isolates 
comparing mock-treated, 10 |ig/ml and 1 mg/ml of trypsin were conducted on the 
same day. Unfortunately supply of the wild isolate PI was limited and as such we 
were unable to test each individual serum against the isolate following trypsinisation.
At lOpg/ml of trypsin, reactivity to both A4U and A4 40-cycle was markedly 
reduced (figure 3.10). Overall reactivity against A4U was reduced by 84.2% and 
against A4 40-cycle by 77.1%. As is clear from figure 3.9, the same could not be
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said for reactivity against 3D7 with overall reactivity only reduced by 5%. All 
correlations between isolates were maintained following treatment with lOpg/ml of 
trypsin, albeit less strongly (table 3.6). Again all correlations remained significant 
when the effects of exposure were considered in a multiple linear regression as 
before (data not shown). Testing all individuals against all isolates pre-treated with 
1 mg/ml abrogated over 93% of the reactivity against both A4 derived isolates and 
reduced reactivity against 3D7 by 55.6%. Furthermore, no correlations between 
responses remained significant.
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Figure 3.9 
Response to trypsin
Graphs illustrate the effect pre-treatment of each isolate with serial dilutions of trypsin had 
on reactivity of a selection of adult sera. The colours are maintained through each graph 
with the same colour referring to the same serum. The same individuals were tested against 
each isolate with the exception of A4U where the monoclonal antibody BC6 was also tested. 
The concentration of trypsin used is plotted along the x-axis with the crude MFI (after 
correction as detailed in the methods) is plotted along the y-axis.
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Figure 3.10
Response to pre-treatment with lOpg/ml of trypsin
Box and whisker plots showing median fluorescence intensity following log transformation after 
Opg/ml (grey boxes) and lOpg/ml (white boxes) of trypsin. The horizontal dashed lines correspond to 
the mean response of 20 non-exposed donors against each isolate plus 3 standard deviations, 
measured against each isolate.
172
Table 3.6
Inter-isolate correlations following trypsin treatment
correlation measured
i ....
Spearman’s rho p-value
A4U -  A4 40-cycle 0.4087 <0.0001
A4U -  3D7 0.4242 <0.0001
A4 40-cycle -  3D7 0.3679 <0.0001
'Spearmans rank correlation coefficients for each pair of comparisons between isolates pre-treated 
with 1 Opg/ml of trypsin. Shown are the coefficients and the significance values.
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Host genotype and responses to the infected erythrocyte surface
The effect of host genotype, both a-thalassaemia and HbAS, on recognition of A4U,
a measure of heterologous response was examined in a subset of individuals.
a) a-thalassaemia
There was no difference in intensity of recognition of the surface of A4U infected 
erythrocytes between those with normal a-globin genotype, those heterozygous for 
a-thalassaemia or those with homozygous a-thalassaemia, in any of the age groups 
tested (figure 3.11). Looking at the median MFI obtained over all the age groups 
and locations tested; there was no significant difference between any of the three 
groups (figure 3.12). This was also the case when responses against A4 40-cycle, 
3D7 and the wild isolate PI were examined (figure 3.13). It is important to note that 
there was no difference in the proportion of individuals parasite positive between the 
three groups (p=0.6686, Kruskal Wallis), nor was there any significant difference in 
the spread of ages represented by the three groups, (p=0.2118, Kruskal Wallis) 
(figure 3.14).
If individuals were categorised according to the number of isolates they recognised, 
0, 1, 2, 3 or 4 and an ordered logistic regression done with the number of isolates 
recognised as the outcome, then after controlling for exposure, age, location and 
parasite status, individuals with either hetero- or homozygous a-thalassaemia were 
56% less likely to be in a higher recognition group, although this result was at the 
threshold for statistical significance (OR 0.44 (95% Cl 0.19 -  1.00) p=0.05.
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b) HbAS
Within the cohort of individuals originally sampled and described thus far, there 
were only 6, amongst those genotyped, with HbAS. We thus established a new 
cohort of individuals purely to look in more detail at antibody responses in those 
with HbAS. 162 people from Ngerenya were sampled in October 2000 as described 
previously. These individuals ranged in age from 9 months to 75 years and 
comprised 104 people with genotype HbAA and 58 people with HbAS. There was 
no significant difference in the proportion of individuals parasite positive (p=0.7589, 
Wilcoxon ranksum) although there was borderline significance in the spread of ages 
represented, (p=0.0541, Wilcoxon ranksum) between the two groups with 
individuals in the HbAS group slightly older (mean age of HbAS individuals 139.5 
months (95% Cl 93.7 - 185.4 compared to mean age of HbAA individuals 96.5 
months (95% Cl 73.9 - 119.1)) However if we limited the analysis to only those 
individuals less than 10 years there was no significant difference between the two 
groups (p=0.8963 Wilcoxon ranksum). Of the 58 individuals with HbAS, 12 had a 
normal a-globin genotype, 28 had either heterozygous or homozygous a- 
thalassaemia and 18 were not typed.
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Figure 3.11
Intensity of response to A4U by age and thalassaemia genotype
Box and whisker plot of median responses to A4U stratified by thalassaemia genotype. Responses 
are ordered by age. Included are individuals from both Chonyi and Ngerenya 
No differences reach significance.
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Figure 3.12
Intensity of recognition of A4U by genotype
Box and whisker plot showing median MFI obtained against A4U by genotype. There were no 
significant differences between the groups.
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A4U
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A4 40-cycle
a a /a a  a-/aa a-/a-
3D7 Wild isolate PI
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Figure 3.13
Responses to all four isolates stratified by thalassaemia genotype
Box and whisker plots showing the median MFI after log transformation and 95 % confidence limits 
obtained to each isolate stratified by thalassaemia genotype. Included are individuals aged less than 
10 years from both areas. There were no significant differences between the groups.
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Figure 3.14
Ages of all individuals within each thalassaemia group
Dot plot showing equality of the ages represented within each genotype. The red crosses illustrate the 
mean. There was no significant difference between the groups.
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Considering the population as a whole, those with HbAS genotype had significantly 
higher MFI for responses against the A4U-infected erythrocyte surface than those 
with HbAA (figure 3.15). If median MFI is plotted against age, then in those aged 5 
years and younger there is a significant increase in response amongst those with 
HbAS genotype (figure 3.16). This is not the case in the older age groups. If this 0- 
5 year age range is looked at in more detail, then the maximum difference in 
response between the two populations, HbAS and HbAA occurs in those aged less 
than 36months, (p=0.0045, Wilcoxon ranksum) (figure 3.17). In a multiple logistic 
regression controlling for the effects of age and parasite status on antibody 
acquisition as well as exposure, using responses to whole schizont extract as a proxy 
measure, then the odds ratio of recognising the surface of erythrocytes infected with 
A4U parasites in HbAS individuals compared to wild-type (HbAA), was 2.47 (95% 
Cl 1.07-5.71) p=0.034.
To assess whether this trend was associated with responses to other isolates, sera 
from the same individuals were tested for recognition of a clinical isolate, P3, taken 
from a 5 year old child with moderately severe malaria. Overall there was no 
significant difference in the level of MFI between HbAA and HbAS individuals 
although the trend was again higher in the HbAS group (figure 3.18). Assessing 
response by age revealed no significant patterns of responses across the age groups 
comparing both genotypes (figure 3.19). The odds of recognising P3 if HbAS 
genotype compared to HbAA did not reach significance in a multiple logistic 
regression model, (OR 1.67 (95% Cl 0.63 -4 .51) p=0.304).
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Individuals were then categorised according to whether they recognised 0, 1 or 2 
isolates and an ordered logistic regression model was used to assess whether or not 
those with HbAS genotype were more likely to recognise a greater number of 
isolates, compared to wild-type HbAA individuals. After including confounding 
variables; age, parasite status and exposure as measured by responses to whole 
schizont extract, the odds ratio of being in a higher category, (ie recognising 2 
isolates compared to 1 or recognising 1 isolate compared to 0 or recognising 2 
isolates compared to 0) if HbAS compared to HbAA was 2.43 (95% Cl 1.18 -  5.02) 
p=0.017.
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Figure 3.15
Intensity of recognition of A4U stratified by sickle cell genotype
Box and whisker plot showing the median log transformed MFI obtained in response to A4U 
according to whether individuals were of the genotype HbAA (wild type) or genotype HbAS (sickle 
cell trait). The p value given refers to the result of a Wilcoxon ranksum analysis comparing the two 
groups.
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Figure 3.16
Intensity of recognition of A4U according to age and genotype
Box and whisker plot showing median MFI according to age and sickle cell genotype, 
refer to the Wilcoxon ranksum test.
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Figure 3.17
Intensity of recognition of A4U in the youngest age groups, according to 
genotype
Box and whisker plots of responses according to sickle cell status, in children less than 5 years. P 
values refer to the Wilcoxon ranksum test.
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Figure 3.18
Intensity of recognition of clinical isolate P3, stratified by sickle cell genotype
Box and whisker plot showing the median log transformed MFI obtained in response to wild isolate 
P3 according to whether individuals were of the genotype HbAA (wild type) or genotype HbAS 
(sickle cell trait). The p value given refers to the result of a Wilcoxon ranksum analysis comparing 
the two groups.
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Figure 3.19
Intensity of recognition of clinical isolate, P3, according to age and genotype
Box and whisker plot showing median MFI according to age and sickle cell genotype. There were no 
significant differences.
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Discussion
In this chapter individuals were studied at a single point in time for the ability to 
recognise a panel of isolates including 3 laboratory clones and a clinical isolate. 
Previous work has described the narrow specificity of agglutinating antibodies 
induced by clinical infection (Marsh and Howard 1986; Bull, Lowe et al. 1998). 
Other studies have described induction of antibody responses to heterologous 
isolates following infection as measured by both agglutination and flow cytometry 
(Iqbal, Perlmann et al. 1993; Giha, Staalsoe et al. 1999; Giha, Staalsoe et al. 1999; 
Ofori, Dodoo et al. 2002). The individuals studied in this chapter were all 
asymptomatic at the time of cross-sectional survey with a proportion in each area 
parasitaemic. Parasitaemia was identified only by microscopy and as a result there 
will be a proportion of individuals within the parasite negative group, with parasite 
loads too low for detection by this method. As all individuals were surveyed at the 
end of the low transmission season in this area, those parasitaemic will contain some 
people harbouring chronic infections persistent since the previous high transmission 
season although as transmission in this area is perennial a number will be newly 
acquired infections. By using the laboratory isolates A4 and 3D7 the antibody 
responses measured will be presumed heterologous, that is directed against targets 
other than those present within the infecting parasite population, in those with 
detectable parasites. In this way these antibody responses can be thought of as a 
marker of the individual’s breadth of response.
The parasite A4U is a particularly interesting isolate to study responses to. Through 
selection with the monoclonal antibody BC6, it consists of a population of infected 
erythrocytes where the majority are expressing on their membrane surface one
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dominant var gene, A4 PyEMP 1. The characteristics of this variant of P/EMP1 are 
given in chapter 4. This contrasts with A4 40 -  cycle which consists of a far more 
heterogeneous group of expressed var genes. When responses to A4U were 
measured by location and across the ages measured, a striking age-associated 
acquisition of antibody responses was observed. This was true in both the high and 
low transmission area. Considering we are potentially measuring responses to a 
single variant of PyEMPl, it is somewhat remarkable that in Chonyi by the age of 6- 
7 years and in Ngerenya by the age of 10-11 years almost 100% of those tested show 
evidence of recognition of this isolate (figure 3.1). Furthermore, having an 
asymptomatic parasitaemia resulted in a greater prevalence of antibodies amongst 
those parasite positive compared to parasite negative, a pattern persisting until early 
adolescence (figure 3.6). The association shown here between the presence of 
parasites and antibodies to this heterologous isolate may reflect an overlap between 
the antibody repertoire induced by chronic infection and epitopes present within the 
expressed A4 var gene. The very narrow specificity of antibody responses induced 
following symptomatic clinical infection has been detailed before (Marsh and 
Howard 1986; Bull, Lowe et al. 1998). It may be that responses generated to isolates 
other than the infecting isolate target alternative more cross-reactive or conserved 
epitopes or that the ability to maintain chronic infections is associated with a broader 
range of antibody specificity due to chronic infections switching through a broader 
range of variants. An alternative possibility, suggested by Bull and colleagues, 
remains that a subset of immuno-dominant epitopes exist against which responses 
are generated early in infection rather that the weeks subsequent to disease (Bull, 
Lowe et al. 2002), antibodies which could potentially be boosted by chronic 
infections. Perhaps A4 PyEMP 1 has within it such epitopes. What was striking, was
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that when a group of children were examined for their heterologous recognition of 
A4U, using the same methodology and positive controls, at the time of presentation 
with clinical non-severe malaria and then weekly thereafter for 5 weeks, only 4 
children demonstrated any recognition of this isolate and then only transiently 
(figure 3.5). This is a result in stark contrast to the prevalence of anti-A4U antibodies 
described in this asymptomatic community cohort of individuals.
As with responses to A4U, the presence of parasites at the time of cross-sectional 
survey resulted in a significantly increased likelihood of recognising both A4 40- 
cycle and 3D7, but not the wild isolate PI (figure 3.7). Although there was 
significantly increased intensity of response in the presence of parasites against all 4 
isolates (table 3.2).
Previous studies looking at the recognition of unselected A4 amongst children in this 
area under the age of 10 years demonstrated age-associated acquisition measured by 
both flow cytometry and agglutination (Kinyanjui 2001). Antibodies were less 
prevalent than found in this study with a maximum recognition of around 40% by 
the age group 8-10 years. However differences in methodology and analysis of the 
flow cytometry acquisition data make any direct comparisons impossible. What was 
clear from the study described above was that overall, children recognised all field 
isolates to a greater extent than the laboratory isolates tested, a finding not seen in 
this work. The field isolate, PI in this work by contrast was recognised to a lesser 
degree than the laboratory isolates tested. This is somewhat unexpected as clinical 
isolates may contain within them many variants and as such we would have expected 
more prevalent recognition within the community. This particular isolate came from
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a symptomatic 5 year old child and previous screening by flow cytometry using a 
pool of children under 10 years, all parasite negative had revealed a response 81% 
that of the maximal response generated by screening a pool of adults from this area 
(data not shown). Thus it may have been expected that the prevalence of recognition 
be greater amongst the younger aged individuals. If the results are expressed as a 
percentage of maximal response however, then by the age of 10 years, the median 
response generated was 79% of maximum.
Previous studies have demonstrated very little reactivity to 3D7 (Jensen, Magistrado 
et al. 2004){Francis Ndung’u personal communication] . It was therefore surprising 
to note the high overall prevalence of antibodies to this isolate amongst individuals 
less than 10 years in this cohort (figure 3.3). When intensity of response was 
estimated by MFI it was clear that IgG binding to this laboratory-adapted isolate was 
actually substantially lower than responses to either of the A4 derived isolates 
(figure 3.4). It is not clear why responses to 3D7 should be lower than those found 
to other isolates. It has been suggested that there is less iyEMPl expressed on the 
surface of 3D7-infected erythrocytes, possibly as a result of a protein transport 
deficit {Sue Kyes personal communication}. Certainly, previous attempts to 
measure P/EMP1 yield through Western blotting revealed a lower yield than other 
isolates {James Beeson personal communication}. A recent study demonstrated that 
parasites of the 3D7 lineage, even those selected for rosetting, had none of the 
complex vesicles shown in other parasite lines to transport both P/EMP1 and RIFINs 
from the parasitophorous vacuolar membrane to the surface of the infected 
erythrocyte. Instead the parasite 3D7 relied on less complex smaller single vesicles
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(Haeggstrom, Kironde et al. 2004). The importance of this to surface expression of 
both P/EMP1 and RIF IN s is as yet unknown.
Recent studies from this area have highlighted the marked protective effect both a- 
thalassaemia and the sickle cell trait (HbAS) have on the likelihood of an individual 
suffering from malaria (Williams, Mwangi et al. 2005; Williams, Mwangi et al. 2005; 
Williams, Wambua et al. 2005). Within this population, around 15% of individuals 
have HbAS with the a-thalassaemia allele frequency at around 0.5. Whereas the 
protection afforded by the thalassaemia genotypes, both hetero and homozygous is 
complete and constant from birth, {Thomas Williams personal communication}, 
individuals with HbAS genotype show increased protection with age up until the age 
of 10 years, a result suggestive of an underlying acquired immune component 
(Williams, Mwangi et al. 2005). It was hypothesised that this age-associated 
protection was a result of enhancement of both innate and acquired protective 
immune mechanisms.
Although the marked protective effect of both sickle cell trait and a-thalassaemia on 
the incidence of clinical malaria is well documented in this area (Williams, Mwangi 
et al. 2005; Williams, Wambua et al. 2005), the precise mechanism of protection by 
both genotypes is unknown.
It has been hypothesised that increased antibody binding to the infected a- 
thalassaemic erythrocyte surface may contribute to the protection afforded by a- 
thalassaemia (Luzzi, Merry et al. 1991; Luzzi, Merry et al. 1991; Williams, 
Weatherall et al. 2002). The increased antibody binding seen was not thought to be
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as a result of P/EMP1-specific binding as there was no difference in mAb BC6 
binding, specific for A4 P/EMP1 as mentioned, between wild-type and heterozygous 
a-thalassaemic red blood cells (Williams, Weatherall et al. 2002). In this study, we 
found no difference in recognition of each individual isolate between the two groups, 
either hetero or homozygous a-thalassaemia, or wild type, however this is perhaps 
not surprising as this increased antibody binding to the infected red cell may be a 
function of the effects of the a-globin deletion on the red cell membrane and in this 
study all erythrocytes used were wild type.
With sickle cell trait the situation is different. In this study individuals were 
significantly more likely to recognise A4U-infected erythrocytes, at least in the 
younger age-groups (figure 3.16). Although no increased recognition of a randomly 
selected clinical isolate was seen, in an ordered logistic regression individuals were 
more likely to recognise more isolates if they were HbAS compared to HbAA. 
These results support earlier work where a significantly higher titre of anti-infected 
erythrocyte antibodies in children with HbAS compared to HbAA was found (Marsh, 
Otoo et al. 1989), and more recent work whereby the presence of HbAS genotype 
was associated with enhanced recognition of two heterologous clinical isolates 
among Gabonese children (Cabrera, Cot et al. 2005). Interestingly the fact that it is 
the younger age groups which show increased recognition of A4U-infected 
erythrocytes is at odds with the increasing protection afforded by the presence of the 
sickle trait with age in children under ten. Undoubtedly the protection afforded by 
this genetic trait is a result of a multitude of factors and is not explained by a single 
phenomenon.
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It is interesting to speculate what might be the target for the antibody responses thus 
described. Previous work has highlighted the variant-specificity of responses 
measured by flow cytometry directed against the infected red cell surface (Staalsoe, 
Giha et al. 1999) and that the adhesion phenotype of the infected erythrocyte 
correlated well with the expressed var gene (Smith, Chitnis et al. 1995). Also by 
using parasites with a deletion on chromosome 9 and therefore an inability to express 
P/EMP1 and in all likelihood other antigens, on the surface of the erythrocyte, Piper 
and colleagues demonstrated marked abrogation of fluorescence intensity, (Piper, 
Roberts et al. 1999), a finding also seen after trypsin treatment of the infected red 
cell, (Williams and Newbold 2003). Thus it would appear the most likely candidate 
for recognition on the infected erythrocyte is P/EMP1.
In this study, by comparing individual responses against the isolates described we 
found strong correlation in responses (figure 3.8). Whilst this may be expected for 
comparisons made between A4U and A4 40-cycle, immune selection resulting in 
structuring of var genes into discrete antigenic groups (Gupta and Anderson 1999), it 
was not expected to such a strong degree between the A4 isolates and either 3D7 or 
the clinical isolate PI. That this correlation was not simply explained by exposure 
was even more remarkable. This finding led to the hypothesis that perhaps what is 
being recognised was not a variant antigen but a conserved target leading to variant- 
transcending responses or at least a subgroup of cross-reactive or common epitopes 
within more diverse antigens. A degree of isolate specificity in antibody response is 
also apparent however, with the line of best-fit not dissecting zero indicating 
preferential recognition of one isolate over another (figure 3.8).
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In order to dissect this response further, each isolate was pre-treated with trypsin. 
All currently identified surface exposed parasite antigens are known to be 
differentially trypsin sensitive (Leech, Barnwell et al. 1984; Sherman, Crandall et al. 
1992; Kyes, Rowe et al. 1999; Winter, Kawai et al. 2005). It was thought that if the 
reactivity measured was not abrogated by trypsin pre-treatment, then perhaps a novel 
antigenic target for heterologous responses may be responsible for the tight 
correlations observed. As shown, reactivity to each isolate was sensitive to trypsin 
to varying degrees, with 3D7 significantly less sensitive than responses to A4. 
However the correlations were maintained after pre-treatment with lO^g/ml of 
trypsin which had abrogated all responses to either of the A4 isolates by more than 
80%. It was only after pre-treatment with 1 mg/ml when there was barely any 
reactivity to A4, that all correlations were lost. A previous study looked in detail at 
precisely the sensitivity of different epitopes within A4 P/EMP1 to trypsin (Fagan 
1999). A4 P/EMP1 is sequentially cleaved by increasing concentrations of trypsin, 
from the N-terminal end with DBL domains 8, y and a to p remaining attached 
through inter-domain disulphide bonds even once the intervening sequence has been 
cleaved. This work also demonstrated the molecular target for the monoclonal 
antibody, BC6, lying within the inter-domain region between domains 8 and s. It is 
known that variant antigens, specifically P/EMP1 differ in their sensitivity to trypsin 
(Gardner, Pinches et al. 1996). Also RIFINs appear to be less trypsin sensitive than 
P/EMP1 (Kyes, Rowe et al. 1999).
It is difficult to conjecture what target might be being recognised to the same extent 
by each individual in this study however the data presented provide evidence of an 
isolate transcending response. It is not possible however to say conclusively whether
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this response is to a relatively trypsin resistant component of PyEMPl or to another 
more conserved target. If a pan-reactive response or a variant-transcending target 
could be established on the surface of infected erythrocytes then the implications for 
vaccine design could be of immense importance.
It was with this aim that we went on to look in more detail at the domain-specific 
response to A4 P/EMP1 domains. Prior to this, however we successfully cloned and 
expressed the domains of A4 P/EMP1 as recombinant fusion proteins. The results 
of this set of experiments are outlined in chapters 4 and 5.
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Chapter 4
Production of expression constructs and expression of 
recombinant proteins
Introduction
The heterologous expression of recombinant protein has become a standard process 
in molecular biology. It has become essential for the characterisation of almost all 
proteins, from determination of antigenicity to functional analysis and vaccine 
development. Among the many systems available for recombinant protein 
production, the gram-negative bacterium Escherichia coli (E. coli) is one of the most 
attractive for reasons including its ability to grow rapidly and at high density, its 
well-characterised genetics and the availability of many types of expression systems 
tailored to individual requirements through the use of different cloning vectors and 
mutant strains of bacteria.
Selection of expression system
In utilising a heterologous expression system, it is hoped that the resultant 
recombinant protein will mirror as far as possible, the native protein in terms of 
conformation and tertiary structure. This is particularly important if the resultant 
protein will be used in functional studies or as an antigen recognised by antibodies in 
human sera. The resultant recombinant protein and how much it resembles the 
native form is dependent on the correct folding pathway and appropriate post-
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translational modifications occurring. Malaria antigens are amongst the most 
difficult proteins to produce in vitro. This stems from the fact their genome consists 
of a high number of A/T repeats. Many systems have been utilised for the 
production of malaria antigens including E. coli (Baruch, Pasloske et al. 1995; 
Baruch, Ma et al. 1997; Abdel-Latif, Khattab et al. 2002), baculovirus (Pang, 
Hashimoto et al. 2002), and yeast (Baruch, Gamain et al. 2002).
Using baculovirus as an expression system has resulted in the production of correctly 
folded proteins (Pizarro, Chitarra et al. 2003). However problems of toxicity have 
been encountered with many recombinant proteins being toxic to the insect cells. As 
a result of this the system achieves low yields of protein making it a rather inefficient. 
Recently expression of malaria proteins in yeast cells has been optimised (Baruch, 
Gamain et al. 2002) (Kocken, Withers-Martinez et al. 2002; Miles, Zhang et al. 2002; 
Pan, Huang et al. 2004). However the complicated manipulation of sequences 
required prior to protein expression and the relatively long cultivation time make it 
unlikely that this method will become standard, reviewed in (Chang 1994).
As mentioned, the P. falciparum genome is extremely A/T-rich in terms of 
nucleotide composition. This complicates the expression of P. falciparum proteins 
in heterologous systems as the resultant abundance of lysine and arginine residues in 
the expressed proteins results in them being positively charged thus hindering their 
expression in E. coli. The high A/T content of the mRNA template also causes 
early termination of the protein and can be responsible for heterogeneity in the final 
expressed protein product. In using the E. coli system, this has meant expression
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can be limited by the rarity of tRNAs in E. coli present in abundance within the P. 
falciparum genome (Yadava and Ockenhouse 2003). This can be circumvented by 
using strains of E. coli which have been transfected with a plasmid carrying extra 
copies of those tRNAs in short supply.
There have been many examples of successful expression of malaria proteins from 
bacterial systems either directly or in combination with a fusion protein (Baruch, 
Pasloske et al. 1995; Baruch, Ma et al. 1997; Fagan 1999; Abdel-Latif, Khattab et al.
2002). Also, there have been no reports of significant post-translational modification 
to any domain of i^EMP 1. In eukaryotes the principal modifications can include 
glycosylation, where carbohydrate molecules are added to the protein structure, 
cleavage, phosphorylation and methylation. These previous successful attempts at 
cloning coupled with the apparent minor role of post-translational modification in 
the expression of P. falciparum proteins led us to use a bacterial expression system 
to express the domains of P/EMP1 in this study.
Selection of expression vector
Many current techniques for bacterial expression utilise fusion proteins. Examples 
include glutathione-S-transferase (GST) (Smith and Johnson 1988), maltose-binding 
protein (MBP) (di Guan, Li et al. 1988) and a simple repeat histidine tag (Stuber 
1990). Although fusion proteins were originally designed to facilitate protein 
purification and immobilisation, it has become apparent that certain fusion proteins 
greatly improve the solubility of the protein of interest. How this happens is not 
entirely clear although it does seem to depend on the order of protein synthesis, with
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importance placed on the fusion protein being synthesised first (Sachdev and 
Chirgwin 1998). Not all fusion proteins are equally proficient at increasing 
solubility, in a study comparing the effectiveness of various fusion partners MBP 
was found to be far superior to alternative fusion protein systems including GST, as 
a solubilising partner (Kapust and Waugh 1999).
This information as well as the fact that GST is derived from Schistosoma japonicum 
(the population under study may have been exposed to Schistosoma haematobium 
which could potentially have a degree of antigenic similarity to Schistosoma 
japonicum) led us to conclude that the expression vector MBP was the optimal 
vector for use in these studies.
First devised in 1988, (di Guan, Li et al. 1988; Maina, Riggs et al. 1988), the pMAL- 
2 vector system allows a cloned gene to be inserted downstream from the malE gene 
of E.coli, which encodes MBP, producing a recombinant protein fused to MBP. This 
vector system utilises the tac promoter and the malE translation initiation signals to 
give high-level expression of the fusion protein,(Duplay, Bedouelle et al. 1984; 
Amann and Brosius 1985) as well as allowing simple purification through the 
affinity of MBP for maltose,(Kellermann and Ferenci 1982). The vector carries the 
laclq gene, which codes for the lac repressor. This keeps expression low in the 
absence of isopropyl-P-D-thiogalactopyranoside (IPTG) induction. The inclusion of 
an ampicillin resistance gene allows for selection of transformed bacteria (figure 4.1).
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Selection of domains for cloning
As described, within the P.falciparum genome there are around 60 copies of a gene 
family called var, coding for proteins known as P/EMP1 (Gardner, Hall et al. 2002). 
The var genes are made up of three distinguishable domains known as Duffy binding 
like domains, (DBL), cysteine rich interdomain regions, (CIDR) and the conserved 
exon 2(Peterson, Miller et al. 1995; Baruch, Ma et al. 1997; Smith, Subramanian et 
al. 2000). Although each variant shares this common structure they are polymorphic 
in terms of sequence. From sequence alignments these domains have been 
characterised into different sub-classes, for the DBL domains a  to s and for the 
CIDR domains a  to y. Figure 4.2 outlines a schematic of one of these genes, the A4 
var gene showing the domains cloned and expressed in this project.
Experiments were conducted using P. falciparum parasites of the laboratory adapted 
A4 lineage. Sequential cloning from the Brazilian line IT 4/25/5, a gift to Dr C I 
Newbold from Dr R Howard, derived this line; figure 4.3 illustrates its derivation. 
Domain sequences were amplified from the parasite line A4 and corresponded to the 
sequence of A4 iyEMPl. This particular variant of P/EMP1 was chosen for a 
number of reasons. It has a well-described and classified sequence already published 
with established domain boundaries. It displays a common cytoadherent phenotype, 
binding to both CD36 and ICAM-1 and is a useful tool in the laboratory as there 
exists a monoclonal antibody, BC6, specific for this variant, allowing in vitro 
selection of A4 parasites expressing specifically A4 P/EMP1 (Smith, Chitnis et al. 
1995; Smith, Subramanian et al. 2000), and lastly previous work undertaken in the 
area of Kenya where these studies were done highlighted recognition of this strain of
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pBR322 ori
Figure 4.1
Map of pMAL-c2X vector (also sister vector pMAL-p2X which differs in that the malE signal 
sequence is maintained allowing export of the recombinant protein to the cellular periplasm if 
required), note the pMAL -c2X vector includes an exact deletion of the malE signal sequence.
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Figure 4.3
Derivation of the A4 laboratory parasite line (Roberts, Craig et al. 1992)
The Ituxi parasite line is a knob-forming, cytoadherent strain originating in Ituxi, Brazil. Mab BC6 is 
a monoclonal antibody specific for the major PfEMPl variant expressed on the surface of 
erythrocytes infected with late stage A4 parasites, A4 PfEMPl. A4U (A4 ultra) are parasites selected 
for expression of A4PfEMPlthrough use of Mab BC6 and A4-40c are parasites, which have been in 
culture for 40 cycles of growth with no immune selection.
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cloned parasite by around 70% of adults and 30% of children as measured by 
agglutination (K. Marsh unpublished data).
The intention was to express each domain of A4 P/EMP1 including the cystiene rich 
interdomain region (CIDR). A4 genomic DNA, kindly supplied by Sue Kyes, 
Oxford, was used as a template for cloning. Primers were designed spanning the 
domain and interdomain boundaries as outlined in the published A4 sequence (Smith, 
Kyes et al. 1998), with restriction enzyme sites attached to allow directed cloning 
into the multiple cloning site of p-MALc2x vector. Sequences of the primers used 
are given in table 4.1. Initially it was felt that separate and 3’ from DBL2p was a 
conserved cystiene rich region called C2. In the original cloning experiments this 
region was not included in the primer design or eventual protein expression. DBL5P 
has also a region 3’ to it which is cystiene rich although not classified as a C2 region. 
This region again was not initially included in the primer design. As information 
became available that these areas were to be classified as part of the P-type domains 
primers were re-designed and the resultant proteins re-expressed {Chris Newbold 
and Sue Kyes personal communication).
Optimisation of PCR
PCR reactions were carried out to amplify selected regions of A4 P/EMP1 DNA for 
cloning. Optimisation experiments were performed prior to using any set of primers 
using variations of thermal cycling times, magnesium chloride concentrations, 
template, and primer concentrations (Harris and Jones 1997; Fagan 1999). 
Optimisation focused on obtaining the exact stringency required to amplify the
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region of interest over competing regions of other var genes. Table 4.2 demonstrates 
the final cycling conditions used. Yields varied between 0.5 and 5jag DNA per 50jal 
reaction. Note that after PCR using the primers specific for domain dbl38, it became 
clear from the size of the DNA amplified that the region cloned using these primers 
was too large. Detailed analysis of the A4 var sequence revealed an intron, which 
had mistakenly been incorporated within the primer boundaries. The reverse primer 
for this domain was thus re-designed and the cloning process re-started. 
Unfortunately no protein was successfully expressed using these primers and the 
attempt was abandoned.
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Table 4.1
Primer sequences used to amplify the sections of DNA corresponding to each 
desired region of the protein.
Name Primers Primer Sequence 5’ to 3’
A4dblla A4 dbla Smal F GCrGaXGGGGGRCATGGTAGGGAGCATOCT
A4 dblal Hindffl R I OOGCAAGCTIOXrATTOCGrrATGAGAAAATG
A4QDRla A4 CXDR1 Smal F GCIGaDCXXX^AGGrGGATTAIGrATATFOG
A4 GDR1 Pstf R CCOCTXXAGCrATGAATGAGCAATAGCATTGG
A4dbl2(3 A4 dblb Smal F GCTOCGCX3GGACGAACCAATATTOCAATGC
A4dblbXbaIR CCOCrCTAGACTACCACOCGCAATGrOGrrTGrGG
A4dbl2(3c2 A4dbl2bc2XbaIR CCrCTAGACrAGCACACATGCAACrFGGrGIG
A4 dbl4y ; A4 dbld Smal F GCrGCOAXXFrGCAATACAAAATATrATGCAAC
A4 dbld Hirdin R OCGGCAACXTIGCrAGGAAGCAAATGTACTGTC
1 A4 dbl5p I A4 dblel Smal F GCTGCXXX^GGGCrrCGAATTGrGAAC
A4 dblel HndEI R CCGGCAAGOTGCrAAGGAGGrGCAGIGCrAGG
A4 dbl5|3c | Mdbl5b+€XbaIR CCTCTAGACTAGATTTGGGATOGrrFATTACIGG
Restriction sites are identified in bold type. Primers named F follow the 5 ’ to 3’ coding sequence of 
the DNA and those denoted R were reverse primers specific for the anti-sense strand. Note for Dbl2(3 
and Dbl5|3 there are two reverse primers, the first one was used initially before the realisation of c2 
being part o f the P-type domain and the second primer was ordered later to incorporate this cysteine- 
rich area as outlined above.
2 0 6
T able 4.2
The final cycling conditions used for the PCR outlined for each domain cloned.
Region M gCh 
Cone.
Temp °C Time/mins No. of Cycles
A4 d b lla  3.5mM
A4 2.5mM  
C ID R la
A4 dbl2(3 2.5mM
94 4 1
94 0.5 
50 0.5 
65 2
35
65 5 1
A4 dbl4y 2.5mM  
A4 db!5P 3.5mM
94 4 1
94 0.5
55 0.5 
65 2
35
65 5 1
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Cloning
DNA was purified from PCR reactions as previously described. Following treatment 
with the appropriate restriction enzymes, DNA inserts were again purified by 
electrophoresis and agarose digestion again as described. Inserts were ligated into 
the p-MALc2x vector, which had been previously cut with the appropriate restriction 
enzymes and undergone treatment with calf intestinal phosphatase to prevent self­
ligation. The resulting plasmid was transformed initially into DH5a strain E, coll 
Ampicillin selection was applied to identify transformed colonies of bacteria.
Screening of Recombinant Plasmids
Plasmid extractions were performed, as described, on clones derived from initial 
transformation reactions. Restriction digests were performed on the purified plasmid 
DNA to determine if an insert of the correct size was present. Digests were done 
using the specific restriction enzymes attached to each primer as described in table 
4.1. A representative sample of digests is illustrated in figure 4.4.
Once the presence of a correctly sized insert had been confirmed, the plasmids were 
transformed into TB1 or latterly BL21-CodonPlus-Ril bacteria cells for expression. 
These cells were grown on LB media plates supplemented with both 
chloramphenicol and ampicillin, for BL21-CodonPlus-Ril cells and ampicillin alone 
for TB1 cells, as described. To further check presence of a correctly sized insert, 
colonies grown on such plates were screened by PCR using p-MALc2x specific 
primers. The forward primer initiates at the 3’ end of the malE gene around 81 bp 
upstream of the primary site in the polylinker. The reverse primer is initiated within
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the lacZa gene. The details of these primers are given in table 4.3. The PCR 
screening was undertaken by lifting an isolated colony from the overnight growth 
plate and adding it briefly to 24pl of PCR buffer containing the p-MALc2x specific 
primers before adding the colony definitively into a 1ml aliquot of LB medium. The 
PCR was run with the cycling times outlined in table 4.4 and the culture was 
incubated at 37°C until the end of the PCR run. Those colonies that were positive for 
the presence of the insert were grown overnight in LB supplemented with ampicillin 
and chloramphenicol or ampicillin alone, shaking at 37°C before being stored at -  
20°C in 20% glycerol.
Initial Expression Screening
Transformed bacteria were checked for successful expression of recombinant 
proteins following plasmid screening. This verified that premature stop codons had 
not been introduced by PCR errors and checked different clones containing the same 
constructs for relative levels of expression. To verify expression of the recombinant 
protein, non-induced cultures were treated and analysed for expression in parallel 
with cultures that had been induced by IPTG.
Initial results showed adequate expression of all constructs when assessed crudely. 
There were variations amongst individual clones and between domains with 
CIDRla proving the most difficult to express at high enough yields. Examples of 
crude expression of all the constructs is shown in figure 4.5.
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Optimisation of Preparative Scale
Once a clone had been identified as an efficient expressor of recombinant proteins 
large scale preparations were performed. Several factors were found to influence 
yield and these were individually investigated for each protein. Yields varied 
between proteins and ranged from 0.1 mg/ml to 2mg/ml of final eluate. Factors 
found to influence yield included temperature at induction, expression time, strain of 
bacteria used for expression, method of cell lysis, and concentration of maltose used 
in elution. Bulk preparations of protein were done using culture volumes of between 
1 and 2 litres, optimisation experiments were carried out on smaller volumes of 50ml. 
Adequate amounts of all the domains were obtained once the elution conditions were 
optimised as described, CIDRla however required more extensive optimisation 
before adequate yields were obtained and this will be described.
Table 4.3 
p-MALc2x specific primers
Prim er region Sequence 5’ to 3’
p-MALc2x malE F 
p-MALc2x M l3 R
GGTCGTCAGACTGTCGATGAAGCC
GTAAAACGACGGCCAGT
2 1 0
Table 4.4
PCR cycling times for screening transformed colonies
Temp °C Time/Mins No Of Cycles
95 1 1
94 0.5 35
50 0.5
65 1.5
65 5 1
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MW 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
1018bp
Figure 4.4
An example of PCR screening for correctly sized inserts
An example of screening transformed bacteria containing the insert CIDRla (761bp including MBP 
fusion) using the p-MALc2x specific primers. As is obvious colonies 3,11 and 19 did not show any 
evidence of containing a correctly sized insert.
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S>:;V. Sf*' ^  *§»I H H I
b)
MW - +
Figure 4.5
Gel showing comparison of IPTG induced (+) and uninduced (-) expression of MBP fusion proteins.
MW molecular weight ladder a) DBL la , b) DBL2(3 c) CEDRla d) DBL4y e) DBL5|L The arrows 
indicate the intact fusion proteins.
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Elution conditions
Overall the most important factor influencing yield was the concentration of maltose 
used to elute the recombinant protein from the amylose resin column. In order to 
optimise elution conditions, 50 ml cultures were grown induced and cells lysed as 
described previously. To the bacterial lysate obtained after sonication, 500p,l of pre­
equilibrated amylose resin was added and the tubes rolled at room temperature for 1 
hour. The lysate and column was spun briefly and the supernatant removed, 2mls of 
column buffer was then added to the column beads and the beads were rolled for 1 
minute and the supernatant removed each time. The column beads were then split 
into 5 x 20pl amounts of amylose resin and to each was added elution buffer with a 
different concentration of maltose added (lOOmM, 50mM, 30mM, 20mM, lOmM). 
Each eppendorf tube containing the column beads and elution buffer was then rolled 
for 30 minutes, centrifuged briefly and the supernatants collected. Protein elution 
was then assessed on a 10% SDS-PAGE gel. Figure 4.6 illustrates elution of 
CIDRla as an example of the effect of increasing the maltose concentration in the 
elution buffer.
Temperature
Growth at low temperature has been found to improve the yields of expression 
constructs in heterologous systems.(Airenne and Kulomaa 1995; Yu, Deng et al. 
1995) The effects have been reported as both reducing degradation of soluble 
proteins and reducing aggregation and resultant insolubility. It was consistently 
difficult to obtain soluble CIDRla with intense bands corresponding to the size of 
the intact fusion protein present within the insoluble pellet suggesting that
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considerable amounts of the protein aggregate within the bacterial cytoplasm. An 
example of the insoluble fraction of this particular protein is illustrated in figure 4.7. 
Induction temperatures of 30°C, 25°C and 20°C were compared to 37°C and it was 
found that that all temperatures lower than 37°C lessened this problem considerably 
with 25°C giving optimal balance between improved yield and lengthened 
incubation time, figure 4.8.
Strain of bacteria
Bacterial strain DH5a was used for all cloning steps and initial protein expression. 
Following this initially, E. coli strain TB1 (F' ara k(lac-proAB) [<t)80dlac A(lacZ)M15J 
rpsL{StrR) thi hsdR) was used for large scale expression. However, expression of all 
the fusion proteins proved extremely unstable in this system and this was thought 
due to the fact this strain was not protease deficient. Of additional concern when 
cloning and expressing from P. falciparum DNA is the high A/T content of the 
genome. As mentioned, the paucity of tRNAs necessary to cope with such a 
nucleotide composition can limit expression of the full-length protein. BL21- 
codonplus-Ril cells were then compared for expression efficiency and found to be 
superior. This strain of E. coli naturally lacks the Ion protease, which can degrade 
recombinant proteins and also has extra copies of the argU, ileY and leuW  tRNA 
genes in the form of a pACYC plasmid. These genes encode tRNAs that recognise 
the arginine codons AGA and AGG, the isoleucine codon AUA and the leucine 
codon CUA respectively, together the tRNAs that most frequently restrict translation 
of heterologous proteins from organisms with AT-rich genomes.
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Figure 4.6
MW SN 100 50 30 20 10 mM Maltose
70 kDa
45kDa
Gel showing CIDRla fusion protein obtained with different concentrations of maltose in the elution 
buffer. Note progressively more protein was obtained with higher concentrations. SN is the bacterial 
lysate after rolling with the columns for 1 hour as described, 70kDa is the predicted size of the 
CIDRla fusion protein. 45KDa is the predicted size of MBP, the fusion partner.
Figure 4.7
MW SN Pellet U
Gel showing the majority of expressed CIDRla present within the bacterial pellet.
MW molecular weight ladder, SN supernatant and U uninduced culture. 70kDa is the predicted size 
of CIDR la .
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37°C 25°C
70kDa
MW U Pellet SN MW Pellet SN U
Figure 4.8
Gel illustrating the effect of lowering the induction temperature from 37°C to 25°C. 
MW molecular weight ladder, SN supernatant, U uninduced, 70kDa is the predicted 
size of the CIDRla fusion protein.
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Summary of expression experiments
Final purified products of all the recombinant proteins are shown in figure 4.9. 
Many proteins suffered from some premature termination or degradation. 
Assessment of the concentration of the proteins was made using two methods. For 
crude estimates of concentration, samples of purified protein were compared on an 
SDS-Page gel to known amounts of bovine serum albumin (BSA). The relative 
intensity of the coomassie stained bands gave an approximate value for the protein 
concentration of the sample.
For more accurate quantification, a soluble phase protein assay was carried out using 
a Protein Assay kit (Bio-Rad). Coomassie Blue was used to stain proteins in 
aqueous solution with results being read by spectrophotometry at 595nm. BSA was 
used as a standard.
Both of these techniques depended on the relative dye binding properties of BSA 
against the experimental samples. These will vary between individual proteins. 
Thus, the results of these assays can only be expressed as values relative to BSA.
Sequencing
Sequencing was performed on the junction sites of the DNA constructs as they were 
produced. This was done using manual sequencing techniques and sought to 
confirm that a correct reading frame had been generated and that the initial sequence
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was correct. This was confirmed for all constructs. Later experiments to verify the 
entire insert sequence were performed using an automated sequencing method. 
Sequence reactions were repeated by the Department of Biochemistry, University of 
Oxford.
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MW MBP DBL5p DBL4y CIDRla DBL2p DBL la
175 KDa 
83 KDa
62 KDa 
47.5 KDa
Figure 4.9
Expression of all domain constructs
Gel showing expression of all the PfEMPl domains expressed. On the right hand side are the protein 
size markers. As some bands are extremely faint the corresponding molecular weight is marked for 
comparison. The domains are labeled across the top of the gel with lane one showing expression of 
MBP alone.
The expected sizes of the fusion proteins are as follows:
D B L la -  90KDa 
DBL2p -  90KDa 
C ID R la-70K D a 
DBL4y -  90KDa 
DBL5P -  80KDa 
MBP -  45KD
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Discussion
Maltose-binding protein would appear to be a successful tool for the expression and 
purification of recombinant proteins. Significant problems were met with when 
eluting the protein in a soluble form, whereas expression of the construct itself was 
efficient. The yield obtained using this system, while adequate is not massive with 
some of the constructs proving easier to purify than others. The CID Rla domain 
proved most difficult to purify, with the majority of the protein expressed remaining 
insoluble after bacterial cell lysis. Many strategies were employed to deal with this, 
though only inducing the protein at a lower temperature made any difference. All 
purification was aided by eluting at a higher maltose concentration than the 
manufacturers recommend.
It is unknown to what degree recombinant proteins must retain their native structure 
in order to raise antisera against them. Previous work has indirectly shown that 
antisera raised against bacterially expressed recombinant proteins can, in one case 
inhibit the function of native P/EMP1 (Baruch, Pasloske et al. 1995), and in another 
study recognise the surface of intact A4 parasitised red blood cells (Fagan 1999). 
The hope in this thesis was that these recombinant proteins would retain tertiary 
structure enough to measure domain-specific antibodies present in the sera of 
individuals resident within a malaria endemic area.
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Chapter 5
Naturally acquired antibody responses to recombinant 
protein domains of Plasmodium falciparum  erythrocyte 
membrane protein-1 (PfEMPl)
Introduction
Having successfully expressed recombinant proteins covering major domains of A4 
PfEMPl, each domain was characterised with regards to its recognition by sera 
collected from adults and children resident in two areas of different P. falciparum 
transmission intensity. The intention was to describe overall patterns of response to 
each domain and how they alter with age and transmission. A further aim was to 
describe individual variation of recognition between individuals and between 
domains. In order to demonstrate that responses to the recombinant domains were of 
importance in vivo, the correlation of responses to each domain with those to the 
surface of A4-infected erythrocytes were measured. Finally I attempted directly to 
purify anti-domain specific antibodies.
Methods
Recombinant proteins corresponding to the major domains of A4 PfEMPl were 
expressed and purified as described in Chapter 4. Reactivity was measured against 
each domain using an ELISA method previously optimized as described in Chapter 2. 
After obtaining informed consent, sera from 1,222 asymptomatic individuals were 
obtained at a cross-sectional bleed in Chonyi and Ngerenya in October 2000 as part
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of an on-going study (Mwangi 2003). The baseline characteristics of the individuals 
tested are summarised in table 5.1. A blood slide was taken at the time of bleed and 
later analysed for the presence of detectable parasites by microscopy. Individuals 
were followed up by weekly active malaria case detection and continuous passive 
case detection. A case of malaria was defined as:
Individuals aged less than 1 year -  fever > 37.5°C plus any parasitaemia 
Individuals aged over 1 year -  fever >37.5°C plus parasitaemia > 2500/pl (Mwangi
2003)
All ELISAs were conducted in duplicate and if a disparity greater than 15% existed 
between the two readings, they were repeated, again in duplicate. In order to 
standardise readings between plates a previously defined positive control serum 
sample was included on each plate in duplicate as well as 5 non-malaria exposed 
donor sera, obtained from Oxford, UK. Sera were tested blind to the age and 
parasite status of each individual, although the location, Ngerenya or Chonyi, was 
known. All sera were tested against each domain in a random order. All ELISA 
data was entered into an Excel spreadsheet and the average of duplicate wells taken. 
An individual was scored as antibody positive if the average OD obtained was 
greater than the mean plus 3 standard deviations of a panel of 20 non malaria- 
exposed donors. This cut-off was chosen in order to fully capture the variability 
which existed in reactivity shown by the non malaria-exposed donors in response to 
some domains, notably CIDRla. As part of a study investigating the relationship 
between malaria disease and genetic mechanisms of resistance, (Dr Thomas 
Williams) a proportion of samples were genotyped for a thalassaemia status (normal,
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heterozygote or homozygote) and for the presence of sickle cell trait (HbAS). All 
genotyping was performed by Dr. Williams, Mr Alex Mwacharia and Mr Sammy 
Wambua at the Centre for Geographic Medicine Research Coast.
Statistical analysis
To investigate the relationship between parasite status at the time of cross-sectional 
bleed and subsequent antibody levels, a multiple linear regression model, controlled 
for age, expressed as a factor of 6 months duration, location and exposure was 
performed. The results are expressed as coefficients describing the difference in 
antibody levels attributable to parasites. The odds of being antibody positive if 
parasite positive were calculated using a multiple logistic regression model with age 
and location as co-variables. Significant differences in two or more continuous 
variables were calculated using the Wilcoxon rank sum test. The Chi-squared test 
for trend was used to assess a trend across groups.
In a randomly selected subgroup of individuals, total IgG responses to the intact A4 
parasitised erythrocyte were measured using flow cytometry (see Chapter 3, table 3.1 
for details of individuals tested). The parasite line A4U (kindly supplied by Mr Bob 
Pinches) was used. This clone of parasite expresses on its surface one dominant var 
gene, A4 through selection with the monoclonal antibody BC6 (Smith, Chitnis et al. 
1995). The correlation of responses to each individual domain with responses to the 
parasitised erythrocyte surface was compared using the Spearman rank correlation 
coefficient.
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5
In order to further clarify whether the responses measured by ELISA to each 
recombinant protein domain reflected domain-specific responses as may occur 
towards the intact erythrocyte surface expressed RyEMPl, an attempt was made to 
purify the domain specific antibodies from sera of individuals. The aim was to 
assess whether or not these responses reacted against the surface of the intact A4 
parasitised erythrocyte through flow cytometry. Domains DBLla and DBL4y were 
selected because of the positive correlation between individual responses to these 
domains with individual responses to the intact parasitised erythrocyte. All statistical 
analysis was performed using Stata version 8 (Statacorp, TX, USA).
Results
Sera from a total of 1222 individuals were tested by ELISA against five recombinant 
proteins corresponding to the DBLla, DBL2p, CIDRla, DBL4y, and DBL5(3 
domains of A4 /yEMPl. Individual patterns of response and overall acquisition of 
antibodies to each domain was assessed.
Naturally occurring antibody responses to recombinant PfEMPl domains 
Evidence for age-associated acquisition of domain-specific IgG was apparent for all 
domains, except CIDRla and DBL2P, in both Chonyi and Ngerenya (Figure 5.1). 
However, it is important to note than when the Chi-squared test for trend was applied 
only to the age ranges over which there is appreciable acquisition of anti-malaria 
disease immunity, ages 6 months to 5 years in Chonyi and ages 6 months to 10 years 
in Ngerenya, there was no significant age-associated trend of antibody acquisition, 
although this study was not designed in order to detect such differences. No
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appreciable increase in antibody acquisition with age was seen with CIDRla, in fact 
in Ngerenya a significant loss of response with age was seen. Acquisition of 
antibody responses to DBL2p was only seen in the higher of the two transmission 
areas, Chonyi. Noticeable differences could be seen in the response to the different 
PfEMPl domains. For example it is clear that a greater proportion of individuals 
recognise D BLla and DBL4y than the other three domains with overall 30.8% (95% 
Cl 26.2 -  35.8%) and 32.5% (95% Cl 27.9 -  37.3%) of individuals recognising 
D B Lla and DBL4y respectively, compared to 18.8% (95% Cl 13.9 -  24.3%), 21.2% 
(95% Cl 16.4 -  26.7%) and 19.6% (95% Cl 14.7 -  25.2%) for CIDRla, DBL2p and 
DBL5P respectively (p<0.0001 for comparison of overall recognition of DBLla or 
DBL4y with any other domain Wilcoxon ranksum).
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Figure 5.1
Proportion of individuals in each age group recognising recombinant domains
Sera from individuals older than one year of age, were tested for reactivity against each recombinant 
protein in turn using ELISA. All individuals were tested in duplicate and if a disparity between the 
results of greater than 15% was obtained the serum was retested. Responses were scored as positive 
if the average OD obtained was greater than the average plus 3 standard deviations of a panel of 20 
non-malaria exposed donors. The solid grey bars refer to individuals resident in Chonyi and the 
hatched bars to individuals resident in Ngerenya. a) DBLla, b) CIDRla, c) DBL2P, d) DBL4y, e) 
DBL5p.. P-values given are chi-squared for trend, C = Chonyi N = Ngerenya
228
There was a clear increase in proportion of responders and rate of acquisition of 
responses in Chonyi compared to Ngerenya. For example with DBL4y the 
maximum response in Chonyi occurs in the 16 -  20 year age group with 61.8% (95% 
Cl 43.6 -  77.8%) of individuals in this age group recognising this domain. This is 
compared to the maximum response in Ngerenya against the same domain, which 
did not occur until the 51 -  85 year age group and was lower at 56.5% (95% Cl 34.5 
-  76.8%). Acquisition of antibody responses against DBL4y was more rapid in 
Chonyi where, by the age of 8 - 9 years 45.2% (95% Cl 32.5 -  58.3%) of children in 
Chonyi responding compared to 18.6% (95% Cl 9.70 -  30.9%) of children resident 
in Ngerenya (p=0.0019 Wilcoxon ranksum). For responses against D B Lla, the 
situation was different with acquisition in both areas continuing throughout 
adulthood. The maximum response in both areas did not occur until the 51 -  85 year 
age group although as with DBL4y, the maximum response was greater in Chonyi, 
67.6% (95% Cl 50.2 -  81.9%) than in Ngerenya at 43.5% (95% Cl 23.2 -  65.5%) 
although this difference was not significant. Overall a greater proportion of 
individuals resident in Chonyi showed evidence of reactivity against DBLla and 
DBL4y but not CIDRla, DBL2p or DBL5p. The two-sample Wilcoxon rank sum 
for the differences in response between the two locations gave the following 
significance values: D BLla p=0.0128, CIDRla p=0.0594, DBL2p p=0.0774, 
DBL4y p=0.0000 and DBL5P p=0.3848. However, as previously described, 
individuals resident in Chonyi had a higher parasite rate than those in Ngerenya at 
the time of cross-sectional bleed, 41.2% (95% Cl 35.5 -  46.8%) of those under 10 
years in Chonyi were parasitaemic at the time of bleed compared to 22.7% (18.0 -  
27.4%) in Ngerenya (p<0.0001) (figure 2.2). As a subsequent section will illustrate,
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the presence of an asymptomatic parasitaemia resulted in a significantly greater 
likelihood of an individual recognising any domain compared to no domains.
Overall the number of domains recognised increased with age in both areas (Figure 
5.2). In six of the age groups, individuals resident in Chonyi recognised a 
significantly greater number of domains. The proportion of individuals not 
recognising any domains was significantly greater in Ngerenya compared to Chonyi 
(figure 5.3). This remained significant when stratifying for parasite status (data not 
shown). There was no difference in the number of domains recognised when 
individuals were analysed by a-thalassaemia genotype, (wild-type, heterozygote or 
homozygote) or by sickle cell genotype, (sickle cell trait, HbAS, or normal, HbAA) 
(figure 5.4). Haemoglobin genotype also made no difference to the recognition of 
each individual domain, (data not shown), nor did limiting the analysis to only those 
domains showing age-associated acquisition, DBLla, DBL4y and DBL5p.
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Figure 5.2
Mean number of domains recognised by age
Graph shoes mean number of domains, plus upper 95% confidence limits, 
recognised by individuals in each age group. The dark grey bars refer to individuals 
in Chonyi and the hatched bars to individuals resident in Ngerenya.
* p value <0.05
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Figure 5.3
Mean number of domains recognised by area
Graph showing the proportion individuals resident in each area recognising either no 
domains, 1 2 3 4 or 5 domains. Shown are means plus upper 95% confidence limits. 
The dark grey bars refer to those individuals resident in Chonyi whereas the hatched 
bars refer to individuals resident in Ngerenya.
* p value <0.05
* * p value<0.005
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Figure 5.4
a) a  Thalassaemia
Dark grey bars refer to wild-type individuals, the light grey bars to heterozygotes for a  Thalassaemia 
and the cream bars are those individuals who are homozygote. Shown is the mean number of 
domains recognised in each age group with upper 95% confidence limits.
b) Sickle cell trait
Dark grey bars refer to wild-type individuals (AA genotype) and light grey bars those with sickle cell 
trait (AS genotype). Again, shown is the mean number of domains recognised in each age group with 
upper 95% confidence limits.
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Association o f asymptomatic parasitaemia and anti-A4PfEMP 1 antibody responses 
in Chonyi and Ngerenya
It was noted in a previous study conducted in this area that analysed antibody 
reactivity to variant antigens exposed on the surface of infected erythrocytes, that the 
presence of asymptomatic parasitaemia at the time of serum collection resulted in a 
higher prevalence of antibodies, as measured by agglutination (Bull, Lowe et al. 
2002). In this study marked variability in the relationship between the presence of 
parasites and reactivity of individual sera against each domain was seen. Using a 
logistic regression analysis taking into account age, exposure (as estimated by 
responses to whole schizont extract) and location, and restricting the analysis to 
those less than 10 years, individuals with parasites in their blood at the time of bleed 
were significantly more likely to recognise any recombinant domain compared to 
recognising no domains (OR 1.94 (95% Cl 1.34 -  2.83) p<0.001). Interestingly this 
effect of parasitaemia on the presence of domain-specific antibodies was absent in 
those aged over 10 years in whom the presence of asymptomatic parasitaemia had no 
effect on the likelihood of recognising any recombinant domain (OR 1.22 (95% Cl 
0.81-1.83) p=0.334).
Using a multiple linear regression model, the effect of asymptomatic parasitaemia on 
the OD value obtained for each domain after controlling for age, location and 
exposure was determined. Having detectable parasites at cross-sectional bleed was 
associated with significantly higher OD values for domains D BLla, DBL2P and 
CIDRla (table 5.2). There was no effect on antibody reactivity against DBL4y or 
DBL5p. Figure 5.5 shows graphically the odds ratios of recognising each domain if
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an individual was parasite positive. Using a logistic regression model, again 
controlled for age, location and exposure, it was clear that the odds of recognising 
D B Lla and DBL2p were significantly increased in the presence of detectable 
parasites.
Individual variation in antibody responses to recombinant domains o f  A4-PJEMP1 
Extensive variation between individuals was found with regards to specificity of 
antibody response (Figures 5.6 and 5.7). Shown are examples of individuals from 
both areas with their antibody responses, measured as OD, graded into quartiles. As 
is obvious, there is marked variability between responses with some individuals 
(C719, C514, C672, N0847) showing high recognition of all five domains and others 
(C659, C754, N0546, N0007) showing poor responses to all domains. It was also 
clear that there were many individuals with responses directed at one domain over 
the others (C334, C712, N0862, N0518, N0456). 461 individuals recognised no 
domains and of these 57.7% were resident in Ngerenya and 42.3% in Chonyi. Of 
these, 61.2% were aged less than lOyrs and 110 (24.0%) were parasitaemic at the 
time of sampling. 350 individuals recognised 1 domain to the exclusion of all the 
others. 38 individuals recognised all 5 domains tested (3.11% of the whole cohort), 
of these 24 were aged over 10 yrs and interestingly of the 14 aged less than 10 years, 
64.3% were aparasitaemic at the time of bleed.
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Table 5.2
Effect of parasite status on antibody levels to each recombinant domain (1)
Domain coefficient1 95% C.I. p-value
D B L la 0.067 0 .0 2 7 -0 .117 0.001
C ID R la 0.044 0 .015 -0 .072 0.003
DBL2p 0.074 0 .029- 0.118 0.001
DBL4y -0.036 -0.078 - 0.006 0.1
DBL5p 0.002 -0.034 - 0.039 0.886
Results from a multiple linear regression giving the coefficients for the effect o f being parasite 
positive on the OD obtained to each domain, compared to having no parasites. Coefficients are 
controlled for the effects on age, location and exposure as estimated by responses to schizont extract.
236
Od
ds
 r
at
io
5
2
5
1
5
0
Figure 5.5
Effect of parasite status on antibody levels to each recombinant domain (2)
Graphical representation of the odds of being antibody positive for each domain if 
parasite positive at the time of cross-sectional bleed. The multiple logistic regression 
model used controlled for both age and location as possible confounders. Shown are 
the odds ratios with 95% confidence intervals. The solid line denotes an odds ratio 
of 1.
*  =  p < 0 . 0 5  * * = p < 0 . 0 0 5
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Figure 5.6
Checkerboard illustrating a selection of individuals from Chonyi.
The key refers to the intensity of reactivity obtained in ELISA to each domain presented along the top 
of each checkerboard, with the darkest blocks being OD’s within the top 25% of responses and the 
lightest blocks being the lowest OD’s obtained. Along the side of each checkerboard is the unique 
number given to each individual and their age in years.
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D B L la  C ID R la DBL2p DBL4y DBL5P serial age(yrs)
IllllitillSli
N0007 4.02
N0546 5.85
N0862 0.81
N0456 4.09
NO 177 3.71
N0311 4.77
N0580 20.30
N0094 18.20
N0518 9.69
N0750 2.53
N0781 1.62
NO 171 12.29
N0016 2.36
NO 156 3.46
N0412 2.82
N0688 10.28
NO 102 3.50
N0706 44.30
N0880 0.43
N0266 2.61
N0847 1.09
N0260 10.11
Key: □  1 *  quartile e a  2»i quartile □  3 quartile 4 iii quartile
Figure 5.7
Checkerboard illustrating a representative selection of individuals from 
Ngerenya.
The key refers to the intensity of reactivity obtained in ELISA to each domain presented along the top 
of each checkerboard, with the darkest blocks being OD’s within the top 25% o f responses and the 
lightest blocks being the lowest OD’s obtained. Along the side of each checkerboard is the unique 
number given to each individual and their age in years.
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There was evidence of a correlation between individual responses to each domain 
(table 5.3). A positive correlation existed between responses to all domains. To 
exclude this correlation simply representing cumulative exposure with age and 
transmission intensity a multiple linear regression was performed looking at the 
association between responses adjusted for age, location, parasite status and 
exposure as measured as responses to schizont extract as before. All positive 
correlations were maintained.
Correlation o f anti-domain antibody responses with antibody responses to the intact 
A4 parasitised erythrocyte
Figure 5.8 shows scatter diagrams correlating responses to each domain against 
responses to intact A4U as measured by flow cytometry. Also shown are the cut 
off levels for positivity (the average of 20 non-exposed donors plus 3 standard 
deviations for each recombinant domain and the average of 20 non-exposed donors 
plus 3 standard deviations for responses against a4U) in red. Using Spearman’s rank 
correlation coefficient to assess significance, only responses to DBLla and DBL4y 
were positively correlated with responses against the intact parasitised erythrocyte, 
(table 5.4). Interestingly responses to CIDRla were significantly negatively 
correlated with responses to the surface of the intact erythrocyte. In an attempt to 
control for exposure accounting for any positive correlation, a multiple linear 
regression model was performed with age, location, parasite status and exposure 
(estimated by responses to schizont extract) as independent variables. Using this 
model, only responses to DBL4y reached significance (data not shown).
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Table 5.3
Inter-domain correlations
correlation spearman’s rho p-value
D B L la  DBL2p 0.4368 <0.0001
D B L la  C ID R la 0.3738 <0.0001
D B L la  DBL4y 0.3074 <0.0001
D B L la  DBL5P 0.4138 <0.0001
DBL2P C ID R la 0.4269 <0.0001
DBL2P DBL4y 0.3123 <0.0001
DBL2P DBL5p 0.4881 <0.0001
C ID R la  DBL4y 0.1696 <0.0001
CIDRla DBL5p 0.3602 <0.0001
DBL4y DBL5P 0.3484 <0.0001
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Figure 5.8
Correlations between responses to each recombinant domain and responses to 
A4U parasitised erythrocytes (1)
Each scattergram shows correlation of individual responses, measured by ELISA, to each domain (y- 
axis) with responses to the intact A4- parasitised erythrocyte, measured by flow cytometry (x-axis). 
The red lines demonstrate the cut-off for positivity, (mean of responses from 20 non-exposed donors 
plus 3 standard deviations for the recombinant domains and mean of responses from 20 non-exposed 
donors plus three standard deviations for responses to the A4-parasitised erythrocyte.
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Table 5.4
Correlations between responses to each recombinant domain and responses to 
A4U parasitised erythrocytes (2)
correlation
spearman's
rho p-value
D B L la  A4 Ultra 0.1256 0.0324
DBL2(3 A4 Ultra 0.0492 0.4038
C ID R la  A4 Ultra -0.1347 0.0217
DBL4y A4 Ultra 0.2869 0.0000
DBL5(3 A4 Ultra 0.0408 0.4887
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Affinity purification o f anti-DBLla and anti-DBL4y antibodies 
Following the purification and concentration process, (figure 5.9 shows SDS-PAGE 
gel of purified anti-DBLla and anti-DBL4y antibodies) antibodies obtained 
demonstrated specificity of response against both purified DBLla and purified 
DBL4y recombinant proteins (figure 5.10). However when responses were 
measured against both intact A4 parasitised erythrocytes and wild isolates obtained 
from symptomatic children by flow cytometry, no reactivity was observed. 
Experiments were repeated at varying dilutions of purified antibody to no avail. 
Whether these antibodies are reacting to epitopes exposed by the process of cloning 
and expression within the bacterial system, epitopes not exposed as part of the full 
A4 PfEMPl molecule, or whether this reflects methodological limitations within the 
affinity purification process is presently unknown.
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MW anti-DBL lot anti-DBL4y
Figure 5.9 
SDS-PAGE gel
Reducing gel showing the presence of 2 discrete bands corresponding to ~150KDa 
obtained after purification of sera on DBLla and DBL4y recombinant proteins.
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Figure 5.10
ELISA specificity of affinity purified anti-DBLla and anti-DBL4y
a) graph of serial dilutions of antibody, both anti-DBLla and anti-DBL4y against purified recombinant 
DBLla. Also shown are responses from a pool of 10 non-exposed donors and the previously screened 
highly positive sera from which the antibodies were purified (2BH)
b) graph of serial dilutions of antibody, both anti-DBLla and anti-DBL4y against purified recombinant 
DBL4y. Also shown are responses from a pool of 10 non-exposed donors and the previously 
screened highly positive sera from which the antibodies were purified (5BH)
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Discussion
PfEMPl is currently the most plausible and best characterised of the erythrocyte 
surface-expressed parasite-induced proteins proposed as targets for the naturally 
acquired immune response (Bull and Marsh 2001). It has been hypothesised that 
naturally acquired immunity develops through the piecemeal acquisition of a large 
repertoire of antibodies directed against variants of this protein (Bull, Lowe et al. 
1998). Supporting this possibility are vaccines based on selected domains from 
specific PfEMPl variants which result in protection against the homologous 
genotype only (Baruch, Gamain et al. 2002).
PfEMPl is a large, diverse and structurally complex molecule. It is composed of an 
intracellular, highly conserved domain and a large, extracellular variant domain. 
Although this extracellular domain is highly polymorphic between PfEMPl variants, 
they share an overall common structure (figure 1.6). Through sequence and 
structural differences PfEMPl variants are associated with diverse serological and 
functional properties. Understanding the naturally occurring antibody response to 
the DBL and CIDR domains making up the extracellular component of a specific 
PfEMPl protein is an important part of evaluating the usefulness of PfEMPl as a 
vaccine candidate. In this chapter, through the use of recombinant protein 
technology, the naturally acquired antibody response to the extracellular domains of 
A4 PfEMPl in the sera of individuals resident in two areas endemic for P. 
falciparum malaria but with different transmission characteristics have been 
evaluated.
247
It is clear that there are differences in the total acquisition of domain-specific 
antibodies and the time over which such responses are acquired both between areas 
and between domains. Responses directed against CIDRla proved difficult to 
analyse satisfactorily. It was found that non-malaria exposed donors recognised this 
domain to high level, (figure 5.8), and so scoring individuals as antibody positive 
using the cut-off as defined resulted in very few individuals scoring positive. 
However it is clear from figure 5.8 that OD’s obtained against CIDRla were 
comparable to those obtained for each of the other domains although there is no 
discernible age-associated acquisition. What is also clear is the spread of values 
obtained by the non-malaria exposed donors against the recombinant CIDRla 
domain was greater than for any of the other domains. It is not clear why 
individuals never exposed to malaria should recognise this particular domain, 
although it has been shown that CIDRla does bind non-immune immunoglobulins 
(Ig) (Chen, Heddini et al. 2000). More recently this particular domain of PfEMPl 
was identified as a polyclonal activator of B cells from non-exposed donors (Donati, 
Zhang et al. 2004). This activation was specific to CIDRla and occurred through 
binding of CIDRla to the Fab fragment of immunolglobulins, both IgG and IgM, 
exposed on the B cell surface. It was also shown to bind directly to various human 
Ig fragments, total non-immune Ig and Ig from different species. However not all 
studies show the same non-immune binding, a recent study looked at IgG levels to 
recombinant CIDRla amongst adults and children resident in Tanzania and 
demonstrated very little reactivity by the non-exposed donors although it was 
striking that as in the results presented here, there was no age-associated acquisition 
of CIDR la-specific responses (Jensen, Magistrado et al. 2004). The situation is 
clearer with regards the other domains. All show acquisition with age and
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differences are clear in the epidemiology of responses between those resident in the 
high and low transmission areas.
Previous studies have described an increased prevalence of antibodies to blood-stage 
antigens amongst individuals with detectable parasites at the time of bleed (Bull, 
Lowe et al. 2002; Kinyanjui, Mwangi et al. 2004; Polley, Mwangi et al. 2004). A 
similar result was obtained in this study with regard to responses to DBLla, DBL2P
V
and CIDRla, but not to DBL4y or DBL5p. This is a curious result for a number of 
reasons. For those domains showing an increased prevalence of antibodies, (DBLla, 
DBL2p and CIDRla), as these recombinant domains were cloned from a laboratory 
parasite line, A4, it implies either that young children possess a degree of cross­
reactive PfEMPl-specific antibodies capable of recognising individual domains or 
that these domains are present perhaps within expressed var genes within the pool of 
wild isolates in this area. For those domains where the presence of parasites makes 
no difference to their recognition (DBL4y and DBL5p), why should this be the case? 
Do these domains possess less cross-reactive epitopes within them or are they less 
ubiquitously present in nature?
In a previous chapter it was described how individuals were significantly more likely 
to recognise A4U-infected erythrocytes if they were carriers of the sickle cell trait 
(HbAS) (figure 3.15). It was with these results in mind that any association between 
the presence or absence of sickle cell trait and antibody recognition of each domain 
was examined. As is shown in this chapter, there was no significant association 
demonstrated between host genotype and antibody reactivity to each domain. The
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question thus remains, what exactly is the target for the increased prevalence of 
antibodies against the surface of A4U-infected erythrocytes amongst those with 
HbAS genotype? Although these results do not exclude the possibility that the 
antigenic target is A4 P/EMP1, problems of maintaining conformation may account 
for the lack of any association, it is notable that similar increased prevalence of 
antibodies amongst those with HbAS have been shown for different randomly 
selected wild isolates (Marsh, Otoo et al. 1989; Cabrera, Cot et al. 2005).
There have been few studies examining directly the presence of naturally occurring 
i^EMP 1 domain-specific antibodies within the sera of individuals resident in malaria 
endemic areas. Oguariri and colleagues compared the prevalence of antibodies in 
the sera of children and adults resident in an area hyperendemic for P. falciparum 
transmission, directed against recombinant DBLla domains from 9 different wild 
isolates. There was a strong correlation between the age of the patients and the 
reactivity against the recombinant DBLla domains. There was no stratification of 
responses according to the presence or absence of detectable parasitaemia (Oguariri, 
Borrmann et al. 2001). Another study described antibody responses, measured by 
ELISA, against three conserved peptides from a laboratory strain of P/EMP1 
(Staalso, Khalil et al. 1998). These peptides corresponded to the relatively 
conserved N-terminal sequence containing the binding site for CD36 and the C- 
terminal sequence making up the intracellular portion of the integral membrane 
protein. The reactivity against the peptides increased with age and was also 
significantly greater in those individuals with an asymptomatic infection compared 
to those with symptoms of acute malaria. This result led to the tentative conclusion 
that the presence of peptide-specific antibodies was associated with asymptomatic
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parasitaemia and therefore protection. However it must be noted that in this study 
those asymptomatically parasitised were significantly older than those with 
symptoms.
The possibility exists that the antibody responses measured in this set of experiments 
do not accurately relate to those produced in vivo. By expressing each domain as a 
recombinant fusion protein, it may be that important conformational epitopes will 
not be accessible to the sera tested or equally that what is being recognised by sera 
are not important targets within the host. In order to address this, initially individual 
responses were compared to responses to the intact expressed A4 iyEMPl molecule 
on the surface of the parasitised erythrocyte. With two of the domains under study, 
DBLla and DBL4y a positive correlation was found although once all responses had 
been adjusted for exposure surrogates, age, parasite status, transmission area and 
responses to schizont extract only DBL4y remained significantly correlated. It was 
hoped that by purifying DBL4y-specific antibodies from human sera it may be 
possible to show recognition of the parasitised erythrocyte by flow cytometry. 
Although the purified anti-sera reacted specifically with the recombinant domain it 
was purified from, unfortunately, no reactivity to the intact erythrocyte was 
demonstrated. Of note previous work has shown that immunisation of rabbits with 
recombinant proteins domains of A4 P/EMP1 resulted in the production of 
polyclonal antisera, specific to each domain. Of these antisera, some recognised the 
surface of the A4 infected erythrocyte through flow cytometry. These included anti- 
DBL4y and anti-DBL5p but not anti-CIDRla or anti-DBLla (Fagan 1999).
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Chapter 6
Heterologous antibody responses and 
protection from clinical malaria
Introduction
Non-sterile immunity to P. falciparum, malaria is acquired by individuals living in 
endemic areas. This immunity enables people to maintain P. falciparum infections 
without the associated morbidity and mortality experienced by non-immune 
individuals (Marsh and Snow 1997). Evidence from the passive transfer of 
antibodies from immune to non-immune individuals suggests this immunity is at 
least in part, antibody mediated (Cohen, Me et al. 1961; Cohen, McGregor et al. 
1961; Edozien, Gilles et al. 1962). Studies examining humoral responses against the 
erythrocyte-surface and their association with protection from clinical disease have 
yielded conflicting results. Following infection individuals develop antibodies 
specific to the infecting isolate (Bull, Lowe et al. 1998; Giha, Staalsoe et al. 2000; 
Chattopadhyay, Sharma et al. 2003). These antibodies conferred protection against 
subsequent infection with that isolate, clinical malaria being caused by isolates 
expressing variants corresponding to gaps in the antibody repertoire of the infected 
child (Bull, Lowe et al. 1998). What is unknown currently is how relatively cross­
reactive responses, assessed using heterologous isolates, are involved in protection 
from disease. Antibody responses to some isolates but not others appear to be 
associated with protection (Marsh, Otoo et al. 1989) (Bull, Lowe et al. 1998; Bull,
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Kortok et al. 2000; Giha, Staalsoe et al. 2000; Dodoo, Staalsoe et al. 2001). The 
antigenic targets involved in the development of protective immunity are presently 
unknown.
In this chapter, using a longitudinal study design, the relationship between antibodies 
to antigens on the surface of four parasite lines and protection from clinical malaria 
was examined. In addition any effect of the presence of asymptomatic parasitaemia 
on this relationship was assessed and the relationship between antibodies to 
individual domains of one expressed var gene, A4 P/EMP1 and disease incidence 
was explored.
Aims
1) To establish the association of asymptomatic parasitaemia at cross-sectional survey 
on subsequent incidence of clinical malaria within a cohort of individuals aged 6 
months to 10 years resident under different transmission characteristics on the coast 
of Kenya.
2) To examine the relationship between asymptomatic parasitaemia and antibody 
responses to four parasite lines in the context of future malaria experience.
3) To examine the association between antibody responses to the surface of 
erythrocytes infected with four parasite lines and protection from clinical non-severe 
malaria.
4) To examine the influence of asymptomatic parasitaemia, present at the time of blood 
assay, on this association.
5) To examine the association between antibody responses to five recombinant 
extracellular protein domains of A4 /yEMPl with protection from clinical malaria.
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Methods
The individuals’ sampled were as described in chapter 3. A cross-sectional survey 
was performed in October 2000, when malaria transmission was low. Blood 
samples were obtained from children by venepuncture and plasma was separated by 
centrifugation and stored at -20°C. The children were examined for fever (axillary 
temperature was taken by use of an electronic thermometer), and their 
parasitological status was determined by use of a Giemsa-stained thin malaria smear. 
Individuals were followed up with weekly active malaria case detection and 
continuous passive case detection. A case of malaria was defined as:
Individuals aged less than 1 year -  fever > 37.5°C plus any parasitaemia 
Individuals aged over 1 year -  fever >37.5°C plus parasitaemia > 2500/pl (Mwangi 
2003)
Antibody responses to the intact parasitised erythrocyte were measured by flow 
cytometry as outlined in chapter 3. Parasite lines used were as previous, A4U, A4 
40-cycle, 3D7 and a clinical isolate PL Antibody responses to each recombinant A4 
PfEMPl domain were measured by ELISA as outlined in chapter 5. Detailed 
descriptions of the methods used are given in chapter 2. Antibody positivity was 
defined as an MFI or OD greater than the mean plus 3 standard deviations of a panel 
of 20 non-exposed donors from Oxford U.K. Parasite positivity was defined as any 
parasites detected by microscopy at the time of cross-sectional survey. All 
individuals involved were asymptomatic and afebrile at the time of blood sampling.
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Statistical analysis
All statistical analysis was performed using Stata8™ (StataCorp. Ca. USA). The 
relationship between parasite status and reactivity to the surface of erythrocytes 
infected with each isolate with future disease experience was assessed using logistic 
regression. The outcome in every case was positivity for recognition of each isolate 
as classified using the cut-off of the mean response from 20 non-exposed donors plus 
3 standard deviations. Initially the data were explored for additional factors 
affecting the likelihood of recognising each isolate. In every case these were 
identified as age (in categories of 6 months duration), location of each individual 
(either Chonyi or Ngerenya) and previous exposure to malaria infection (estimated 
by responses to whole schizont extract). The likelihood of recognition of each 
isolate was then compared in those individuals parasite positive and those parasite 
negative at cross-sectional survey after individuals had been stratified by future 
disease experience.
When the relationship between antibody responses, the presence of microscopically 
detectable parasites and clinical malaria was investigated, a multiple logistic model 
was performed after identification of significant confounding variables. These were 
identified as age (categorised as a factor of six months duration), location (Chonyi or 
Ngerenya) and exposure (estimated from responses to whole schizont extract). The 
outcome variable was at least one episode of malaria as defined previously. 
Individuals were categorised according to whether or not they had detectable 
parasitaemia at cross-sectional survey and were positive or negative for recognition 
of each isolate. This variable was then analysed as the main explanatory variable in
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a multiple logistic regression with each group compared to the group of children 
both parasite and antibody negative.
When investigating the likelihood of having a greater number of episodes of clinical 
malaria, an ordered logistic regression was used. Individuals were scored 0, 1, 2, 3 
or 4 according to the number of episodes of malaria they suffered during the six 
month follow up, the resultant odds ratio obtained gives the likelihood of being in a 
higher numbered group (i.e. having 2 episodes compared to 1, 3 compared to 2 etc) 
depending on which structured antibody/parasite group the individual fell into. 
Again confounding variable age, location and exposure were included.
Where differences in two continuous variables were assessed, no assumptions of 
distribution were made and the Wilcoxon ranksum test was used to calculate 
significance. Where more than two variables were compared the Kruskal Wallis test 
was used.
Kaplan-Meier survival curves were plotted using time in days to an episode as 
previously defined.
Results
The epidemiology o f  malaria disease in Ngerenya and Chonyi 
As described in chapter 2, a previous study undertaken in this area defined the 
optimal clinical definition of malaria (children <1 year -  fever greater than 37.5°C 
and any parasitaemia: children > 1 year -  fever greater than 37.5°C and 
parasitaemia > 2500 parasites/ pi) and from this demonstrated a higher incidence of
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clinical malaria disease in the lower of the two transmission areas under study (IRR 
0.66 (95% Cl 0.61 -  0.72) p<0.001 (Mwangi, Ross et al. 2005). For the individuals 
studied in this work, the odds of experiencing a clinical attack of malaria in Chonyi 
in those aged 5 to 10 years was significantly lower than the risk in those aged less 
than 5 years (OR 0.22 (95% Cl 0.11-0.41) p<0.0001). Whereas in Ngerenya the 
odds of clinical attack in the older aged children was not significantly different from 
the children aged less than 5 (OR 1.27 (95% Cl 0.79-2.03) p=0.322). Only in those 
aged 10 years or more in Ngerenya, was there a significant reduction in the 
likelihood of individuals suffering from malaria (OR 0.127 (95% Cl 0.07-0.24)
p<0.001).
At the time of cross-sectional bleed in October 2000, 43.2% of individuals in Chonyi 
and 23.6% in Ngerenya had parasites detectable by microscopy (figure 2.2). When 
the proportion of individuals suffering at least one attack of clinical malaria during 
the follow-up period was plotted by age, stratified by parasite status at the time of 
cross-sectional bleed, it was striking that among the children under the age of 24 
months in Chonyi, a significantly greater proportion of those parasitised suffered at 
least one attack of malaria compared to those with no detectable parasites. This was 
less obvious in Ngerenya within the youngest age group but those aged between 12 
and 24 months demonstrated clearly the same pattern of susceptibility, (figure 6.1). 
To further assess whether or not asymptomatic parasitaemia at cross-sectional survey 
identified a group of individuals at more risk of suffering an episode of clinical 
malaria in the subsequent six months, we first explored the data for any possible 
confounding influences using logistic regression. We identified age (in six month 
categories), location (either Chonyi or Ngerenya) and previous exposure (using
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response to whole schizont as a proxy measure) as significant associations. The 
odds of experiencing an episode of clinical malaria, as defined above, was then 
compared in those parasite positive and parasite negative with the listed confounding 
variables included in a multiple logistic regression. Overall the odds ratio for 
becoming a case of malaria in the six months following cross-sectional bleed if 
parasite positive compared to parasite negative was 1.93 (95% Cl 1.38 -  2.70) 
pO.OOOl. To exclude the possibility that the initial clinical disease episode was as a 
result of the asymptomatic parasitaemia detected at cross sectional survey, we 
excluded the first 30 days of follow-up after the cross-sectional bleed. Despite this 
there remained a significant increased likelihood of becoming a case if parasite 
positive (OR 1.49 (95% Cl 1.10 -  2.20) p=0.040).
The association between parasite status and antibody responses according to future 
disease experience
As described in the preceding chapters, the presence of parasites at cross-sectional 
bleed was associated with significantly increased antibody responses to the intact 
parasite isolates A4, 3D7 and the wild isolate PI, also to the recombinant A4 
PfEMPl domains DBLla, DBL2P and CIDRla. However, if individuals were 
stratified according to whether or not they became a case of clinical malaria in the 
subsequent six months, then the relationship between the presence of parasites and 
antibodies to the infected erythrocyte surface was more complicated than at first 
thought. In order to establish whether this relationship was true whether or not 
individuals went on to become a case of clinical malaria, we initially checked for any 
variables other than parasite status, confounding the outcome of antibody positivity 
in a logistic regression. These were identified as age (in six month categories),
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location, and exposure, as estimated by responses to whole schizont extract. A 
multiple logistic regression was then performed on individuals classified as either a 
control (no episode of malaria in the subsequent six months) or a case (at least one 
episode of malaria in the subsequent six months). The results are displayed in table 
6.1. There is a marked difference in the relationship between antibody positivity and 
the presence of parasites between the cases and controls. There is no apparent 
association between recognising each of the isolates tested and the presence of 
asymptomatic parasitaemia in those who went on to become a case of malaria. In 
contrast there is a definite and clear positive association between the likelihood of 
recognising each individual isolate and the presence of parasites in those apparently 
protected from clinical malaria, at least in the subsequent six months.
We then went to do the same analysis on responses to individual A4 PfEMPl 
domains (table 6.2). As already discussed, only three domains showed an increased 
likelihood of antibody positivity in the presence of parasites; DBLla, DBL2p and 
CIDRla. When this relationship was analysed by future disease experience as above, 
the results were less clear cut. Whereas responses to DBLla and DBL2p were 
increased in likelihood in the presence of parasites in those acting as controls, as was 
found for responses to the intact infected red cell, responses to CIDRla, DBL4y or 
DBL5P were not similarly increased in this subgroup of individuals. It is notable 
that responses to DBLla were also increased in those parasitaemic who became a 
case and that responses to CIDRla showed the opposite association, an increased 
likelihood of response if parasitaemic in those who did become a case as opposed 
those who were apparently protected.
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Figure 6.1
Average numbers of individuals suffering at least one episode of malaria
Shown are the proportion (plus upper 95% confidence limit) of individuals in each year group 
suffering at least one episode of malaria (as defined in the text) over the follow-up period in both 
areas. Individuals are stratified into those parasite positive (grey bars) and parasite negative (hatched 
bars) at the time of cross-sectional bleed.
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Table 6.1 A ssociation between antibody responses and parasite positivity
stratified by future disease experience
Individuals with no episodes of malaria1
Isolate Odds ratio2 95% confidence interval p-value
A4U 6.18 2.15 - 17.7 0.001
A4 40-cycle 12.6 2.98 - 53.12 0.001
3D7 11.97 2.43 - 58.9 0.002
Clinical isolate PI 4.03 1.07- 15.09 0.039
Individuals with at least one episode of malaria1
Isolate Odds ratio2 95% confidence interval p-value
A4U 1.7 0.43-6.71 0.44
A4 40-cycle 1.34 0.35 - 5.09 0.07
3D7 0.83 0.19-3.41 0.79
Clinical isolate PI 0.64 0.12-3.31 0.59
'Malaria defined as: individuals aged >lyear - fever >37.5°C plus parasitaemia>2500/pl, individuals 
aged < lyear - fever>37.5°C plus any parasitaemia
2Odds ratio refers to likelihood of being antibody positive, for responses against each isolate in turn, if 
parasite positive compared to parasite negative at cross-sectional survey. All individuals stratified 
initially by whether or not they experienced at least one episode of clinical malaria in the six months 
subsequent to the bleed.
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Association o f antibodies to the intact infected-erythrocyte surface and protection 
from clinical malaria
We next explored whether children who subsequently became a case of clinical 
malaria (cases) differed in their antibody responses to the parasite isolates tested, 
compared to children who did not become a case (protected). As the rate of 
acquisition of immunity differed between the two areas as described, individuals 
were examined over different age ranges in each area. In Chonyi differences in 
antibody levels were assessed in those individuals aged between 6 months and 5 
years were assessed, with responses in Ngerenya examined over the age range 6 
months to 10 years. Overall there were no significant differences over the age 
groups described between antibody reactivity to A4U in those who became future 
cases compared to those who did not (p=0.4292 between individuals resident in 
Chonyi and p=0.1406 between individuals resident ion Ngerenya, Wilcoxon 
ranksum). No significant differences were found with responses to any other isolate 
tested (data not shown). However, if individuals were categorised according to 
whether or not they had a microscopically detectable parasitaemia at cross-sectional 
survey, then marked differences were apparent between those who became cases and 
those who did not, at least in Chonyi (figure 6.2). Amongst those children parasite 
positive at cross-sectional survey, there was a clear and significant difference 
between those classified as future cases and those apparently protected, with those 
children not suffering from
262
T able 6.2 A ssociation between anti-dom ain specific antibody responses and
parasite positivity stratified by future disease experience
Individuals with no episodes of malaria1
Domain Odds ratio2 95% confidence interval p-value
D B L la 1.39 1.05 - 1.87 0.024
C ID R la 1.52 1 .1 0 -2 .1 0 0.01
DBL2(5 1.19 0 .8 4 -2 .1 0 0.33
DBL4y 0.91 0 .6 7 - 1.21 0.513
DBL5p 0.76 0.53 - 1.08 0.125
Individuals with at least one episode of malaria1
Domain Odds ratio2 95% confidence interval p-value
D B L la 1.99 1 .00 -3 .9 5 0.049
C ID R la 1.25 0 .6 0 -2 .5 8 0.552
DBL2(3 2.96 1 .4 2 -6 .1 6 0.004
DBL4y 1.45 0 .6 9 -3 .0 6 0.325
DBL5p 1.69 0 .7 8 -3 .6 6 0.185
'Malaria defined as: individuals aged > lyear - fever >37.5°C plus parasitaemia>2500/pl, individuals 
aged <lyear - fever>37.5°C plus any parasitaemia
2Odds ratio refers to likelihood of being antibody positive, for responses against each domain in turn, 
if parasite positive compared to parasite negative at cross-sectional survey. All individuals stratified 
initially by whether or not they experienced at least one episode of clinical malaria in the six months 
subsequent to the bleed.
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clinical isolate 
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protected case protected case
Figure 6.2
Antibody responses according to parasite status and future disease experience 
1. Chonyi
Box and whisker plots showing median MFI (log transformed) plus interquartile range. Individuals 
are categorised according to whether they had microscopically detectable parasitaemia at cross- 
sectional bleed (graphs a, c, e and g) or not (graphs b, d, f  and h) and also according to whether they 
experienced at least one case of clinical malaria (case) or not (protected). Responses to each parasite 
are shown.
* p<0.05
** p<0.005 ns not significant
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Figure 6.3
Antibody responses according to parasite status and future disease experience 
2. Ngerenya
Box and whisker plots showing median MFI (log transformed) plus interquartile range. Individuals 
are categorised according to whether they had microscopically detectable parasitaemia at cross- 
sectional bleed (graphs a, c, e and g) or not (graphs b, d, f  and h) and also according to whether they 
experienced at least one case of clinical malaria (case) or not (protected). Responses to each parasite 
are shown.
* p<0.05
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an episode having significantly increased antibody levels measured against each of 
the isolates tested. In Ngerenya, no significant differences were seen in those 
individuals parasite positive, possibly because of a lower parasite prevalence in this 
area (figure 6.3). Those children with no microscopically detectable parasitaemia 
showed a markedly different pattern of responses (figures 6.2 and 6.3 - graphs b, d, f, 
h). In Chonyi, there was significantly less antibody present within individuals 
apparently protected, against the parasite lines A4 40-cycle and 3D7, and although 
there was no significant difference between responses to A4U and the clinical isolate 
PI, the trend was the same. In Ngerenya, again differences were on the whole not 
significant although the general trend was the same, the exception being antibody 
levels to A4 40-cycle which showed differences in the same direction as those seen 
in Chonyi.
The notable effect the presence of a microscopically detectable parasitaemia had on 
the association of antibody responses and clinical malaria was further evident in a 
Kaplan-Meier survival curve (figure 6.4). Although overall there was no significant 
difference in the cumulative proportion of individuals experiencing clinical malaria 
between those individuals scoring positive for antibody recognition of A4U and 
those scoring negative, when individuals were stratified by parasite status, then there 
was a significant survival advantage amongst those antibody positive and parasite 
positive.
These results led us to categorise individuals into 4 groups depending on both their 
antibody status in response to each isolate (either positive or negative as defined
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previously) and parasite status at cross-sectional survey (either microscopically 
detectable parasites present, i.e. parasite positive or absent, parasite negative). The 
four groups were as such:
Group Antibody status Parasite status
ab + pf + positive positive
ab + pf - positive negative
ab - pf + negative positive
ab - pf - negative negative
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Figure 6.4
Kaplan-Meier survival curve according to antibody status.
Graphs show proportion of individuals experiencing clinical malaria with time in days over the six 
month follow up period. Individuals are categorised according to whether they scored positive for 
recognition of A4U at cross-sectional bleed (black lines) or not (grey lines).
* p<0.05 (logrank)
**p<0.005 (logrank)
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Figure 6.5
Kaplan-Meier survival curve according to antibody and parasite status.
Graphs show proportion of individuals experiencing clinical malaria with time in days over the six 
month follow up period. Individuals are categorised according to whether they scored positive for 
recognition of each parasite line in turn and whether or not they had microscopically detectable 
parasites at cross-sectional bleed 
**p<0.005 (logrank)
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Figure 6.6
Kaplan-Meier survival curve according to antibody and parasite status with 
first 30 days of follow up censored.
Graphs show proportion of individuals experiencing clinical malaria with time in days over the six 
month follow up period. Individuals are categorised according to whether they scored positive for 
recognition of each parasite line in turn and whether or not they had microscopically detectable 
parasites at cross-sectional bleed 
*=p<0.05
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Figure 6.5 shows the Kaplan-Meier curves obtained for each of the four groups. As 
is obvious the group of children with parasites detected at cross-sectional survey but 
no concomitant heterologous antibody response to all parasite lines appeared to be 
differentially susceptible to clinical malaria. There remained a significant difference 
against two of the parasite lines tested if the first 30 days were censored (figure 6.6).
Examining the base-line characteristics of the children in each of the four groups 
revealed some important differences. Children both antibody positive and parasite 
positive with regards all four parasite lines, were significantly older than children in 
the other three groups (data not shown). There were no significant differences 
between the ages of the children in the other three groups. For this reason the 
likelihood of acquiring at least one episode of clinical malaria in the subsequent six 
months was investigated according to group in a multiple logistic model with age 
(categorised into six month intervals), location and exposure (estimated from 
responses to whole schizont extract) as confounding variables. Table 6.3 shows the 
results for responses to A4U overall and within each location separately. Both 
overall and within Chonyi only, those children parasite positive at cross-sectional 
survey with no concomitant antibody response to A4U had a significantly increased 
risk of experiencing at least one episode of clinical malaria in the subsequent six 
months. This remained so if the first 21 days after the cross-sectional survey was 
censored. The same pattern was observed with responses to the other three parasite 
lines overall (table 6.4).
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When the outcome examined was number of malaria episodes, an ordered logistic 
regression model was used with the same confounding variables included. Again the 
group of children antibody negative and parasite positive were significantly more 
likely to experience a greater number of malaria episodes in the subsequent six 
months. This was true for all parasite lines tested (table 6.5).
Association o f anti-A4PfEMP 1 domain-specific antibody responses and protection 
from clinical malaria in Chonyi and Ngerenya
In order to investigate any association of domain-specific antibody responses with 
protection from clinical malaria, initially the univariate association between 
detectable serum IgG to each antigen (measured as OD), and whether or not the 
individual had an episode of clinical malaria during the follow-up period was 
investigated by fitting the continuous variable against a binomial distributed 
outcome using logistic regression. As antibody reactivity is known to increase with 
exposure, a multiple logistic regression was then performed with age, converted to a 
factor of age-groups of six months duration, location either Chonyi or Ngerenya and 
reactivity to schizont extract, as a marker of exposure, expressed as a continuous 
variable included as co-dependent variables. Results are expressed as odds ratios per 
10 fold increase in antibody levels.
When the antibody positivity to the PfEMPl recombinant domains were analysed as 
a whole within Chonyi, no association was found between antibody response and 
subsequent disease experience (table 6.6). However by categorising individuals into 
those who were parasite positive at the time of bleed and those parasite negative, a 
positive association between the presence of anti-DBLla antibodies and protection 
from subsequent clinical malaria was evident in those parasite negative at the time of
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bleed. No association with protection from or susceptibility to malaria was observed 
with antibodies against any other recombinant domain in Chonyi and antibody 
responses to none of the domains were associated with protection in Ngerenya (table
6.7).
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6
Discussion
That the majority of the burden of malaria morbidity and mortality fall on young 
children in endemic areas must imply that significant immunity to malaria disease 
develops with time and exposure. Older children and adults are resistant to severe 
malaria and death although they remain susceptible to infection (Marsh 1992). 
Defining an individual as immune or non-immune however is problematic. As the 
risk of severe malaria disease and death declines in young children, the parasite 
prevalence is still rising, similarly the mean number of clinical malaria attacks falls 
during the period parasite prevalence is still increasing. Furthermore, during the 
period when young children are most at risk of severe malarial disease and death, 
they spend the majority of the time asymptomatically parasitised (Marsh, Otoo et al. 
1989). The marked differences in relationships of susceptibility to parasitisation, 
mild clinical disease and severe life-threatening disease and death with age, (figure
6.7), seems to that the immune mechanisms responsible for protection against severe 
malaria are not the same as those that protect against infection or mild disease. This 
is supported by modelling work suggesting that immunity to severe disease is 
apparent after only few symptomatic infections (Gupta, Snow et al. 1999). Although 
the immune effectors and their targets resulting in protection from severe disease 
must be the most important mechanisms to identify, in terms of vaccine design and 
understanding the biology of immune acquisition, it is more often that studies use 
mild disease
and infection as markers of susceptibility. Certainly for the studies described in this 
thesis, logistics of identifying large numbers of cases of severe malaria disease 
negated using this as our outcome. If mild malaria disease is chosen as the outcome
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marker of susceptibility, then problems can arise in defining exactly what constitutes 
a case of clinical malaria. In some areas, 80% of children can have microscopically 
detectable parasites present in their blood at any one time. In this cohort of 
individuals 43.2 % of people sampled in a cross-sectional survey were parasitaemic. 
Thus the presence of parasites per se in conjunction with non-specific symptoms 
such as fever may not accurately define an individual’s illness as being due to 
malaria. The studies undertaken in this thesis were embedded in a longitudinal study 
examining the optimal definition of clinical malaria in different age groups (Mwangi, 
Ross et al. 2005). The resultant definition is the definition of clinical malaria used 
in this work. By measuring a single putative immune response and relating it to the 
incidence of clinical malaria over time, as was done in these studies, it must be 
assumed that this response, if present, can be measured in every individual, at a 
single point in time. The results outlined in chapter 3, and previous work from this 
area, suggest that this may not be entirely the case (Bull, Lowe et al. 2002; Kinyanjui, 
Mwangi et al. 2004; Polley, Mwangi et al. 2004). It was noted that the prevalence 
and amount of antibodies to a range of blood-stage antigens were consistently higher 
amongst children asymptomatically parasitised compared to those with no parasites 
detectable by microscopy. Given that all children in these areas move between being 
parasite positive and parasite negative relatively frequently, it may be that immune 
responses measured are short-lived and as a result the ability to detect the response 
short-lived.
278
Table 6.6 Association of serum IgG levels to recombinant domains of PfEMPl
7
in October 2000 with clinical malaria in Chonyi, Kenya for the period October 
2000 until March 2001
Chonyi (age adjusted) slide all n=596
Antigen Odds Ratio p-value \95% Conf. Intervall
D BLla 0.75 0.580 0.26 2.11
DBL2P 0.63 0.472 0.18 2.21
CIDRla 0.71 0.365 0.33 1.50
DBL4y 0.89 0.791 0.37 2.13
DBL5P 0.72 0.517 0.26 1.95
Chonyi (age adjusted) slide positive 11=197
Antigen Odds Ratio p-value [95% Conf. Intervall
D BLla 1.79 0.423 0.43 7.49
DBL2P 0.51 0.491 0.07 3.51
CIDRla 0.51 0.287 0.15 1.76
DBL4y 2.47 0.251 0.53 11.64
DBL5P 0.66 0.691 0.09 4.88
Chonyi (age adjusted) slide negative n=399
Antigen Odds Ratio p-value [95% Conf. Intervall
D B L la 0.05 0.020 0.04 0.63
DBL2P 0.26 0.208 0.32 2.10
CIDRla 0.72 0.553 0.25 2.10
DBL4y 0.49 0.290 0.14 1.81
DBL5P 0.49 0.343 0.11 2.11
Odds Ratios are adjusted for age and reactivity to schizont extract.
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Table 6.7 Association of serum IgG levels to recombinant domains of PfEMPl 
in October 2000 with clinical malaria in Ngerenya, Kenya for the period 
October 2000 until March 2001
Ngerenya (age adjusted) slide all n=617
Antigen Odds Ratio p-value [95% Conf. Intervall
D BLla 1.04 0.925 0.47 2.32
DBL2P 1.32 0.621 0.44 3.94
CIDRla 1.15 0.620 0.65 2.07
DBL4y 0.64 0.333 0.26 1.58
DBL5p 0.84 0.672 0.37 1.89
Ngerenya (age adjusted) slide positive n=148
Antigen Odds Ratio p-value [95% Conf. Intervall
D BLla 1.76 0.90 0.51 6.10
DBL2P 1.51 0.749 0.12 18.77
CIDRla 2.20 0.220 0.622 7.81
DBL4y 0.85 0.864 0.15 4.93
DBL5P 0.97 0.977 0.18 5.33
Ngerenya (age adjusted) slide negative n=469
Antigen Odds Ratio p-value [95% Conf. Intervall
DBLla 0.96 0.944 0.31 2.97
DBL2P 1.12 0.861 0.31 4.11
CIDRla 0.79 0.549 0.38 1.66
DBL4y 0.57 0.314 0.19 1.69
DBL5P 0.76 0.589 0.28 2.05
Odds Ratios are adjusted for age and reactivity to schizont extract.
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Those parasite negative and antibody negative may be either unable to make the 
response and so a true antibody negative, or may be perfectly capable of making 
such a response if challenged and thus falsely classified as antibody negative. The 
importance of these potentially short-lived responses have been highlighted recently 
in a number of studies where no relationship between a given immune response and 
protection was observed in the cohort as a whole, but when individuals parasite 
positive at the time of sampling were analysed separately a clear protective effect 
was observed (Bull, Lowe et al. 2002; Kinyanjui, Mwangi et al. 2004; Polley, 
Mwangi et al. 2004). The ‘boosting’ of antibody responses amongst those parasite 
positive at the time of sampling seen in these studies and others is not as apparently 
straightforward as at first thought. When the relationship between antibody levels 
and parasites was analysed by future disease experience, ie individuals stratified by 
those who became a case of clinical malaria in the subsequent six months and those 
who did not, the increased intensity and prevalence of antibody responses in 
association with parasites was only apparent in those who did not go on to became a 
case of clinical malaria (table 6.1). It is difficult to assess whether this fact is telling 
something important about anti-malaria immunity.
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Age (years)
Figure 6.7
Relative risks of infection (triangles), morbidity (squares), severe disease (circles) 
and death (diamonds) among a population aged 0-15 years located in a stable 
endemic area on the Kenyan coast.
(Adapted from (Snow and Gilles 2002))
It may be that the ability to respond appropriately to challenge in the form of 
parasites, by the production of relatively cross-reactive antibodies or a broader range 
of antibody responses, or even the production of antibodies targeting less 
immunogenic conserved targets is a marker of relative immunity and those 
individuals unable to respond in this way are more susceptible. Or it may simply be 
that both parasite positivity and antibody positivity are surrogate markers of 
cumulative exposure and that there is no direct association between the two variables. 
Stringent measures were used to ensure that differences in previous exposure 
between the two groups were accounted for. Within the multiple logistic models, 
age, a proxy measure of exposure (responses to whole schizont extract) and location 
(high or low transmission) were all included as significant co-dependent variables. 
Nonetheless it is impossible to exclude the possibility that previous exposure 
remained inadequately accounted for. Certainly previous work has demonstrated a 
similar finding and in this work no measure of previous exposure altered the 
association between antibodies and parasites (Bull, Lowe et al. 2002).
The importance of the relationship between asymptomatic parasitisation and 
antibody responses on the one hand, and protection from or susceptibility to 
subsequent disease on the other was given further support in this work with the 
identification of a susceptible sub-group of individuals. By stratifying individuals 
according to their antibody and parasite status at cross-sectional survey, we were 
able to identify those children most at risk of subsequent clinical malaria. Those 
children with parasites but with no concomitant rise in heterologous antibody levels 
experienced significantly more attacks of clinical malaria in the subsequent six 
months even after attempting to control for confounding variables such as age and
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exposure (table 6.3, table 6.4 and figure 6.5). This susceptibility was the case with 
responses against any of the isolates tested. It has been hypothesised that the 
development of immunity against clinical malaria is associated with the ability to 
maintain chronic asymptomatic infections. Chronic asymptomatic infections 
themselves have been speculated to directly protect against super-infections, a 
process called premunition (Serjent and Parrot 1935). Work in humans suggested 
that premunition was related to the multiplicity of clones present within the 
established controlled infection (al-Yaman, Genton et al. 1997; Smith, Felger et al. 
1999). The protection afforded by the ability to maintain chronic infections is 
supported by the observation that, with age, disease incidence decreases at a time 
when the prevalence of parasitaemia increases (Marsh 1992). This is of course at 
odds with the observation in this chapter that being parasitaemic per se was 
associated with an increased susceptibility to mild clinical malaria. Previous work 
from this area showed no association between asymptomatic parasite carriage at the 
end of a dry season and either protection from or susceptibility to severe malarial 
disease (Bull, Lowe et al. 2002). Work carried out in Senegal under low to moderate 
transmission (EIR 5-10) demonstrated an association between asymptomatic 
parasitisation at the end of a dry season with protection against subsequent mild 
clinical malaria (Males, S published abstract). It is not clear if these contrasting 
results reflect different methodologies, different outcome measures of clinical 
malaria or are due to different levels of exposure amongst the individuals studied. 
The increased susceptibility observed in those with parasites and poor concomitant 
heterologous antibody responses might reflect a poor inherent ability to respond 
appropriately. Such children have been reported in a number of studies (Giha, 
Staalsoe et al. 1999; Ofori, Dodoo et al. 2002; Kinyanjui, Bull et al. 2003) although
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on an individual basis it is not known if these children are actually more susceptible 
to clinical malaria. There was also a suggestion within this data, and previous data 
from the same area, that having antibodies to the infected erythrocyte surface in the 
absence of detectable parasites was associated with susceptibility (Kinyanjui, 
Mwangi et al. 2004). This may simply indicate a recently treated symptomatic 
infection and may thus be reflective of a sub-population of individuals at increased 
risk in terms of either challenge or inherent host susceptibility factors.
Of course all of these differences in susceptibility may simply be highlighting 
differences in exposure and thus risk between the groups. Those with parasites at the 
time of sampling have a defined exposure, whereas those without microscopically 
detectable parasites will be a more heterogeneous group in terms of likelihood of risk 
and thus any difference in protection or susceptibility may be more difficult to 
disentangle.
Studies identifying targets for protective immunity on the infected erythrocyte 
surface have had conflicting results. Whereas following infection children develop 
antibodies specific to the infecting isolate associated with protection (Bull, Lowe et 
al. 1998), it is not clear how relatively cross-reactive antibodies, or responses 
directed against less immunogenic conserved targets are involved in protective 
immunity. In Kenya, the ability of sera to agglutinate a randomly selected isolate 
was not associated with protection (Bull, Lowe et al. 1998; Bull, Lowe et al. 2002). 
However in Sudan, antibodies directed against an isolate from Ghana were 
associated with protection while antibodies to six Sudanese isolates were not and in 
Ghana responses to a Sudanese isolate and to a Ghanaian isolate demonstrated an
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association with protection but responses to another Ghanaian isolate did not (Giha, 
Staalsoe et al. 2000; Dodoo, Staalsoe et al. 2001). It should be noted however that in 
none of these studies was asymptomatic parasitaemia taken into account at the time 
the sera were assayed. Whether antibodies directed against these isolates are 
genuinely more protective or these isolates are in some way different in the antigens 
expressed, perhaps expressing to a greater degree a cross-reactive or conserved sub­
set of variant antigens or whether these results are simply reflecting differences in 
prevalence and the ability of these measured responses to act as surrogate markers of 
protection is unknown. In this study, responses to four parasite lines, including one 
selected to express one dominant var gene, were associated with protection in those 
with asymptomatic parasitaemia. Identifying the targets for this response is of 
considerable importance both for vaccine development and improved understanding 
of the acquisition of immunity in children in malaria endemic areas. It was with this 
aim we assessed whether antibodies directed against recombinant domains of A4 
PyEMPl were also associated with protection from clinical malaria.
Overall in each area studied, we could find no association with the presence of 
domain-specific antibodies and protection (table 6.6 and table 6.7). However by 
categorising individuals according to the presence or absence of parasites at cross- 
sectional survey, we found an association with disease incidence in those with anti- 
DBLla antibodies and no detectable parasites. This association was only evident in 
the higher transmission area. It is difficult to satisfactorily explain this result. 
Certainly previous studies examining the association between circulating antigen- 
specific antibodies and protection from clinical malaria the protective effect was 
only seen in those individuals possessing both antibodies and parasites at the time of
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bleed (Kinyanjui, Mwangi et al. 2004; Polley, Mwangi et al. 2004). It is likely that 
by expressing each domain as a recombinant fusion protein, important 
conformational epitopes are lost and also possible that targets on each recombinant 
protein are functionally unimportant in vivo.
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Chapter 7
Concluding Remarks
The results presented in this thesis have highlighted the complicated and effective 
acquisition of natural immunity that occurs in malaria endemic areas. By examining 
responses to the surface of the infected red cell, from individuals in areas of differing 
transmission intensity it was possible to compare the effects of different levels of 
challenge in attaining specific anti-red cell surface immune responses and the effect 
these responses had on the likelihood of suffering clinical malaria.
In particular it was striking that children resident in both the high and the low 
transmission area develop such a wide breadth of responses. This was particularly 
apparent with responses detected to the laboratory cloned isolate A4U. This parasite 
had been selected to display one variant of P/EMP1 on the surface of infected 
erythrocytes through use of a monoclonal antibody, BC6. Despite this 100% of 
children whose immune responses were examined showed evidence of recognition of 
this variant by the age of 7 years in the high transmission area and 10 years in the 
low transmission area. The broad extent of responses present within this population 
of children was further illustrated by the increased prevalence and intensity of 
recognition of this laboratory clone in the presence of asymptomatic parasite carriage. 
That these responses were almost totally absent amongst children from the same area 
with symptomatic malaria, both at the time of disease presentation and during 12 
weeks of convalescence may imply that the ability to maintain asymptomatic 
parasite carriage is not only associated with a broader range of responses but also
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possibly that susceptibility to clinical malaria may be associated with the breadth of 
immune response. Certainly the ‘boosting’ seen in both antibody prevalence and 
intensity in the presence of asymptomatic parasite carriage was only apparent 
amongst those children who remained protected from clinical malaria during the 
season immediately following the cross-sectional bleed. A result which must tell us 
something important regarding an individual’s ability to remain protected from 
clinical disease.
Regarding the effects of host genotype on the ability of an individual to produce a 
specific immune response, results in this thesis support earlier work where a 
significantly higher titre of anti-infected erythrocyte antibodies was noted in children 
with HbAS compared to HbAA (Marsh, Otoo et al. 1989), and more recent work 
whereby the presence of HbAS genotype was associated with enhanced recognition 
of two heterologous clinical isolates among Gabonese children (Cabrera, Cot et al. 
2005). There was no effect of thalassaemia status on immune responsiveness with 
regards recognition of the same isolates.
There remains no reliable and reproducible in vitro marker of protection from 
clinical malaria. Even defining an individual child as immune or non-immune is 
problematic as has been discussed. Within the cohort of individuals studied in this 
work, the presence of an asymptomatic parasitaemia at the end of a low transmission 
season conferred increased risk of subsequent clinical malaria. What was surprising 
was that this increased susceptibility was almost entirely accounted for by those 
individuals with parasites but with no concurrent detectable antibody response to the
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surface of P. falciparum infected erythrocytes. This association was not variant 
specific, being present with all 4 parasite isolates tested although the level of 
protection afforded by antibodies present with asymptomatic parasite carriage did 
differ between the isolates tested.
The question of what might be the target of these responses is a question of 
considerable importance and interest. It was unexpected and somewhat exciting to 
demonstrate the remarkably strong correlation in individual responses between the 
different parasite clones and isolates studied. That, statistically, this could not be 
accounted for simply by exposure was even more unanticipated. Although not 
absolutely certain, the most likely erythrocyte surface exposed antigen as a target for 
these responses remains P/EMP1 and models akin to those hypothesised for 
placental malaria by Beeson and colleagues can be applied in this case (Beeson, 
Rogerson et al. 2006). It may be that within different P/EMP1 variants, each highly 
diverse, there exists more conserved perhaps less immunogenic regions. Antibodies 
to these conserved regions may be important in conferring protection. Alternatively 
there may be a restricted number of nonetheless antigenically diverse P/EMP1 
variants and acquiring a repertoire of antibodies against these would confer 
protection. That we were unable to see any association between recognition of 
individual A4 P/EMP1 domains and protection from clinical disease was possibly 
due to the method of expression chosen, with conformational epitopes being of 
greater importance, or perhaps the regions chosen for expression were too long and 
thus lacked specificity for any potential protective response to be recognised as such. 
Of course the possibility of the presence of an as yet unidentified surface-expressed 
antigen remains. The identification and characterisation of protective targets on the
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infected erythrocyte surface is of profound importance in the understanding of the 
naturally acquired protective immune response and in the development of an 
effective malaria vaccine.
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